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Abstract and Keywords
Quinone reductase 2 (NQO2) is a mammalian enzyme that catalyzes the reduction of quinone
using an unusual co-substrate, dihydronicotinamide riboside (NRH). In addition, NQO2 has a
secondary function, which is to modulate the 20S proteasomal degradation of p53 in a redoxdependent manner. This alternate function has been characterized in its sister enzyme
quinone reductase 1 (NQO1) and yeast quinone reductase Lot6p, but relatively few studies
have investigated the role of NQO2 beyond quinone catalysis. From studies of Lot6p, it was
proposed that quinone reductases could be categorized as flavin redox switches. In this
thesis, the how NQO2 functions as a flavin redox switch and how inhibitors can modulate
NQO2 was investigated. Initially, a method was developed to reconstitute recombinant
NQO2 with FAD. Having purified functional NQO2, reduced structures of NQO2 were
solved in complex with four different inhibitors: the antimalarial drug chloroquine, CK2
inhibitor DMAT, DNA intercalating agent ethidium bromide, and acridine orange. In all four
reduced structures, the hydrogen bond network and the orientation of inhibitors in the active
site of NQO2 were changed by the presence of water molecules compared to the oxidized
structures. For the structure of reduced NQO2 in complex with chloroquine, there was also a
global conformational change. These reduced structures together showed that NQO2 has two
functional states, and indicated mechanistic features of a flavin redox switch in NQO2. To
understand how these inhibitors affect NQO2 signalling in cells, the CK2 inhibitors and
DNA intercalating agents were further studied in tissue culture. Even though the cytotoxicity
of these compounds was not dependent on NQO2, p53 levels were modulated in an NQO2dependent manner. In conclusion, this thesis has shown that in addition to quinone catalysis,
NQO2 functions as a flavin redox switch, and NQO2 inhibitors have the ability to modulate
this process.

Keywords
Quinone reductase 2, flavoprotein, antimalarial drugs, primaquine, chloroquine, CK2
inhibitors, TBB, TBBz, DMAT, DNA intercalating agents, ethidium bromide, acridine
orange, doxorubicin, X-ray crystallography, enzyme kinetics, ping-pong mechanism, flavin
redox switch, 20S proteasomal degradation, p53 degradation.
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Chapter 1

1

Introduction to Quinone Reductase 2
1.1

General Introduction

Cancer is the uncontrolled growth of cells caused by the induction of oncogenes, and
inactivation of tumor suppressors. On this basis, the development of molecular targeted
therapy operates on the principle that if these drivers of cancer can be controlled
individually, then a regimen of therapeutic agents can ultimately reverse the process of
cancer progression. This principle was clearly demonstrated by the success of the drug
imatinib to induce complete cytogenetic remission in patients with chronic myelogenous
leukemia (CML) by targeting the BCR-Abelson kinase (BCR-Abl) (1). The hallmark of
CML is a translocation of chromosome 9 to chromosome 22 in which the normally
inactive Abl kinase is fused to BCR, forming the onco-gene BCR-Abl (2). By inhibiting
the onco-protein that drives the proliferation of cells, imatinib successfully prevented
cells with BCR-Abl from multiplying. While this illustrated the success of molecular
targeted therapy, cancer is rarely driven by a single onco-protein.
Validation studies revealed that imatinib also bound to other targets. Using a chemical
proteomics approach, two groups independently showed that quinone reductase 2
(NQO2) was a prominent non-kinase target of imatinib (3, 4). NQO2 is a detoxification
enzyme, which alternatively functions to stabilize the tumor suppressor p53 from
1

degradation (5, 6) . The antileukemic effects of imatinib are dependent on p53 activation
in addition to BCR-Abl inhibition, so the interaction between imatinib and NQO2 may
contribute to the therapeutic effects of the drug (7). These studies together illustrated the

1

Reference 6 by Gong et al. has been retracted as of February 1st, 2015. Retraction:
NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor
Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and
Activation of p53. (2015). Cancer Research, 75(3), 615–615.

2

point that although compounds are designed to inhibit one target, they can act in
combination with other targets to elicit a favorable therapeutic effect.
Protein kinase CK2 (CK2) is another dysregulated kinase in cancer. The overexpression
of CK2 in cancer attenuates apoptosis by the phosphorylation of caspases and caspase
substrates, and inhibition of CK2 can induce apoptosis in cancer cells (8). In the past two
decades, numerous CK2 inhibitors have been developed, yet how the inhibitors affect the
phosphorylation pattern in cells is still poorly understood. In an attempt to identify CK2
substrates and to validate the inhibitors’ mechanism of action, an inhibitor-resistant CK2
construct was made to restore CK2 activity in the presence of inhibitors (9). Despite the
restoration of CK2 activity in the presence of two inhibitors, TBBz and DMAT, both
inhibitors still induced apoptosis in cells. Thus, CK2 inhibition was not entirely
responsible for cell death and the inhibition of other proteins contributed to apoptosis.
Using a proteomics approach, NQO2 was again identified to be an unintended off-target
binding protein of TBBz and DMAT (9). Together, this raises the possibility that the
efficacy of CK2 inhibitors is also partially due to the off-target inhibition of NQO2.
Initially discovered in the 1960’s by William-Ashman and coworkers, NQO2 was
purified as a mammalian cytosolic flavo-protein. It catalyzed the reduction of quinone
using dihydronicotinamide riboside (NRH), but not NAD(P)H or dihydronicotinamide
mononucleotide (NMNH) (10). NQO2 was left unstudied for almost three decades until it
was discovered to be genetically and structurally related to the widely-known enzyme
quinone reductase 1 (NQO1) (11). The identification of NQO2 as a homologue of NQO1
suggested that the two enzymes shared the same catalytic machinery and function, but
their substrate and inhibitor specificity was strikingly different (11). For the next ten
years, several groups identified NQO2 to be the target of different bioactive compounds.
These compounds included targeted kinase inhibitors (imatinib and nilotinib (3, 4), CK2
inhibitors (9), PKC inhibitors (12)), antimalarial compounds (primaquine, chloroquine,
and quinacrine (13)), natural flavonoid (quercetin (5)), stilbenoid (resveratrol (14)), and
hormone (melatonin (15)). While these inhibitors can prevent NQO2 catalysis at
micromolar to low nanomolar concentrations, how they disrupt normal cell functions in
an NQO2-dependent manner is uncertain. During this period, NQO1 was shown to
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stabilize p53 from 20S proteasomal degradation (16). This led to the discovery that
NQO2, like NQO1, also modulated p53 protein levels (6, 17). Recently, NQO2 was also
shown to indirectly regulate the AKT/cyclin-D1/Rb and the NFκB signalling pathways
(18, 19). Together, it would appear that NQO2 has cellular signalling functions in
addition to quinone reduction. Similarly, studies of yeast quinone reductase Lot6p also
showed that Lot6p has a cell signalling function (20). Lot6p was a poor catalyst of
quinones but was able to stabilize transcription factor Yap4 from 20S proteasomal
degradation in an NADH dependent manner (20, 21). In this regard, it was postulated that
quinone reductase could be categorized in a larger protein family called the flavin redox
switch. From these studies, it would appear that NQO2 has physiological roles as a flavin
redox switch.
In this thesis, I hypothesize that NQO2 functions as a flavin redox switch that senses
intracellular NRH and recognizes potential cytotoxic compounds to modulate p53 levels
in cells. To this end, several oxidized and reduced structures of NQO2 in complex with
inhibitors were solved. The structural changes in NQO2 upon reduction revealed
mechanistic features in NQO2 that resembled flavin redox switches. Extending the
investigation of inhibitors to cell culture, it was also found that inhibitors modulate p53
differently compared to NQO1. In this chapter, major concepts pertaining to the role of
NQO2 as a flavin switch will be presented. First, NQO2 catalysis will be introduced
because it is fundamental to NQO2’s function as an enzyme and as a flavin redox switch.
Next, the biological process of p53 stabilization from 20S proteasomal degradation, and
how quinone reductase could function as a flavin redox switch will be explained in
greater detail. Finally, several NQO2 inhibitors will be introduced to show the diversity
of compounds that bind NQO2 and affect p53 modulation.

1.2

Structure and Kinetics of Quinone Reductase 2

Historically, NQO2 was thought to function as a detoxification enzyme because it was a
homologue of quinone reductase 1 (NQO1) with 48% sequence identity ((11)). NQO1
catalyzes an obligate two-electron reduction of quinone to hydroquinone, and prevents
the catalysis of single electron reductions of quinone by phase I enzymes such as
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cytochrome P450, which generates semi-quinone species. Since semi-quinones can
undergo redox-cycling that generates harmful reactive oxygen species, NQO1 functions
to detoxify quinone compounds. In this regard, NQO2 was anticipated to perform the
same function.
NQO2 is a 26 kDa metallo-flavo-protein that is catalytically active as a dimer.
Structurally, each monomer is composed of a Rossmann fold that coordinates one copy of
flavin adenine dinucleotide (FAD). NQO2 is catalytically dead when depleted of its
flavin co-enzyme, but its activity can be restored using FAD or a high concentration of
flavin mononucleotide (FMN) (10). The active site of the enzyme is located at the
interface between the two protomers where the isoalloxazine ring of FAD makes up the
base of the active site, and residues from the second protomer make up the top (Figure
1.1). Each NQO2 protomer coordinates one FAD co-enzyme, and there are two active
sites in the NQO2 dimer. Since most crystal structures of NQO2 are composed of a dimer

Figure 1.1 Surface Representation of Quinone Reductase 2.
Each protomer of NQO2 (coloured as red or blue) coordinates an FAD co-enzyme and
the active site is made up of the isoalloxazine ring from one protomer and residues from
the other protomer (at the center of the figure).
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in the asymmetric unit, the two protomers are not identical. It is currently not known
whether the two subunits act independently or cooperatively, since structural studies
show that inhibitors can occupy the two active sites in different orientations. Another
feature of NQO2 is the presence of a metal ion located roughly 10 Å	
  away	
  from	
  the	
  
active	
  site	
  (22).	
  Between	
  the	
  metal	
  ion	
  and	
  the	
  active	
  site	
  are four residues that make
up an electron transport bridge.	
  The	
  identity	
  of	
  the	
  metal	
  ion	
  is	
  copper	
  when	
  isolated	
  
from a mammalian source, and zinc when purified from Escherichia coli using a
recombinant construct. However, the role of the metal ion in the catalysis of quinone is
currently unknown since 100 mM EDTA did not decrease its catalytic activity (23). In
the following sections, a detailed introduction on each component of NQO2 catalysis
(FAD co-enzyme, nicotinamide co-substrate, quinone substrate, and inhibitors) and how
they influence the role of NQO2 as a flavin redox switch will be presented.

1.2.1

The Ping-pong Mechanism of NQO2 Catalysis

Flavin redox switches are a class of proteins that can adopt different conformations
depending on the redox state of its co-enzyme FAD. For NQO2, the redox state of FAD
is dependent on the amounts of substrates and co-substrate available in the environment.
In this regard, a comprehensive understanding of NQO2 catalysis is required to
appreciate the complexity of NQO2 as a flavin redox switch. Similar to NQO1, NQO2 is
able to catalyze the reduction of quinone using a ping-pong mechanism (Figure 1.2)(11).
This catalytic mechanism can be described as two half-reactions: an oxidation reaction of
NRH, and a reduction reaction of quinone. In the oxidation half-reaction, a nicotinamide
co-substrate enters the active site and transfers two electrons to the isoalloxazine rings of
FAD, reducing FAD to FADH2. The oxidized nicotinamide would then exit the active
site, leaving NQO2 in its reduced state. In the reduction half-reaction, a quinone substrate
enters the active site to pick up the two electrons, producing hydroquinone. After the
hydroquinone leaves the active site, NQO2 returns to its original oxidized state. In
summary, the dihydronicotinamide co-substrate and the quinone substrate alternately
occupy the active site, and NQO2 cycles through two redox states for each catalytic turn
over.
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Figure 1.2 Ping-pong Mechanism of NQO2 Catalysis and Inhibition.
Due to the nature of the ping-pong mechanism where each catalytic turn over requires the
entry and exit of two substrates, NQO2 catalysis is not considered to be an enzyme with
high catalytic rates. In a review of enzyme catalysis documented in the BRENDA
database, it was found that the median catalytic turnover (Kcat) was roughly 10 s-1 (24).
Compared to carbonic anhydrase, one of the fastest enzymes known, with Kcat value of
over 1 × 105 s-1, the catalysis of menadione reduction using NRH by NQO2 is relatively
slow (Kcat = 43 s-1)(5). To further understand the efficiency of NQO2 catalysis, the
steady-state kinetics for a ping-pong mechanism described by equation 1.1 will be
examined.

Vobs
[A][B]
=
Vmax K M(A) [B]+ K M(B) [A]+[A][B]
Equation 1.1 Ping-pong Mechanism.
The rate of quinone reduction is dependent on the two Michaelis constants (Km) for the
quinone substrate (A) and the nicotinamide co-substrate (B), the substrate concentrations,
and the maximum velocity (Vmax). A detailed examination of this equation indicates that
the catalysis of NQO2 in practice could be much slower than theoretical estimates. To
illustrate this point, consider the catalytic rate when both substrate concentrations are
present at their respective Km values (ie. substitute all the variables with 1). The Vobs/Vmax
will be at 1/3, meaning that the rate of catalysis is only one third of maximum velocity.
At five times the concentration of their respective Km values (ie. Substitute [A], [B] with
5, and Km(A) and Km(B) with 1), Vobs/Vmax will be at 25/35, or 71%. Therefore, the
theoretical kcat or Vmax is only attainable at very high concentrations of both substrate and
co-substrate. From these calculations, it appears that NQO2 catalysis is largely dependent

7

on the availability of both the quinone substrate and dihydronicotinamide co-substrate.
Without dihydronicotinamide, NQO2 will likely be in an oxidized state even in the
presence of quinone, and vice versa. In this regard, the catalytic efficiency of NQO2 as a
detoxification enzyme may be much lower in a cellular context. As a flavin redox switch,
the redox state of NQO2 is intimately tied to the presence of substrates and co-substrates
in cells.

1.2.2

The FAD Co-enzyme

FAD is crucial to NQO2’s enzymatic and signalling function. As an enzyme, the obligate
two-electron transfer to quinone is only possible with the FAD co-enzyme. During a
catalytic turnover, a hydride ion (a proton and two electrons) is transferred to the
isoalloxazine ring of FAD. At this stage, FAD would be reduced to FADH- where one
proton and one electron reside at the N5 atom of FAD, while the other electron is shared
between the N1, O2, and O4 atom in a tautomeric state (Figure 1.3). In NQO1, theoretical
calculations showed that the second electron preferentially resides at the O2 atom and
could be protonated by a nearby residue (25). Upon reduction, the electron transfer at the
N5 atom breaks the planarity of the three ringed members of isoalloxazine. In proteinfree FADH2, the isoalloxazine ring is characterized by a “butterfly bend” of 10 - 28º
along the N5-N10 axis (26). In the protein bound form, the butterfly bend varies. For
example, the FAD ring bent up to 34º in reduced thioredoxin reductase, while the
bending of FAD in NQO2 was roughly 5° (27, 28). Maintaining FADH- in a planar
formation requires relatively little energy, around 4 kcal/mol according to Dixon and
coworker’s estimation (26), which could be stabilized by a single hydrogen bond (~4.3
kcal/mol). As an enzyme, the relatively planar geometry of FAD could contribute to its
catalytic efficiency and substrate specificity. As a signalling molecule, the additional
hydrogen bond could alter the conformation of the protein (29).
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Figure 1.3 Chemical Structure of the Isoalloxazine Ring, FMN, and FAD.

1.2.3

The Nicotinamide Co-substrate

The discovery of NQO2 in 1962 by William-Ashman and coworkers showed that NQO2
was unable to use the common co-substrates NAD(P)H and NMNH, but used NRH
instead (Figure 1.4) (10). This was followed up in 1997 by Jaiswal and co-workers who
showed that while NQO1 efficiently catalyzed the reduction of quinone using NAD(P)H
(kcat/Km = 440 min-1 µM-1), NQO2 used NAD(P)H poorly with a catalytic efficiency
roughly 700-fold lower than NQO1 (kcat/Km = 0.62 min-1 µM-1) (5). Instead, NQO2 used
NRH nearly as efficiently as NQO1 used NAD(P)H (kcat/Km = 95 min-1 µM-1). To further
illustrate that NQO1 and NQO2’s co-substrates are exclusive to each other, a study also
showed that NQO1 used NRH 500-fold less efficiently than NAD(P)H, as NRH inhibited
NQO1 catalysis with a Ki value of 2.39 mM (30). Since then, several other N-alkyldihydronicotinamide derivatives have been identified to be co-substrates of NQO2 with
an appreciable kinetic efficiency (31). Though virtually all in vitro studies of NQO2
utilized these dihydronicotinamide derivatives, it is not known why NQO1 and NQO2
use the dihydronicotinamide co-substrates exclusively.
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Figure 1.4 Chemical Structure of Nicotinamide Derivatives and
Dihydronicotinamide.
Quinone reductase is part of the flavodoxin superfamily that can catalyze a diverse range
of quinones. They are widely found in organisms ranging from bacteria to mammals.
Base on sequence similarity, quinone reductases can be organized into three groups:
those with C-terminal domains (NQO1-like), those lacking C-terminal domains (NQO2like), and those lacking C-terminal domains with an internal deletion of 18 residues
(flavodoxin-like) (32). In a review of quinone reductase from 14 species of plants, fungi
and bacteria, it was surprising that NQO2 was the only enzyme that preferentially used
NRH (33). A structural study of NQO1 in complex with NADP+ showed that the Cterminal domain of NQO1 coordinated the negatively-charged phosphate and AMP
moiety of NADH during catalysis (34). But neither truncation of the C-terminal domain
of NQO1, nor insertion of the C-terminal domain from NQO1 to NQO2, changed their
co-substrate specificity (35). This indicated that the C-terminal domain alone was
inadequate in conferring substrate specificity towards NADH. Mutating residues in the
NQO2 active sites to resemble NQO1 was also unable to alter the co-substrate specificity
to use NADH (36). Instead, it increased the overall catalytic activity of NQO2 using
NRH and synthetic BNAH. These studies together indicated that NQO2 had evolved to
avoid using NADH, yet it is unclear whether NRH is readily available in cells.
Knox and coworkers have a long-standing interest in using the prodrug CB1954 in
treating cancer. They have found that reduction of CB1954 by NQO2 can increase the
cytotoxicity of CB1954 up to three orders of magnitude (31). V79 cells are Chinese
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hamster lung fibroblast cells that have minimal NQO2 expression and activity. In these
cells, the toxicity of CB1954 was only increased 1.4 times in the presence of NRH. But
when NQO2 was transfected into these cells, the IC50 of CB1954 was increased up to
3000-fold (31). Strikingly, the presence of NQO2 did not change the IC50 of CB1954 in
cells without NRH co-treatment. This indicated that NRH and other NQO2 co-substrates
were absent in normal proliferating cells, and suggested that NQO2 by itself was not
catalytically active. In contrast, NQO1 substrates mitomycin C and EO9 were readily
reduced without the addition of NADH (37, 38). Furthermore, how NRH is produced in
cell is currently unknown. Given that NQO2 requires a high concentration of co-substrate
to efficiently catalyze quinone, the lack of NRH in cells challenges the perspective that
NQO2 functions primarily as a catalyst.

1.2.4

The Quinone Substrates

The notion that NQO2 is a detoxification enzyme is based on its similarity to NQO1 in
catalyzing a two-electron transfer to quinone. For NQO1, menadione (vitamin K3) and
several benzo- and napthoquinones are classic examples of the quinone substrate (39).
NQO2 was also able to reduce menadione, but it did so 15-fold less efficiently than
NQO1 when its preferred co-substrate was used (5). Furthermore, while napthoquinones
are common substrates of NQO1, they were not recognized by NQO2 (40). In a screen of
commercially available quinones, only one substrate, coenzyme Q0 was identified for
NQO2 (40). Since coenzyme Q0 is not a naturally occurring compound, it is unclear what
natural quinone compounds NQO2 recognizes. From these observations, it appears that
NQO1 and NQO2 catalyze different quinone substrates.
At high concentrations, menadione exhibits substrate inhibition for both NQO1 and
NQO2. This indicates that it could act as both a substrate and an inhibitor of the system
depending on its concentration (23, 41). How menadione behaves in an enzymatic assay
is well characterized, but whether menadione acts as a substrate or inhibitor in cells is not
clear. On one hand, mice deficient of NQO1 were more susceptible to menadione toxicity
compared to wild-type mice (42). On the other hand, mice deficient of NQO2 were less
sensitive to menadione toxicity when challenged with the same compound compared to
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wild-type mice (43). Therefore, NQO1 and NQO2 deletion had opposite effects in mice
treated with menadione. In the scenario where NQO1 is actively metabolizing menadione
in the presence of NAD(P)H, the deletion of NQO1 could sensitizes cells to menadione
toxicity. In contrast, if NQO2 is being inhibited by menadione by the lack of NRH in
healthy cells, this interaction could elicit cellular signals that increase menadione’s
cytotoxicity. As such, the deletion of NQO2 would abrogate this signalling event,
rendering menadione less cytotoxic. Drawing from these speculations, it demonstrates
that the physiological function of NQO2 is very complex. NQO2 function could be vastly
different from NQO1, and the role of NQO2 as a detoxifying enzyme or a signalling
protein is intimately linked to the availability of a reducing co-substrate.
In addition to menadione, several synthetic substrates of NQO2 have been identified.
They include prodrug CB1954, several quinone methides, acetaminophen and potentially
paraquat (Figure 1.5). The prodrug CB1954 is a dinitrobenzamide aziridine that functions
as a DNA alkylating agent. Upon a four electron transfer to the nitrogen groups by
quinone reductase, CB1954 is able to form DNA crosslinks and is up to 3000-fold more
cytotoxic than its parent compound (31). Initially, it was found that rat NQO1 can
activate CB1954 and selectively kill Walker 256 (rat breast carcinoma) cells while
sparing HEK295 (human embryonic kidney) cells (44). However, human NQO1 was not
able to catalyze this reaction, and CB1954 was unable to selectively kill human cancer
cells. Instead, human NQO2 reduced the CB1954 1000-fold more efficiently than NQO1
when cells were supplemented with NRH or other NQO2 co-substrates (5). This
illustrates that the substrates are unique to NQO1 and NQO2.
Both NQO1 and NQO2 were able to reduce ortho- and para-quinone methides in vitro
(45). In these molecules, one of the two carbonyl groups was replaced with a methylene
group. Biologically, these compounds were more reactive than quinone and could
undergo redox cycling when reduced (46). Finally, paraquat and acetaminophen toxicity
were shown to be mediated by NQO2 and their toxicity diminished in the presence of
NQO2 inhibitors (47, 48). Paraquat is an herbicide that is lethal when ingested and could
be an indirect substrate of NQO2. Acetaminophen is a common medication and was
shown to be a weak substrate of NQO2. From these observations, it appears NQO2-
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mediated reduction of compounds is responsible for activating toxic compounds rather
than detoxifying them.

Figure 1.5 Chemical Structure of NQO2 Substrates.

1.2.5

ROS Generation and Auto-oxidation

It was recently shown that NQO2 can produce reactive oxygen species (ROS) in the
presence of substrates and co-substrates (49). When the first structural analysis of NQO2
was published (PDB ID: 1QR2), Foster and co-workers noted a bound metal ion in
NQO2. It was connected to the O(2) atom of FAD through the following four residues,
forming an electron transfer bridge: Y155, N161, Y132, and H173 (22). The metal ion
was not present in NQO1 and it was proposed that it could be important in the reduction
of quinone in NQO2. However, mutating the residues that coordinated the metal ion did
not significantly change the rate of quinone reduction, and EDTA did not noticeably
affect NQO2 activity either (23, 36). Thus, the role of the bound metal ion is currently
unknown. When NQO2 was isolated from a mammalian source, it was found to contain
copper. Since copper is a reactive metal, it is possible that this metal participates in ROS
generation (50). As an enzyme, the generation of ROS indicates that it could mediate
oxidative stress in cells. As a flavin redox switch, auto-oxidation represents a mechanism
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of switching from a reduced state to an oxidized state that could be important in
temporally regulating NQO2’s signalling function.

1.2.6

The Inhibition Mechanism

In 1962, William-Ashman and coworkers showed that a small concentration of
anthracene derivatives (10 nM) was able to inhibit the catalytic activity of NQO2 (10).
They further showed that much like the dihydronicotinamide co-substrates, inhibitors of
NQO1 and NQO2 were exclusive to one another. The active site of NQO2 is a large
hydrophobic pocket and numerous molecules with a restricted planar moiety could inhibit
NQO2 catalysis. In the past two decades, numerous bioactive compounds were found to
inhibit NQO2 using two methods: pull-down of NQO2 from a compound-conjugated
matrix, and direct screening. The former identified types of molecules such as kinase
inhibitors, antimalarial compounds, natural stilbenoids, and hormones. The latter
identified compounds like flavonoids (40) and DNA intercalating agents (51). All of
these compounds also disrupt cellular proliferation, but it is currently unknown whether
this results from NQO2 inhibition.
The interactions between a compound and an enzyme can be described by enzyme
inhibition or by direct binding experiments. For NQO2, which catalyzes using a pingpong mechanism, inhibitors can either compete against dihydronicotinamide, quinone, or
both substrates (Figure 1.2). Described in terms of direct binding, inhibitors can directly
bind to oxidized, reduced, or both redox states of NQO2. To investigate the mode of
inhibition, Kwiek and co-workers presented a comprehensive analysis of three NQO2
inhibitors: the antimalarial drugs primaquine (PQ), chloroquine (CQ), and quinacrine
(QC) (23). In their study, PQ competed with the dihydronicotinamide co-substrate for the
oxidized FAD site. In contrast, CQ and QC competed with the quinone substrate for the
reduced FAD site. A direct binding assay further confirmed that PQ bound oxidized
NQO2 while CQ did not. These observations showed that not only could these
compounds inhibit catalysis, but they also have a binding preference towards a specific
redox-state of NQO2. By directly binding to either redox-states, NQO2 inhibitors could
stabilize the protein in an oxidized or reduced state. For a flavin redox switch, these
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interactions could propagate distinct signals in a cellular environment. From this
perspective, NQO2 inhibitors could induce signalling events even when concentrations of
a substrate or co-substrate are low in a cell.

1.2.7

Role of NQO2 Catalysis

In this section, each component of NQO2 catalysis was expounded. The substrates, cosubstrates, and inhibitors of NQO1 and NQO2 are almost exclusive to one another, and
the inferred detoxification role of NQO2 was challenged. To catalyze quinones
efficiently, NQO2 would require a high concentration of dihydronicotinamide cosubstrate. However, it appears that little, if any, endogenous levels of NQO2
dihydronicotinamide co-substrate are present in cells. Furthermore, inhibitors of NQO2
also have the potential to stabilize NQO2 in a redox-specific state. From these
observations, the ability of NQO2 to reduce quinone is questioned. In the following
section, how NQO2 could function as a flavin redox switch will be explored.

1.3

NQO2 as a Flavin Redox Switch

The wild-type p53 gene is a tumor suppressor that protects a cell from genomic instability
by inducing cell cycle arrest or apoptosis in response to genomic stress. In a study of p53mediated apoptosis, p53 activated redox-related genes to generated ROS that damaged
the mitochondria (52). Among the p53-induced genes identified was one that shared
sequence homology with mammalian NADPH-quinone oxidoreductase and ζ crystallin,
and was named p53-inducible gene 3 (PIG3). Based on this finding, Asher and coworkers
speculated that oxidoreductase could regulate p53 in a feedback loop, and experimentally
showed that p53 degradation was modulated by NQO1 (16). However, PIG3 and NQO1
were very different proteins in terms of sequence, structure, and function. Instead of
detoxifying quinone to prevent ROS generation, PIG3 produced ROS (53, 54).
Regardless, since the discovery that NQO1 can modulate p53 degradation, NQO2 was
also shown to modulate p53 (6, 23). In this section, an introduction of the flavin redox
switch will be presented and the notion that quinone reductase can function as a flavin
redox switch will be illustrated. Next, the specific mechanism of how NQO1 and NQO2
stabilize p53 from 20S proteasomal degradation will be presented.
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1.3.1

Flavin Redox Switch

Flavin redox switches are a class of proteins that senses specific physiological conditions
and propagate a signal for the cell to respond to (29). In the presence of a specific
substrate, electron donor, or light, the reduction of its flavin co-enzyme FAD or FMN
activates the flavin redox switch. The reduced isoalloxazine ring of flavin then alters the
hydrogen bond network within the protein, leading to a change in protein conformation.
In turn, the activated reduced state is responsible for regulating transcription factors,
controlling membrane binding, and modulating post-translational modifications. The
flavin redox switch can be turned off by the oxidation of flavin in most cases, but it is
irreversible in some. An example of a flavin redox switch is phototropin, which regulates
photosynthetic proteins in plants. They are light sensing proteins that contain two lightoxygen-voltage (LOV) domains and a kinase domain. The FMN co-enzyme in the LOV
domain is reduced by light and makes a covalent bond with a nearby cysteine residue.
This causes a conformational change in the LOV domain, resulting in the activation of
the kinase domain. The phosphorylation of phototropin substrates then induces the
production of photosynthetic proteins in cells.
2

Most flavin redox switches are characterized by having a PER-ARNT-SIM (PAS)
domain; this encompasses the LOV domain (55). In contrast, quinone reductase is
composed of a flavodoxin-like domain that is structurally and sequentially distinct from
the PAS domain (33). As such, the function of quinone reductase as a flavin redox switch
cannot be directly inferred. In yeast, Lot6p is the sole orthologue of human NQO1 and
NQO2, and it was found to physically associate with the 20S proteasome in a redoxdependent manner (20). Specifically, Lot6p modulated the degradation of Yap4, a yeast
transcription factor involved in oxidative stress response (20, 56). Further investigation
showed that oxidative stress induced apoptosis-like cell death in a Lot6p-dependent
manner (57). As an enzyme, Lot6p was shown to be a poor catalyst because it reduced
quinone slower than non-enzymatic reactions (21). From this perspective, it was

2

PER – Period protein; ARNT – aryl hydrocarbon receptor nuclear translocator protein; and SIM
– single-minded protein.
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speculated that Lot6p functioned primarily as a regulator of 20S proteasome rather than
as a catalyst. Furthermore, inhibitors of NQO1 and NQO2 (curcumin and resveratrol
respectively) inhibited Lot6p catalysis and also stabilized the protein from thermal
denaturation (58). This indicated a possible role for inhibitors to affect how Lot6p
regulates the 20S proteasomal degradation of Yap4. While there is no p53 homologue in
yeast, these studies demonstrated that the quinone reductase family could have a
functional role in modulating protein degradation as a flavin redox switch in addition to
quinone catalysis.

1.3.2

The p53 Tumor Suppressor

The tumor suppressor p53 is the “master guardian and executioner” of the genome (59).
It is a transcription factor that induces cell cycle arrest or apoptosis in response to a
diverse range of genotoxic and oncogenic stress. Structurally, p53 is composed of an Nterminal unstructured region, a stable DNA binding domain region, and a trans-activation
C-terminal region. A number of post-translational modifications in p53 drives the
translocation of p53 into the nucleus where it forms a homo-tetramer to induce various
pro-apoptotic genes (60). In the COSMIC database that curates all available cancer
genomes, the p53 gene was found to be mutated in roughly 30% of all cancer types
(http://cancer.sanger.ac.uk/, accessed July 11, 2015)(61). Since cells with defective p53
are impeded from activating apoptosis in the presence of genomic stress, cancers lacking
p53 function could tolerate a higher level of genomic instability and become more
aggressive. Recently, it was shown that restoration of wildtype-p53 led to cancer
remission in a mouse model (62). Therefore, being able to manipulate NQO2 as a flavin
redox switch using NQO2 specific inhibitors could be an avenue of inducing wildtypep53 in cells.

1.3.3

Mechanism of p53 Degradation by 20S proteasome

The degradation of p53 has been an area of extensive research because it is rapidly
degraded and only has a half-life of 20 minutes (63). In the conventional pathway of p53
degradation, the protein is first poly-ubiquitinated by hdm2 E3 ligase. It is then
recognized by the 26S proteasome and degraded in an ATP-dependent manner (Figure
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1.6). NQO1 was initially identified to protect p53 from proteasomal degradation because
it was thought that oxidoreductases could regulate p53 (16). It was shown that
dicoumarol, an inhibitor of NQO1, enhanced the degradation p53. Furthermore, the
inhibitor-induced degradation was prevented by the overexpression of NQO1, the
treatment with proteasome inhibitor MG132, and the presence of SV40 large T antigen.
The degradation of p53 was independent on the hdm2 regulation pathway, and wild-type
NQO1 was necessary to mediate the effects of dicoumarol (64). Surprisingly, mutant p53
with the most frequently mutated arginine residues (R174H, R273H, and R248H) were
resistant to NQO1 inhibitor-induced degradation (65). Mechanistically, p53 was degraded
by the 20S core proteasome particle (proteasome 26S without the 19S regulatory subunit)
alone, without ubiquitination or the addition of ATP (66). This alternate degradation
pathway of p53 was regulated by NQO1 in a NADH dependent manner, and was thought
to be the default pathway of p53 degradation in cells (67, 68). Since the 20S core
proteasome could degrade intrinsically disordered proteins, it was speculated that the
proteasome recognized the unstructured regions of p53 (68, 69). In addition to p53,
NQO1 also prevented 20S proteasomal degradation of p73 and ornithine decarboxylase,

Figure 1.6 p53 Degradation Pathway by 26S and 20S Proteasome.
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which indicated that NQO1 could modulate other proteins with intrinsically disordered
regions (66, 70). These studies together showed that NQO1 can stabilize the basal levels
of proteins including p53 by regulating the 20S proteasome, and NQO1 inhibitors can
prevent this to some degree (71).
Similar to NQO1, NQO2 was also shown to stabilize p53 in the presence of NRH. Mice
deficient of NQO2 were highly sensitive to tumorigenesis in a chemically induced skin
cancer model and had a lowered basal level of p53 (72). Moreover, mice deficient of both
NQO1 and NQO2 were more susceptible to tumorigenesis, and its p53 regulation was
drastically impaired compared to the single knockout mice (73). At the molecular level,
the degradation of p53 by 20S proteasome was verified using an in vitro degradation
assay of [35]S-methionine-labeled p53, and NQO2 was able to stabilize p53 in an NRH
dependent manner (6). From these studies, it is clear that NQO1 and NQO2 can modulate
basal expression of p53 by controlling its 20S proteasomal degradation. To date, the only
known physiological condition known to activate p53 in an NQO1/NQO2 dependent
manner is the inhibition of pyrimidine nucleotide synthesis (17). However, the
mechanism behind how NQO1 or NQO2 modulates this process is currently unknown.
The function and regulation of p53 rely on numerous signals and cellular conditions in
addition to 20S proteasomal degradation. In light of the complex modulation of p53, how
NQO2 behaves as a flavin redox switch and how NQO2 inhibitors affect this switch
remains poorly understood. In the following section, several inhibitors of NQO2 will be
introduced to illustrate the potential link between NQO2 inhibition and cell signalling.

1.4
1.4.1

Inhibitors of NQO2
Discovery of NQO2 Inhibitors

NQO2 inhibitors normally characterized to prevent catalysis of quinone reduction could
stabilize NQO2 in a specific redox-state to modulate p53 stabilization in cells. Since the
discovery of NQO2, a number of proteomic studies have identified NQO2 to be the target
of biologically active compounds such as antimalarial drugs, kinase inhibitors,
resveratrol, and melatonin. These unrelated compounds bound to NQO2 with a sub-
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micromolar affinity and they represent the majority NQO2 inhibitors studied in depth to
date. While these compounds perturb biological processes, most of these inhibitors also
bind to other targets. Accordingly, how NQO2 mediates their biological effects remains
ambiguous. Another approach to discovering NQO2 inhibitors was by screening known
or newly synthesized compounds that inhibited NQO2 catalysis. Motivated by making a
more selective NQO2 inhibitor, NQO2 inhibitors with nanomolar affinity have been
developed. In this section, a brief overview of the inhibitors used in this thesis will be
presented, with an emphasis on how they were discovered to bind NQO2. The following
well-characterized compounds will also be introduced because they affect cellular p53
levels in some way: 9-aminoacridine, imatinib and nilotinib, melatonin, and resveratrol.
The list of all the compounds discussed here is presented in figure 1.7.

1.4.2

Primaquine and Chloroquine

Primaquine (PQ) and chloroquine (CQ) are antimalarial drugs routinely used to treat
parasitic infections of Plasmodium sporozoites transferred by mosquitos. The two
inhibitors target different stages of malarial infection: PQ clears infections from the liver
while CQ clears infections from blood (74, 75). To investigate how these drugs function,
Graves and co-workers employed a proteomics strategy to search for a protein target of
PQ and CQ (13). Cell lysate from malaria-infected blood cells was immobilized on an
ATP-sepharose column and proteins that eluted in the presence of PQ and CQ were
identified. Surprisingly, no parasitic protein was found. Instead, NQO2 was identified
and was potently inhibited by the concentration of drugs used in clinical treatment. This
discovery demonstrated the possibility that inhibition of NQO2 could contribute to
antimalarial effects.
The interaction between the two drugs and NQO2 also indicated that NQO2 could be
involved in other diseases for which PQ and CQ are used as therapeutics. Specifically,
PQ is used to treat pneumocystis pneumonia, and is active against leishmaniasis and
trypanosomiasis in vivo (76–78). CQ has been used to treat rheumatoid arthritis, systemic
lupus erythematosus, amoebic hepatitis, and is under clinical trials for use in HIV1/AIDS (79, 80). Furthermore, CQ is cytotoxic to several human cancer cell lines and is
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Figure 1.7 Chemical Structures of NQO2 Inhibitors.
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being investigated for use as a cancer therapeutic agent (81–83). Mechanistically, CQ
was shown to stabilize wild-type p53 from degradation and induced apoptosis in
glioblastoma cells (84). However, it is unclear how NQO2 mediate the pharmacological
effects of these two inhibitors. To understand how the two inhibitors affect NQO2 as a
flavin redox switch, a structural analysis of NQO2 and the two inhibitors will be
presented in chapter 3.

1.4.3

CK2 Inhibitors TBB, TBBz, and DMAT

Protein kinase CK2 (CK2) is a serine/threonine protein kinase, involved in cell cycle
control, cell proliferation signalling, tumorigenesis, and other cellular processes (8, 85,
86). Since it is overexpressed in many tumor types, it is a potential cancer therapeutic
target and numerous CK2 inhibitors have been developed (87). In particular, 4,5,6,7tetrabromobenzotriazole (TBB), 4,5,6,7-tetrabromobenzimidazole (TBBz), and 2dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), are three widely-used
CK2 inhibitors that can induce apoptosis in cells (88, 89). Despite being optimized for
CK2 specific inhibition, both TBBz and DMAT inhibit at least three other subfamilies of
kinases unrelated to CK2 (DYRKs, PIM, and HIPK (90)). Therefore, the exact pathways
through which CK2 inhibitors induce apoptosis in cells remain debatable. Using a similar
approach to find targets for CQ and PQ, NQO2 was identified as a target of TBBz and
DMAT (9). Specifically, NQO2 was eluted from an ATP-Sepharose column in the
presence of TBBz and DMAT, but not TBB. This correlated with the observation that in
cells TBBz and DMAT, but not TBB, induced apoptosis response even when CK2
activity was restored. Together, this shows that inhibition of NQO2 may contribute to
apoptosis.
In prostate cancer cells, TBB induced apoptosis in cell lines that had wildtype p53 but not
in cell lines with a mutant or no p53 expression (91). TBB and DMAT also induced p53
expression and apoptosis in biliary tract cancer cells (92). However, the direct
involvement of NQO2 in inhibitor-induced apoptosis has not been demonstrated. In
Chapter 4, the inhibition of NQO2 by TBB, TBBz, and DMAT will be characterized, and
cellular studies with these compounds will be presented in Chapter 6.

22

1.4.4

DNA Intercalating Agents

In a virtual screen for NQO2 inhibitors, a number of planar molecules were identified
(93, 94). Among these were 9-aminoacridine (9AA) and imidazoacridine-6-one C1311
(C1311), which were also known to intercalate DNA. While DNA intercalating agents
can cause DNA damage leading to p53 activation, 9AA induced p53 expression
independent of genotoxic stress (82). C1311 was also shown to be cytotoxic to a number
of solid tumors and leukemia, but p53 status was not a determinant of the inhibitor’s
efficacy (95). When C1311 was modified so that the DNA intercalating properties were
diminished without changing its ability to inhibit NQO2, it became less cytotoxic (96).
From these findings, even though NQO2 inhibition was not responsible for the
cytotoxicity of the compounds, p53 could still be modulated in an NQO2 dependent
manner. In chapter 5, an investigation into whether other DNA intercalating agents can
also inhibit NQO2 or not will be presented.

1.4.5

Imatinib and Nilotinib

Imatinib and nilotinib are inhibitors of BCR-Abl. In normal cells, wild-type Abl is under
strict regulation and remains inactive. In CML, a chromosomal translocation of the Abl
gene to the BCR gene makes the fusion gene BCR-Abl. This renders the gene product
BCR-Abl kinase constitutively active. By binding to the ATP site of BCR-Abl, imatinib
and nilotinib inhibited the unregulated activity of BCR-Abl and reversed the oncogenicity
of CML (1). Using an inhibitor-conjugated affinity matrix, two groups independently
showed that NQO2 was a prominent unintended non-kinase target of imatinib and
nilotinib (3, 4). This interaction was further characterized by X-ray crystallography, but
how NQO2 inhibition contributes to the efficacy of these inhibitors is currently unknown
(97). Using a mouse CML model, leukemic cells deficient of p53 were less sensitive to
the cytotoxic effects of imatinib, even though BCR-Abl was inhibited (7). This showed
that p53 was partially responsible for the antiproliferative effects of imatinib, and points
to the possibility that NQO2 was involved.
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1.4.6

Melatonin

Melatonin is a hormone pivotal to the regulation of circadian rhythm, which was shown
to have anticancer effects (98). Using radioactive-labeled melatonin, two high affinity
targets (MT1 and MT2) and a low-affinity target (MT3) were discovered in hamsters
(99). MT1 and MT2 were identified as membrane bound G-protein coupled receptors,
and MT3 was identified as NQO2 (15). At one nanomolar concentration (1 nM),
melatonin induced p53 expression (100). However, the induction of p53 was likely
caused by MT1 and MT2 interactions because NQO2 inhibition would require a greater
concentration of melatonin (KI = 130 µM; (101)). Based on the melatonin moiety, a
number of high affinity NQO2 inhibitors were developed (101). The compound with the
3

strongest affinity was S29434 with an IC50 of 14 nM, and it was recently used to study
the NQO2-mediated toxicity of paraquat and the generation of ROS by NQO2 (47, 49).
As high affinity inhibitors of NQO2 such as S29434 continue to be used, it would offer
insight into how targeted NQO2 inhibition affects cell signalling pathways.

1.4.7

Resveratrol

Resveratrol is an antioxidant commonly found in grape skins and red wine. This
compound has been studied intensively due to its potential role in cardioprotection and
cancer prevention. Using a resveratrol-immobilized affinity column, NQO2 was
identified to be a prominent target of resveratrol (14). To date, twenty other targets have
been identified, but resveratrol binds to NQO2 with the highest affinity (Kd = 35nM)
(102). Several studies have shown that resveratrol induced p53 expression, but the
concentrations used in these experiments would also bind to targets other than NQO2
(103, 104). As such, it is currently unclear how the inhibition of NQO2 by resveratrol
contributes to p53 regulation.

3

S29434 was initially named as NMDPEF: N-[2-(2-methoxy-6H-dipyrido[2,3- a:3,2-e]pyrrolizin-11yl)ethyl]-2-furamide]
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1.4.8

Effects of NQO2 Inhibition

In this section, several inhibitors of NQO2 that are cytotoxic to cells were highlighted.
Some of these compounds affected apoptosis and p53 induction independent of NQO2
catalysis. Many of the inhibitors also bound to a wide range of proteins while others
intercalated DNA. In addition, inhibitors of NQO2 can suppress NF-κB and affect
AKT/Rb/Cyclin D1 signalling, which can modulate p53 (18, 19, 105). In light of the
complex regulation of p53, it is difficult to specify how NQO2 inhibitors affect p53
protein levels through direct binding to NQO2. Since inhibitors have the potential to alter
NQO2’s function as a flavin redox switch by stabilizing NQO2 in either oxidized or
reduced states, these inhibitors could directly modulate p53 levels though NQO2
interactions.

1.5

Scope of Thesis Project

NQO2 is an enzyme inhibited by a myriad of compounds and has cellular signalling
functions. My hypothesis is that NQO2 functions as a flavin redox switch that senses
intracellular NRH and recognizes many potential cytotoxic compounds to modulate p53
levels in cells. In this thesis, the structural understanding of how NQO2 functions as a
flavin redox switch was advanced and how inhibitors interact with NQO2 were
investigated. The studies of inhibitors were also extended into cellular systems to show
that some inhibitors do modulate p53, but they do so in an unexpected manner.
In preparing recombinant NQO2 expressed in Escherichia coli, it was found that NQO2
lacked the co-enzyme FAD, which prevented accurate analysis of kinetic and structure
studies. This led to the development of a method to fully reconstitute NQO2 with FAD
(Chapter 2). Overcoming this hurdle, the oxidized NQO2 structure with the inhibitors PQ
and CQ were solved. Next, the first crystal structure of reduced NQO2-inhibitor complex
was obtained by reducing NQO2-CQ crystals in an anoxic environment. A global
conformational change of NQO2 was seen in the reduced state, which showed that NQO2
shared common features with other flavin redox switches (chapter 3).
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The identification of NQO2 as a target of CK2 inhibitors prompted a kinetics and
structural investigation with these inhibitors. Using a modified inhibited-kinetic model,
the degree to which TBB, TBBz, and DMAT competed with the dihydronicotinamide cosubstrate or the quinone substrate was determined. Specifically, TBBz was found to bind
oxidized NQO2 exclusively and DMAT bound both oxidized and reduced NQO2 with
similar affinities, while TBB bound to NQO2 with a low affinity. Compared to the ATP
binding site of CK2, the electrostatic potential of the NQO2 active site was different in
charge. The difference in how the compounds bound NQO2 and CK2 indicated that the
binding of NQO2 by kinase inhibitors was fortuitous rather than by design (Chapter 4).
Next, three DNA intercalating agents were identified as novel inhibitors of NQO2. EtBr,
AO, and doxorubicin were found to inhibit NQO2 with nanomolar affinities. Specifically,
EtBr and AO were identified to be the highest affinity reduced-state inhibitors of NQO2.
Structural analysis of these compounds with reduced NQO2 confirmed that hydrogen
bond network in the NQO2 active site was different compared to its oxidized active site.
It was further shown that a non-toxic concentration of AO could inhibit NQO2 catalysis
in cells, thus AO is a suitable mechanistic probe of NQO2 function in cells (Chapter 5).
To further understand how inhibitors affect the signalling role of NQO2, NQO2
inhibitors were studied in tissue cultures. Endogenous NQO2 was knocked out in human
HCT116 cancer cells using CRISPR/Cas9 technology to compare the role of NQO2 in
cells treated with substrate, co-substrate, and inhibitors. It was found that while NQO2
status did not affect the cytotoxicity of NQO2 inhibitors, the presence of NQO2 affected
how inhibitors modulated p53 levels (Chapter 6).
Using both structural and cellular techniques, the work presented in this thesis has
advanced the molecular understanding of how NQO2 behaves as a flavin redox switch.
Reduced NQO2 in complex with four different inhibitors were characterized in detail and
together illustrated that NQO2 could be differentially modulated by state-specific
inhibitors. In this regard, several anoxic techniques were also developed in
crystallography and ITC to study reduced NQO2. Cellular investigations revealed that
NQO2 modulation of signalling events was a very complex process. Altogether, this
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thesis supports the role of NQO2 as a flavin redox switch and shows that inhibitors could
modulate NQO2 in ways in addition to inactivating NQO2 catalysis.
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Chapter 2

2

Flavin Adenine Dinucleotide Content of Quinone
Reductase 2: Analysis and Optimization for StructureFunction Studies4

Quinone reductase 2 (NQO2) is a broadly expressed enzyme implicated in responses to a
number of compounds, including protein kinase inhibitors, resveratrol, and antimalarial
drugs. NQO2 includes a flavin adenine dinucleotide (FAD) co-enzyme, but X-ray
crystallographic analysis of human NQO2 expressed in Escherichia coli showed that
electron density for the isoalloxazine ring of FAD was weak and there was no electron
density for the adenine mononucleotide moiety. Reversed-phase high-performance liquid
chromatography (HPLC) of the NQO2 preparation indicated that FAD was not present
and only 38% of the protomers contained flavin mononucleotide (FMN), explaining the
weak electron density for FAD in the crystallographic analysis. A method for purifying
NQO2 and reconstituting with FAD such that the final content approaches 100%
occupancy with FAD is presented here. The enzyme prepared in this manner has a high
specific activity, and there is strong electron density for the FAD co-enzyme in the
crystal structure. Analysis of NQO2 crystal structures present in the Protein Data Bank
indicates that many may have sub-stoichiometric co-enzyme content and/or contain FMN
rather than FAD. This method of purification and reconstitution will help to optimize
structural and functional studies of NQO2 and possibly other flavoproteins.

2.1

Introduction

Quinone reductase 2 (NQO2) is an unusual enzyme with an interesting history. During
the early 1960s, Williams-Ashman and coworkers observed that rat tissue extracts,
especially from kidney, liver, and heart, have the ability to couple the oxidation of
dihydronicotinamide riboside (NRH) to the reduction of menadione. This novel enzyme
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activity could be distinguished from NAD(P)H-linked reducing activities because the
NRH-dependent activity was inhibited by estradiol but not by dicoumarol (1). The
enzyme in question was purified from bovine kidney and shown to include tightly bound
flavin adenine dinucleotide (FAD) as a co-enzyme. At the time, this was the only enzyme
known to couple oxidation of NRH to reduction of compounds such as menadione, and
its physiological function was a mystery. Because a degradative pathway for NRH was
not known, Williams-Ashman and coworkers speculated that the enzyme may unction to
oxidize cellular NRH so that the resulting nicotinamide riboside (NR) could be degraded.
These early observations did not receive further attention until 1990 when a human
cDNA (complementary DNA) corresponding to the enzyme was discovered (2). The
sequence had very strong similarity (49% identity) to quinone reductase 1 (NQO1), and
on this basis the protein product was defined as ‘‘quinone reductase 2’’ (NQO2). The
connection between NQO2 and the enzyme purified by the Williams-Ashman group was
finally made in 1997 when Talalay and coworkers published a detailed enzymatic
characterization of NQO2 and showed that it had properties similar to those described by
Williams-Ashman and coworkers (3).
NQO2 remains a fascinating and enigmatic enzyme. The substrates and physiological
function of NQO2 are not well defined. NQO2 is the only enzyme listed in the BRENDA
database (http://www.brenda-enzymes.org) that preferentially uses NRH as a reductant,
but the biological ‘‘rationale’’ for this preference is not obvious and it is not known what
nicotinamide derivative is the dominant co-substrate under physiological conditions. Its
‘‘sister’’ enzyme, NQO1, uses NADH or NADPH as a co-substrate and is thought to
provide a cytoprotective function, acting as a detoxification protein that catalyzes an
obligatory two-electron transfer to quinone substrates, thereby preventing a single
electron reduction and the generation of reactive radical species (4). Despite the structural
similarities between the enzymes, an analogous cytoprotective function for NQO2 is not
consistently supported by the available data; however, NQO2 is receiving increasing
attention because of its interaction with, and/or modification of, a number of drugs and
biologically active molecules, including kinase inhibitors, resveratrol, and antimalarial
drugs (5).
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NQO2 catalysis proceeds via a ping-pong kinetic mechanism, where the bound FAD coenzyme is first reduced by NRH or a related dihydronicotinamide derivative and then the
substrate replaces the nicotinamide at the active site. NQO2 is inhibited by compounds
with planar aromatic ring systems, and in all cases examined so far the inhibitors bind
adjacent to the isoalloxazine ring of FAD and are coordinated by tryptophan residues in
the catalytic pocket. Our interest in NQO2 arose because it was identified as a target for
two inhibitors of the protein kinase CK2 (6). To understand the specificity determinants
for this interaction, we co-crystallized a recombinant form of NQO2 with the inhibitors;
although the crystals diffracted to high resolution and yielded excellent electron density
maps for protein atoms, the electron density for the FAD co-enzyme was weak and there
was no electron density for the inhibitors. We traced the origin of this problem to a substoichiometric amount of FAD in the enzyme preparation, resulting in a low occupancy
for bound FAD in the crystals. The relatively low occupancy of FAD in the crystals
means that there is a smaller contribution from the co-enzyme to the diffraction
intensities, which is accounted for in the crystallographic model by elevated atomic
displacement parameters (ADPs) for the FAD. An analysis of the ADPs for the FAD coenzyme in available NQO2 structures indicates that this may be a fairly common
occurrence for recombinant NQO2 expressed in Escherichia coli. To obtain stronger
electron density for FAD and bound substrate or inhibitor, a simple step was added to the
purification procedure that yields enzyme with a stoichiometric amount of FAD. Crystals
of this NQO2 preparation yield greatly improved electron density maps for the entire
FAD co-enzyme, and this modification will help us to obtain detailed information on
inhibitor binding.

2.2
2.2.1

Materials and Methods
Reagents

FAD, flavin mononucleotide (FMN), phenylmethanesulfonyl fluoride (PMSF), and
bovine serum albumin (BSA) were purchased from Sigma–Aldrich. Tris base,
(NH4)2SO4, Hepes, NaH2PO4, and NaCl were purchased from EMD Chemicals.
Lysozyme, ampicillin, dithiothreitol (DTT), and guanidine–HCl were purchased from
Bioshop Canada. Routine protein determinations were made using the Lowry assay with
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a BSA standard. Enzymatic substrates 3-(4,5-dimethylthiozol-2-yl)-2,5diphenyltetrazolium (MTT), 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine
(SCDP), and menadione were purchased from Sigma–Aldrich.

2.2.2

Cloning and Protein Expression

Full-length human NQO2 was cloned into the vector pPro-Ex HTa (Invitrogen) to a
His6–NQO2 fusion construct with a tobacco etch virus (TEV) protease cleavage site
between the hexahistidine tag and NQO2. The construct was verified by sequencing and
transformed into an E. coli BL21(DE3) background for protein expression. Cultures were
grown at 37°C in 2×YT medium with ampicillin (3 mM) to an OD600 of 0.6 to 0.9, and
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 4.2 mM), cells
were grown for an additional 4 h. Cells were harvested by centrifugation and resuspended
in 50mM sodium phosphate, 500 mM NaCl, and 20 mM imidazole (pH 7.0) (buffer A),
treated with lysozyme (0.1 mg/ml) and PMSF (1 mM), and lysed using a French press at
10 kPa.

2.2.3

Protein Purification

All steps were carried out at 4 °C. The cell lysate was applied to a Chelating Sepharose
Fast Flow column (5 ml, GE Healthcare) with bound Ni2+ and equilibrated with buffer A.
The column was washed exhaustively with buffer A, and protein was eluted by raising
the imidazole concentration to 250 mM. NQO2-containing fractions were treated with
TEV protease (7) at a 1:100 protease/ protein ratio, including DTT (5 mM), at 4 °C
overnight. Three further additions of TEV protease and DTT were made at 6-h intervals;
complete cleavage of the affinity tag was confirmed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE), and untagged NQO2 was dialyzed into
50 mM Tris–HCl (pH 8.0) in preparation for anion-exchange chromatography. The
partially purified NQO2 was applied to a 1.6 × 15-cm column of Q-Sepharose HP (GE
Healthcare) equilibrated with 50 mM Tris–HCl and eluted with a linear gradient of NaCl
from 0 to 500 mM over 200 ml. Fractions containing NQO2 were pooled, concentrated to
5 ml, and applied to a 2.6 × 65-cm column of Superdex 200 (GE Healthcare) equilibrated
with 50 mM Tris–HCl and 150 mM NaCl (pH 8.0) and running at 2 ml/min. Fractions
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containing NQO2 were pooled and concentrated to 15 to 35 mg/ml by ultrafiltration.
Purified NQO2 was aliquoted, flash-frozen, and stored at -80 °C for analysis and
crystallization.

2.2.4

Optimization of FAD Content in NQO2

To remove bound FMN and achieve stoichiometric amounts of bound FAD, the
purification method outlined above was used with the following changes. Pooled
fractions from the anion exchange column were concentrated to 5ml (protein
concentration ~10 mg/ml or 390 µM) and supplemented with guanidine–HCl and FAD to
final concentrations of 3 M and 10 mM, respectively. The solution was incubated on ice
for 5 min and applied to the gel filtration column equilibrated with 50mM Tris–HCl, 150
mM NaCl, and 10 µM FAD (pH 8.0).

2.2.5

Crystallization, X-ray Diffraction, and Refinement

NQO2 was crystallized by hanging drop vapor diffusion against reservoirs containing 0.1
M Hepes and 1.3 to 2.0 M (NH4)2SO4 (pH 7.0). Data were collected at beamline CMCF-1
of the Canadian Light Source or a laboratory source. Data were processed using
MOSFLM (8) and Scala (9); structure solution and refinement was carried out using
PHENIX (10) with 1QR2 (11) as the starting model.

2.2.6

Determination of Flavin Nucleotide Content in NQO2
Preparations

The amounts of NQO2 in the final preparations (Table 1) were determined by amino acid
analysis (Advanced Protein Technology Centre, Hospital for Sick Children, Toronto,
Canada, http://www.sic kkids.ca/Research/APTC/Amino-Acid-Analysis/index.html). The
FAD and FMN contents of NQO2 were quantified by reversed-phase HPLC based on a
published method (12). To release bound nucleotide, samples of NQO2 were heated to
100 °C for 10 min and passed through a syringe filter (0.45 µm nominal pore diameter) to
remove denatured protein. To resolve FAD and FMN, a Symmetry C300 C18 column
(Waters) was developed isocratically with 10% (by volume) methanol and 10 mM
ammonium acetate (pH 5.0). The eluent was monitored at 450 nm, and integrated peak
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areas were calibrated to the amount of flavin nucleotide using a series of 50-µl injections
of mixtures containing 86 to 860 pmol of FAD and 156 to 1560 pmol of FMN. NQO2
samples were diluted to a concentration of less than 40µM so that less than 2000 pmol
FAD/FMN would be sampled in each 50-µl injection.

2.2.7

Steady-state Kinetic Assay

Enzyme activity was measured using a coupled assay, where menadione reduced by
NQO2 subsequently reduces MTT. The assay buffer contained 240 µM (0.1 mg/ml)
MTT, 500 µM SCDP as co-substrate (13), and 50 µM menadione as substrate. The assay
was carried out in a 1-ml volume under stirring at 30 °C. The reaction was initiated by
injection of 2 to 3 ng (1 µl of 2–3 mg/ml) of NQO2-containing solution. The change in
absorbance was monitored at 610 nm using a Cary 100 spectrophotometer with
associated kinetics software (Varian Instruments). The change in absorbance was
converted to moles of menadione reduced per minute using an extinction coefficient for
MTT of 11.3 × 103 M-1 cm-1.

2.2.8

B-factor Analysis

Average atomic displacement factors (ADPs), or B-factors, were calculated using the
‘‘What If’’ web interface (http://swift.cmbi.ru.nl/servers/html/index.html) and Moleman
(http://xray.bmc.uu.se/usf/). The average ADPs and normalized ADPs (nADPs) for FAD,
and the separate FMN and adenosine monophosphate (AMP) moieties, were calculated in
Excel. Hydrogen atoms were not included in these calculations.
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2.3
2.3.1

Results
Expression, Purification, and Crystal Structure Analysis of
NQO2

NQO2 was expressed as a hexahistidine-tagged construct with a TEV protease cleavable
linker. After affinity purification and removal of the affinity tag, NQO2 was purified by
ion exchange and gel filtration chromatography. Analysis of the final preparations by
SDS–PAGE indicated that the affinity tag had been removed and the protein was greater
than 90% pure (Figure 2.1). This method of purification yielded NQO2 that readily
formed crystals diffracting to high resolution. For preparation 1, the refined structure
yielded excellent agreement with crystallographic data and good stereochemical
parameters (Table 2.1). However, the average ADP for the FAD co-enzyme was 40.4Å2,
nearly double the average ADP for protein atoms (22.3 Å2) and higher than the average
solvent ADP (30.5 Å2). Closer analysis showed that the FAD could be divided into FMN
and AMP on the basis of average ADP values of 28.2 and 57.2 Å2, respectively (Table
2.1). Consistent with these high ADPs, electron density for the isoalloxazine ring and
associated ribityl was relatively weak and discontinuous and was almost absent for the
AMP moiety (Figure 2.2A).

Figure 2.1 SDS-PAGE Analysis of Purified NQO2.
The final preparation 1 (left lane) and preparation 2 (right lane) were analyzed, and the
positions of molecular weight markers (kDa) are shown.
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Table 2.1 Crystallographic Data and Refinement
NQO2 Preparation 1
Wavelength (Å)
0.9791
Space Group
P212121
Unit Cell Dimenstions (Å)
55.95, 83.15, 106.57
Resolution
35.5 - 1.84 (1.94 - 1.84)a
Rsym
0.050 (0.168)a
I/σ(I)
24.8 (9.8)
Completeness
99.1 (94.6)
Redundancy
7.3 (6.6)
Unique Reflections
55611
Rwork/Rfree
0.184/0.218
Ramachandran Plotb (%)
Most Favoured
89.2
Additionally Allowed
10.3
Generously Allowed
0.5
Disallowedb
0
RMS Deviations
Bond Lengths (Å)
0.018
Bond Angles (degrees)
1.795°
Dihedral Angles (degrees)
17.7°
2
Mean B values (Å )
Protein All Atoms
22.3
Main Chain Atoms
20.8
Side Chain Atoms
23.5
Solvent
30.5
FAD
40.4
FMN
28.2
AMP
57.2
a
b

Values in parentheses represent the highest resolution shell
As defined in Procheck (14).

NQO2 Preparation 2
1.5418
P212121
56.45, 82.99,106.49
15.0 - 1.96 (2.07 - 1.96)a
0.066 (0.273)a
14.8 (4.8)
97.7 (95.7)
4.0 (3.9)
34670
0.158/0.211
89.7
9.8
0.5
0
0.018
1.665°
19.1°
19.3
17.7
20.6
27.5
20.4
13.9
29.3
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Figure 2.2 Electron Density Maps for FAD in NQO2 Preparations.
Electron density maps (2Fo-Fc, contoured at 1.2 𝜎) are shown for the FAD molecule in
refined NQO2 crystal structures from preparation 1 (A), which contained 0.32
equivalents of FMN per protomer, and preparation 2 (B), which was saturated with FAD.
Crystallographic data and refinement statistics for the two structures are provided in
Table 2.1.

2.3.2

Analysis and Optimization of FAD Content of NQO2

The relatively high ADPs and weak electron density for the bound co-enzyme prompted
us to measure the flavin content of the NQO2 preparation. Using HPLC, FAD was not
detectable in preparation 1; instead, 0.38 equivalents of FMN were present per NQO2
protomer (Table 2). We attempted to increase the FAD content of the enzyme by simply
adding 100 µM FAD to the protein solution obtained after Ni2+-NTA (nitrilotriacetic
acid) affinity chromatography, which increased the amount of bound FAD but failed to
exchange FAD for FMN (data not shown). We also attempted, unsuccessfully, to
exchange FMN for FAD by gel filtration chromatography in the presence of 10 µM FAD
(data not shown). The expected KD for flavin co-enzymes is in the mid- to low-nanomolar
range (15) and a very slow rate of exchange is consistent with our inability to displace
bound FMN. To facilitate rapid exchange of bound FMN with FAD, guanidine was
included in the buffer to partially denature the protein (15); NQO2 was incubated briefly
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on ice in a solution of 3 M guanidine–HCl along with a high concentration (10 mM) of
FAD and then gel-filtered in a nondenaturing buffer (preparation 2) (Figure 2.1 and Table
2.2). NQO2 prepared in this manner is fully saturated with FAD, and crystals formed
from this preparation yield structures with relatively low ADPs for the bound FAD
(Table 2.1). Electron density maps for the refined structure are strong and continuous for
the entire FAD molecule (Figure 2.2B).

2.3.3

Spectroscopic Properties of NQO2

The absorption spectrum of NQO2 that is fully saturated with FAD (preparation 2) is
provided in Figure 2.3 along with the absorption spectrum for preparation 1, which had
0.38 equivalents of FMN per protomer and no FAD. The two spectra have been adjusted
to represent a solution of NQO2 at a concentration of 1 mg/ml. At wavelengths above
320nm, the spectra appear to be qualitatively similar and are characteristic of the oxidized
flavin (16). The peak at 450 nm has absorbance of 0.20 and 0.52 for preparations 1 and 2,
respectively, roughly in line with the relative flavin contents of the two preparations
determined by HPLC (Table 2.2).

Figure 2.3 Absorbance Spectra of NQO2 Preparations 1 and 2.
Shown are the absorbance spectra for NQO2 preparation 1, with 0.38 equivalents of
FMN (gray curve), and preparation 2, which is fully saturated with FAD (black curve).
The curves have been scaled to represent the proteins at a concentration of 1 mg/ml.
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Table 2.2 Flavin Co-enzyme Content of QR2 Preparations
Fractional Flavin Saturationa
kcatb (s-1)
Preparation
FMN
FAD
Total
1c
0.38 ± 0.03
0
0.38 ± 0.03
31 ± 1
d
2
0
1.2 ± 0.1
1.2 ± 0.1
39 ± 3
a

Average ± S.D. for three determinations.
Average ± S.D. for four determinations with 500 µM SCDP as co-substrate and 50 µM
menadione as substrate.
c
protein purification was unmodified
d
protein purification was modified by incubation with 3M guanidine and 10mM FAD
prior to gel filtration
b

At wavelengths in the UV, the presence of the adenine ring in the bound FAD of
preparation 2 increases the absorption of the complex and blue-shifts its maximum from
280 to 273 nm compared with preparation 1, which contains only FMN. NQO2 that is
fully saturated with FAD has an absorption maximum of 273 nm with an absorbance (1
mg/ml solution) of 3.73, yielding an extinction coefficient at 273 nm of 1.06 × 105 M-1
cm-1 with an A273/A450 ratio of 7.2. The extinction coefficient at 280 nm is slightly lower
at 1.02 × 105 M-1 cm-1 with an A280/A450 ratio of 6.9. Together, the absorption maximum at
273 nm with an A273/ A450 ratio of 7.2 should be a reasonably good indicator that an
NQO2 preparation is fully saturated with FAD. Note that if one is not concerned with the
nature of the bound flavin—whether FMN or FAD—the flavin content of NQO2 can be
determined spectrophotometrically by denaturation of a known amount of NQO2 with
0.2% SDS and then measure the liberated total flavin (as FMN and/or FAD) at 473 nm,
where the two have the same extinction coefficient of 9200 M-1 cm-1 (12).

2.3.4

FAD B-Factors and Occupancy in NQO2 Crystal Structures

In the NQO2 crystals from preparation 2, which is saturated with FAD, the FMN moiety
exhibits average ADPs that are significantly lower than the average ADPs for the protein
(13.9 Å2 for FMN moiety vs. 19.3 Å2 for all protein atoms), whereas the AMP portion has
average ADPs that are close to those of the bound solvent (29.3 Å2 for the AMP moiety
vs. 27.5 Å2 for bound solvent). Because there is no difference in the occupancy in this
case (i.e., there is no free FMN associated with the protein according to the HPLC
analysis), the difference in ADPs must be due to increased motion or disorder in the AMP
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portion of FAD. This is consistent with a surface accessibility calculation showing that
less than 14% of the FMN portion is accessible to solvent compared with just over 27%
for the AMP portion.
The FAD ADP analysis was extended to NQO2 structures deposited in the Protein Data
Bank (as of March 2011). To make comparisons of ADP between different structures, the
ADPs were normalized to the protein ADP (nADP) (17); an nADP is equal to the
difference between the ADP of the atom in question and the average ADP for the protein
divided by the standard deviation of the protein ADPs. Thus, nADPs have a mean of 0
and a standard deviation of 1, facilitating comparisons between structural models refined
against different crystallographic datasets. The average nADP for the entire FAD
molecule ranges from 0 to 3 for the available NQO2 structures (Figure 2.4, bottom
panel). Each structural model incorporates FAD at full occupancy (i.e., an occupancy of 1
in the coordinate file). Given that bacterial cultures can become depleted in FAD during
protein overexpression, the most likely explanation for the range of nADPs for the FAD
moiety is that the structures have sub-stoichiometric amounts of FAD and/or are
populated by FMN in place of FAD. For example, in the case of the NQO2 preparations
we have examined, the nADP for FAD in crystals from preparation 1, with only 0.38
equivalents of FMN per subunit, was roughly 1.4 compared with an nADP of 0 for
preparation 2, which was fully saturated with FAD.
The FAD in these structures was further analyzed by dividing it into FMN and AMP
portions (Figure 2.4, top and middle panels, respectively). Most of the structures,
including that derived from NQO2 preparation 2 (this study), had negative values for the
normalized ADP of FMN, indicating that its overall ADP is lower than the average for
the protein. Based on these observations and the known FAD content of preparation 2, it
is possible that structures with normalized ADPs above approximately -0.5 for the FMN
portion have less than a full equivalent of bound co-enzyme. Similarly, for the AMP
portion, a normalized ADP above approximately 1 may be due to the presence of FMN
rather than FAD and/or the presence of apo protomers.
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Figure 2.4 nADP Distribution for FAD in NQO2 Crystal Structures.
The average nADPs for the FAD molecules in available NQO2 crystal structures are
shown in the bottom panel. Also shown are the average nADPs for the FMN and AMP
portions (top and middle panels, respectively). All of the crystal structures except 3FW1
were in space group P2 2 2 with an NQO2 dimer in the asymmetric unit; the gray and
black bars represent the A and B chains of the dimmer, respectively. 3FW1 was
crystallized in space group I422 with one protomer in the asymmetric unit. The structures
are described in the following references: 1QR2 and 2QR2, Foster and coworkers (11);
2QWX, 2QX4, 2QX6, 2QX8, and 2QX9, Calamini and coworkers (18); 1XI2, Fu and
coworkers (19); 3GAM and 3G5M, Maiti and coworkers (20); 2BZS, Abu Khader and
coworkers (21); 2QMY and 2QMZ, Fu and coworkers (22); 1SG0, Buryanovskyy and
coworkers (23); and 3FW1, Winger and coworkers (24).
1

1

1
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2.4

Discussion

It can be difficult to achieve stoichiometric ligand occupancy in protein crystals because
the crystallization conditions often include high concentrations of salts and other
molecules that can compete with and/or weaken the binding of the ligand. The result is
that ligand will be present at partial occupancy, which manifests itself during refinement
as elevated ADPs and relatively poor electron density for the ligand. This problem is
compounded in NQO2 because the FAD co-enzyme itself is noncovalently bound.
Ligands that bind tightly to NQO2 generally contain a planar polyaromatic moiety that
stacks on the isoalloxazine ring of FAD; therefore, if the FAD co-enzyme itself is present
at less than 1:1 stoichiometry, obtaining crystals with a full ligand occupancy will be
impossible and the electron density for the bound ligand will be relatively poor.
Flavin synthesis in E. coli is sufficient to support exponential growth and continues for
up to 2 h after reaching stationary phase (25). However, overexpression in E. coli of
FAD-containing proteins such as NQO2 can result in depletion of the flavin pool and/or
insufficient production of FAD from FMN, leading to production of proteins with substoichiometric amounts of bound FAD. E. coli does not have the genes required for flavin
import (26, 27); therefore, the addition of riboflavin to the culture medium will not solve
this problem. Attenuating the expression of the recombinant gene by using a weak
promoter or a lower concentration of IPTG improved the production of hologlycerophosphate oxidase (28), another FAD-linked enzyme. On this basis, differences in
the expression vector and/or culture conditions could result in varying proportions of the
FAD-bound, FMN-bound, and apo NQO2 enzymes that cannot be distinguished by
conventional chromatographic techniques. This might explain some of the variation seen
in NQO2 crystal structures available in the Protein Data Bank.
We wanted large quantities of NQO2 for structural studies, and because the apo form of
NQO2 appears to be quite stable, our approach was to saturate NQO2 with FAD after
overexpression and partial purification. To effect full exchange of FMN with FAD,
NQO2 was incubated for a short time with a high concentration of FAD under partially
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denaturing conditions (3 M guanidine at 4 °C) and then gel-filtered to rapidly remove the
denaturant and unbound FMN. This simple procedure yielded NQO2 that was fully
saturated with FAD and easily crystallized. We are currently using enzyme prepared in
this manner to obtain structures of NQO2 in complex with new ligands, and it is clear
that fully saturating NQO2 with FAD has markedly improved the quality of the electron
density maps.
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Chapter 3

3

Chloroquine Binding Reveals Flavin Redox Switch
Function of Quinone Reductase 25

Quinone reductase 2 (NQO2) is an FAD-linked enzyme and the only known human
target of two antimalarial drugs, primaquine (PQ) and chloroquine (CQ). The structural
differences between oxidized and reduced NQO2 and the structural basis for inhibition by
PQ and CQ were investigated by x-ray crystallography. Structures of oxidized NQO2 in
complex with PQ and CQ were solved at 1.4 Å resolution. CQ binds preferentially to
reduced NQO2, and upon reduction of NQO2-CQ crystals, the space group changed from
P212121 to P21, with 1-Å decreases in all three unit cell dimensions. The change in crystal
packing originated in the negative charge and 4–5º bend in the reduced isoalloxazine ring
of FAD, which resulted in a new mode of CQ binding and closure of a flexible loop
(F126 – L136) over the active site. This first structure of a reduced quinone reductase
shows that reduction of the FAD cofactor and binding of a specific inhibitor lead to
global changes in NQO2 structure and is consistent with a functional role for NQO2 as a
flavin redox switch.

3.1 Introduction
Despite 6 decades of routine use in treating malaria, the pharmacologic mechanisms of
primaquine (PQ) and chloroquine (CQ) are not completely understood, although it is
known that the two antimalarial drugs work at different stages of the Plasmodium life
cycle. Malaria begins when Plasmodium sporozoites gain entry to the bloodstream via a
bite from an infected mosquito, after which the parasite infects liver cells. During this
liver stage infection, the 8-aminoquinoline, PQ (Figure 3.1), acts as hepatic schizontocide
to clear infection (1). If left untreated, the parasites mature into merozoites and are
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released into the bloodstream to infect erythrocytes. In erythrocytes, the parasites either
spawn into more merozoites or mature into gametocytes capable of infecting mosquitoes
through additional bites. During the erythrocytic stage of infection, the 4-aminoquinoline,
CQ (Figure 3.1), acts as a blood schizontocide to clear infection (2). As such, PQ and CQ
are routine medications for treating malaria. In recent years, however, the emergence of
chloroquine-resistant Plasmodium falciparum has rendered CQ ineffective in most
endemic areas. PQ, on the other hand, is still widely used as a prophylaxis of malaria
because parasites rarely exhibit resistance against this drug.

Figure 3.1 Structures of Primaquine and Chloroquine
Primaquine (left) and chloroquine (right) are two antimalarial drugs that act at different
stages of the Plasmodium life cycle.
In terms of therapeutic mechanisms, PQ is thought to work by generating toxic oxygen
species via its reactive metabolites (3). CQ, on the other hand, is thought to prevent a
detoxification of excess heme in the parasite, which is generated as a result of its
metabolism of hemoglobin (3). Despite these findings, no protein target has been
identified for either drug in the parasite, causing some controversy about the mode of
action of the two drugs (4, 5). This led Graves and coworkers (6) to search for target
proteins of CQ and PQ using a proteomics approach. Surprisingly, no parasitic protein
targets were identified; instead, two human proteins present in infected erythrocytes,
quinone reductase 2 (NQO2) and aldehyde dehydrogenase 1, were identified. Of the two
proteins, NQO2 was potently inhibited by concentrations of the quinoline drugs used in
clinical treatment, whereas aldehyde dehydrogenase 1 was not. It is not known whether

54

the inhibition of NQO2 by PQ and/or CQ plays a role in the antimalarial effects of the
drugs.
The identification of NQO2 as a human target of PQ and CQ is intriguing because both
drugs are used to treat non-malarial diseases. For instance, PQ is used to treat
pneumocystis pneumonia and is active against leishmaniasis and trypanosomiasis in vivo
(7–9). Similarly, CQ is used to treat rheumatoid arthritis, systemic lupus erythematosus,
and amoebic hepatitis; is under clinical trials for use in HIV-1/AIDS; and is being
investigated for use in cancer chemotherapy (10–12). Thus, the inhibition of NQO2 may
contribute to the therapeutic effects of PQ and CQ against diseases other than malaria.
NQO2 is a cytosolic and ubiquitously expressed metalloflavoprotein that catalyzes the
two-electron reduction of quinone substrates. It has been the subject of extensive study
over the last 15 years and binds a number of bioactive compounds, including imatinib
(13, 14), inhibitors against CKII and PKC (15, 16), resveratrol (17), and melatonin (18,
19); however, the only natural substrate identified is ubiquinone, and the physiological
function of NQO2 is not understood (20). NQO2 is a member of the thioredoxin family
of enzymes but is unique in that it uses dihydronicotinamide riboside (NRH) as a
reducing co-substrate rather than NADH or NADPH. The oxidized form of the cosubstrate, nicotinamide riboside, is involved in NAD metabolism (21), but the cellular
source of the reduced form, NRH, is not known, and it is not clear why NQO2 has
evolved to use NRH. In addition to an enzymatic role in quinone reduction, NQO2
stabilizes the p53 tumor suppressor against 20S proteasomal degradation in the presence
of NRH (22, 23). Furthermore, NQO2 is capable of generating reactive oxygen species
(24). Yet the current understanding of NQO2 and its inhibition does not adequately
explain the effects of PQ and CQ on malaria and non-malarial diseases.
PQ and CQ inhibit NQO2 with different mechanisms. Kinetic studies show that PQ and
CQ both inhibit NQO2 in the micromolar range, with KI values of 1.0 and 0.6 µM,
respectively (25), but PQ exhibits competitive inhibition against the reducing co-substrate
(NRH), whereas CQ competes with the quinone substrate. This pattern of inhibition can
be explained by the ping-pong kinetic mechanism that NQO2 uses. The tightly bound
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FAD co-enzyme is first reduced by NRH to FADH2; nicotinamide riboside is replaced by
the quinone substrate, which is then reduced by FADH2. As such, NQO2 can exist as
either the oxidized (NQO2ox) or reduced (NQO2red) form, and inhibitors may have a
higher affinity for one or the other.
To provide a structural basis for the difference in specificity between PQ and CQ, we
solved high resolution crystal structures of NOQ2ox in complex with either PQ or CQ as
well as NQO2red in complex with CQ. The NQO2red-CQ complex is particularly
interesting because CQ is present in a completely different orientation compared with the
NQO2ox-CQ complex and this difference in binding is accompanied by movement of an
active site loop, a change in crystal packing, and a change in space group symmetry. The
structure of the NQO2red-CQ complex provides support for the idea that, in common with
some other flavin-containing proteins (26), NQO2 acts as a redox-sensitive “switch” that
is responsive to the presence of cellular NRH in conjunction with binding of certain
bioactive compounds.
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3.2
3.2.1

Methods
Protein expression and Purification

Recombinant NQO2 was expressed in Escherichia coli and purified as described
previously (27). A critical step in the purification was full reconstitution of the enzyme
with the FAD cofactor. When expressed in E. coli, recombinant NQO2 typically contains
substoichiometric levels of flavin mononucleotide (FMN) and no FAD. A partial
denaturation of NQO2 and reconstitution with FAD was incorporated into the
purification procedure, leading to full saturation of the enzyme with FAD, as reported
previously (27).

3.2.2

Crystallization of NQO2

NQO2ox was co-crystallized with 1 mM PQ or CQ by hanging drop vapor diffusion
against reservoirs containing 0.1 M HEPES, pH 7.5, and 1.3–2.0 M (NH4)2SO4. To
prepare NQO2red-CQ crystals, crystals of NQO2-CQ were soaked in 1 µl of reducingsoak solution consisting of 0.1 M HEPES, pH 7.5, 2.0 M (NH4)2SO4, 10 mM 1-(3sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP; an NRH analog), and 1
mM chloroquine, for 2 min; the soak was repeated until crystals turned pale yellow.
Whereas larger rod shaped crystals (0.5 mm × 0.2 mm) cracked when introduced into the
reducing soak, medium size crystals (0.3 mm × 0.1 mm) remained intact. The reduced
crystals were transferred to a soak of 1 mM chloroquine, 2.0 M (NH4)2SO4, 0.1 M
HEPES, pH 7.5, to decrease the of the amount of SCDP, which may be competitive with
CQ at high concentrations. Crystals were then briefly passed through a cryoprotectant
solution (20% glycerol, 2.0 M (NH4)2SO4, 0.1 M HEPES, pH 7.5) and plunged into liquid
nitrogen. To prevent autoxidation of NQO2, the entire crystal mounting process from
harvesting to cryocooling was performed under an anoxic atmosphere in a glove bag
purged with N2. To prepare for the reduction protocol, the glove bag was initially
evacuated and flushed with nitrogen for 5 min. All soaking solutions were then
deoxygenated by sparging with nitrogen gas inside the glove bag. In the dry nitrogen
atmosphere, crystals and crystal soak solutions quickly evaporated; therefore, to maintain
an appropriate level of humidity, the nitrogen used to flush the glovebag was bubbled
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through a flask of crystallization reservoir solution (0.1 M HEPES, pH 7.5, 2.0 M
(NH4)2SO4).

3.2.3

X-ray Data Collection, Refinement, and Analysis

Data were collected at the CMCF-1 beamline of the Canadian Light Source, processed
using XDS (28) or MOSFLM (29), and merged using Scala (30). The structures were
solved by molecular replacement with Protein Data Bank entry 1QR2 as a starting model
(31); refinement was carried out using PHENIX (32). Given the high resolution of the
crystallographic data, NCS restraints were not used for any of the refinements.
Topology files for PQ and CQ were generated using PHENIX.ELBOW in conjunction
with small molecule crystal structures of the two compounds (33, 34). For refinement of
the NQO2red structure, the FAD topology file was modified to allow bending along the
N5–N10 axis of FAD: the planarity restraints incorporating N5 and N10 of the
isoalloxazine ring were removed so that it was separated into two planes, one
incorporating the pyrimidine ring and the second incorporating the benzyl ring. Also, the
bond length, bond angle, and dihedral angle restraints involving N5 and N10 were
removed. The degree of bending in the isoalloxazine ring was calculated by finding
equations for the two planes using principal component analysis incorporating all atoms
in each of the two planes. The final structures for NQO2ox-PQ, NQO2ox-CQ, and
NQO2red-CQ were deposited in the Protein Data Bank as 4FGJ, 4FGK, and 4FGL
respectively.
To validate the observed changes in FAD structure and, in particular, to assess the
contribution of the FAD and FADH2 stereochemical restraint files to the structure of the
isoalloxazine ring, each model was refined using an identical simulated annealing
strategy with the FADH2 stereochemical restraint file to assess the degree of bending
along the N5–N10 axis. In each case, the refinement was performed three times using the
same starting model with a different random seed to calculate a final average bending
angle. To ensure an “active” convergence to an optimal conformation, FAD in the
starting model of NQO2 was bent to an angle of around 30°.
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3.3
3.3.1

Results
Oxidized NQO2-Primaquine Complex

NQO2 was co-crystallized with PQ in space group P212121. Crystals of NQO2-PQ
diffracted to 1.35 Å and contained a homodimer in the asymmetric unit; the structure was
solved by molecular replacement and refined to an Rfree value of 0.167 (Table 3.1).
Primaquine was initially modeled in a single orientation in both active sites of the
homodimer (Figure 3.2A), and after several rounds of refinement, a second orientation
was incorporated to fully account for the electron density (Figure 3.2B). The occupancies
for bound PQ molecules refined to values of around 0.5 for each of the conformations,
indicating that PQ binds with roughly equal affinity in each mode. In both orientations,
the quinoline ring of PQ is buried in the active site, making planar stacking interactions
with the FAD isoalloxazine ring and the phenyl ring of F178. PQ also makes contact with
additional aromatic residues (W105, F106, and F126), which form the interior wall of the
active site. As well, both orientations of PQ make a water-mediated hydrogen bond with
the side chain of Asn161. In the first orientation of PQ (Figure 3.2A), a water molecule
(position 557 in A chain and 450 in B chain) mediates hydrogen bonding between the
aromatic nitrogen in the quinoline ring and the side chain of N161. In the alternate
orientation (Figure 3.2B), the quinoline ring is flipped 180°, and the water molecule
mediates a hydrogen bond between the 6-methoxy group of PQ and the side chain of
N161.

3.3.2

Oxidized NQO2-Chloroquine Complex

NQO2 catalysis proceeds by a ping-pong mechanism. The reducing co-substrate, NRH,
binds in the active site, reduces the FAD, and then dissociates; the quinone substrate then
enters the active site and undergoes a two-electron reduction. Thus, NQO2 can exist in
either an oxidized (NQO2ox) or reduced (NQO2red) state, and inhibitors of NOQ2 will
exhibit a preference for one or the other. Kinetic studies indicate that CQ exhibits
competitive inhibition against the quinone substrate and therefore binds preferentially to
NQO2red (25). However, high concentrations of CQ will also compete against the
reducing co-substrate, NRH, indicating that CQ also has affinity with NQO2ox. To fully
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characterize CQ binding to NQO2, we co-crystallized NQO2ox in complex with CQ.
NQO2ox-CQ crystals diffracted to 1.4 Å, and the structure was refined to an Rfree of 0.175
(Table 3.1).

Table 3.1 Crystallographic Data Collection and Refinement Statistics.
Crystal
Ligand
Wavelength (Å)
Space Group
Unit Cell Dimensions (Å)

Oxidized NQO2
Primaquine
Chloroquine
1.033217
1.033217
P212121
P212121
56.5, 83.0,
56.37, 83.11,
106.5
106.60

Reduced NQO2
Chloroquine
0.97949
P21
54.31, 105.71,
82.00
β = 90.17°
48.3 - 1.20
0.041 (0.288)
19.3 (4.4)
99.8 (99.9)
3.7
287298
0.1059/0.1362

Resolution
30.1 - 1.35
32.7 - 1.40
a
Rsym
0.066 (0.63)
0.065 (0.50)
a
I/σ(I)
10.4 (2.4)
14.5 (3.7)
a
Completeness
99.5 (98.8)
99.6 (99.0)
Redundancy
4.8
7.3
Unique Reflections
110793
98537
Rwork/Rfree
0.1413/0.1666 0.1325/0.1745
Ramachandran Plotb (%)
Most Favoured
90.7
89.9
89.9
Additionally Allowed
8.8
9.5
9.6
Generously Allowed
0.5
0.5
0.4
Disallowed
0
0
0.1
RMS Deviations
Bond Lengths (Å)
0.008
0.007
0.009
Bond Angles (deg)
1.255
1.223
1.174
Dihedral Angles (deg)
14.594
14.471
14.188
Mean A.D.P. values (Å2)
Protein All Atoms
12.8
18.1
12.7
Main Chain
11.7
16.3
11.3
Side Chain
13.8
19.6
13.8
Solvent
25.0
28.6
25.3
FAD
12.3
17.3
11.4
Inhibitor
17.5
26.3
22.1
a
Values in parentheses refer to the highest resolution shell.
b
Ramachandran plot statistics were calculated using PROCHECK (35).
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Figure 3.2 Binding of Primaquine and Chloroquine to Oxidized NQO2
(A - B) PQ is bound to the A subunit in two alternate conformations. The B subunit of the
NQO2ox-PQ homodimer contained similar electron density and was modeled in the same
way as the A subunit. (C - D) The active sites for the NQO2 ox -CQ structure. Electron
density in the NQO2 ox-CQ subunit A (C) was different from that observed in the B
subunit (D), and CQ was modeled in two alternate conformations in the B subunit. The
electron density represents the final 2Fo - Fc maps contoured at 1σ around the inhibitors.
(E) The two positions of CQ in the B subunit correspond to two different conformations
of the active site loop, comprising residues 126 –136. The active site loop in the “open”
conformation (light shading) accommodates CQ when it is deeply buried in the active
site, whereas the “closed” conformation (dark shading) is adopted when CQ is bound in a
more peripheral location. One-letter amino acid codes are used.
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Electron density for the bound CQ was initially quite poor, but a large peak (greater than
10 σ) in the difference (Fo - Fc) electron density map was used to position the CQ
chlorine atom, after which the rest of the CQ molecule was placed in the remaining
electron density. For the “A” subunit of the homodimer, CQ is present in one position,
with the quinoline ring less deeply buried than primaquine and the aminopentane arm
projecting toward the solvent (Figure 3.2C). In the active site of the “B” subunit,
additional difference density was observed after several rounds of manual adjustment and
refinement, and an alternate orientation of CQ was modeled into the structure (Figure
3.2D). The occupancies for the two modes of CQ binding to the B subunit refined to 0.52
and 0.48. In conjunction with these two positions for CQ, an active site loop consisting of
residues 126–136 was modeled in two different conformations (Figure 3.2E). In the
position of CQ unique to the B subunit, in which the quinoline ring is more deeply buried
in the active site, the bulky aminopentane arm of CQ interferes with the ability of the
126– 136 loop to close over the active site, and therefore the loop adopts an “open”
conformation (Figure 3.2E). There is no evidence of cooperative interactions or
nonequivalence between the two subunits of NQO2, and therefore this minor difference
in CQ binding between the A and B subunits probably originates from different crystal
packing environments.

3.3.3

Reduced NQO2-Chloroquine Complex

The reduced form of NQO2 (NQO2red) was not sufficiently stable to allow for cocrystallization with CQ. To obtain crystals of NQO2red in complex with CQ, crystals of
NQO2ox-CQ were treated with SCDP (an NRH analog) in an anoxic environment until
the crystal was bleached, indicating reduction of FAD to FADH2, and then frozen and
stored in liquid nitrogen for data collection. Data from three such crystals of NQO2red-CQ
were collected and processed (Table 3.2). In all three cases, the crystallographic data for
NQO2red could be processed using the P212121 space group, with unit cell dimensions ~1
Å shorter in all three directions compared with those for NQO2ox-CQ. However, data
processed in P212121 yielded unacceptably high Rsym values, making it clear that the
crystals had undergone a structural transition to a lower symmetry space group with four
rather than two protomers in the asymmetric unit. Data processed and merged in P21
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yielded acceptable Rsym values (Table 3.2), and the highest resolution data set was used
for refinement and analysis (Table 3.1). The NQO2 structure underwent several rounds of
manual rebuilding and refinement to yield an Rfree of 0.17. Analysis of the
crystallographic data indicated the presence of pseudomerohedral twinning, and further
refinement in Phenix using the twin operator (h, - k, -l) yielded an estimated twin fraction
of 0.15, with a final Rfree value of 0.136 and improved electron density maps. This is the
first structure of a reduced quinone reductase, and the combined effects of FAD reduction
and chloroquine binding are described below.

3.3.4

Chloroquine Binding to Reduced NQO2

The reduced isoalloxazine ring is expected to be deprotonated and carry a negative
charge when it is bound to NQO2. In solution, N1 of FADH2 exhibits a pKa of 6.8 (36);
when FAD is bound to NQO2, N1 accepts a hydrogen bond from the amide nitrogen of
G149, making it highly unlikely that N1 is protonated in NQO2red. Instead, the negative
charge, which would be delocalized between N1 and O2, is neutralized by two hydrogen
bonds donated to O2, one from the ring hydroxyl of Y155 and a second from the amide
of G150.
Table 3.2 Space Group Change upon Reduction of NQO2-chloroquine Crystals
Crystal 1a
(1.24 Å resolution)
P212121c
P21c

Crystal 2a
(1.35 Å resolution)
P212121c
P21c

Crystal 3a,b
(1.15 Å resolution)
P212121c
P21c

Unit Cell
a
53.75
53.67
53.90
53.68
54.24
54.29
b
81.68
105.61
81.84
105.56
82.02
105.71
c
105.67
81.68
105.66
81.66
105.71
82.01
β
90
90.14
90
90.35
90
90.16
Rsym
0.171
0.070
0.327
0.061
0.347
0.061
a
Crystals of NQO2ox in complex with chloroquine were soaked with SCDP, an NRH
analogue, to effect reduction of the FAD cofactor.
b
Crystal 3 was used for structure solution, refinement, and detailed analysis.
c
Data were indexed, processed and merged in either P212121 or P21 using Mosflm and
Scala.
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Reduction of FAD drastically changes the nature of its interaction with CQ. In NQO2ox,
CQ tends to be rather deeply buried and able to make direct contact with aromatic
residues that line the back wall of the active site (Figure 3.2C), with the chlorine atom
positioned above C5A of the isoalloxazine ring. In the NQO2red structure, the quinoline
ring of CQ has flipped so that the opposite face interacts with the surface of reduced
FAD, and the chlorine atom is positioned roughly above O2 on the periphery of the
isoalloxazine ring (Figure 3.3A-B). The mode of CQ binding in NQO2red allows CQ to
participate in a water mediated hydrogen-bonding network that is centered on the proton
on N5, a characteristic feature of reduced FAD (Figure 3.3C). The keystone for this
network is a water molecule (HOH 32, 312, 204, and 92 in chains A, B, C, and D,
respectively) that accepts hydrogen bonds from the N5 proton of FAD and also from the
proton on N4 of the CQ quinoline ring. The keystone water donates a hydrogen bond to a
second water molecule (HOH 149, 154, 157, and 63 in chains A, B, C, and D,
respectively) that in turn donates hydrogen bonds to O4 of the FAD and to the carbonyl
oxygen of G174. The relative positions of these water molecules are conserved in all four
subunits of the asymmetric unit. The geometry of the interaction between the keystone
water and the FAD N5 atom deviates from what would be expected for a good hydrogen
bond; the angle between CQ-N4, the keystone water, and FAD-N5 is 79 ± 1° (mean ±
S.D. for four subunits) rather than a more typical angle of 110°. In addition to these
hydrogen bonds, the aromatic rings of W105, F106, F126, and F178 enclose the two
water molecules; indeed, the keystone water appears to donate a hydrogen bond to the
indole ring of W105, whereas the second water may donate a hydrogen bond to the
benzene ring of F178 (37).
The 2Fo - Fc electron density for bound CQ is extremely well defined in one of the NQO2
dimers (C and D chains) of the asymmetric unit, and there is clear density for a third
water molecule in the active sites of the CD dimer (Figure 3.3B). This third water
molecule donates a hydrogen bond to the second water and to the chlorine atom on CQ,
and it accepts a hydrogen bond from the side-chain amide nitrogen of N161. In the
second dimer (A and B chains) of the asymmetric unit, there was additional electron
density for the bound CQ, and therefore a second CQ molecule was included in a slightly
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Figure 3.3 Binding of Chloroquine to reduced NQO2.
(A-B) CQ binds NQO2red active sites in the two dimers of the asymmetric unit; the electron
density corresponds to 2Fo - Fc maps contoured at 1σ around CQ. (A) In the active site of the A
subunit, CQ bound in two alternative positions, one of which corresponds to the position
observed in the C and D subunits, whereas the second is shifted slightly. The electron density and
positions of bound CQ were similar for the B subunit. (B) In the active site of the C subunit, CQ
was modeled in the same single position. The electron density in the D subunit was similar. (C)
The hydrogen bonding network, with the “keystone water” bridging N4 of CQ and N5 of the
FAD isoalloxazine ring. (D) The active site loop (residues 126–136) is shown in the fully closed
conformation (green) observed in NQO2red-CQ; in this state, residue I128 makes van der Waals
contact with CQ. For reference, the conformations of the loop observed in crystals of oxidized
NQO2 are shown in gray.
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different orientation from the first (Figure 3.3A). For the A and B subunits, the third
water molecule was not present. This minor difference in CQ binding between the two
reduced NQO2 dimers in the asymmetric unit may be a product of their interaction with
each other or may be due to differences in the surrounding crystal packing environment.
Regarding the stereochemistry of the bound inhibitors, it is noteworthy that both CQ and
PQ have a single stereocenter and exist as racemic mixtures. For the structures of
NQO2ox with bound PQ or CQ, the electron density for the aminopentane arm was
generally weak, and it was not possible to discern whether the protein selectively bound a
single enantiomer. In the case of NQO2red, however, the (R)-CQ enantiomer was built
into the structure, and there was enough electron density for the aminopentane arm to
exclude binding of the (S)-CQ enantiomer. In this regard, binding of CQ to reduced
NQO2 may be stereoselective for the (R)-enantiomer.

3.3.5

Structural Changes in FAD

Crystals of NQO2ox in complex with CQ were consistently isomorphous with other
oxidized forms, indicating that the CQ itself is not sufficient for the observed structural
change in crystals of the NQO2red-CQ complex. Instead, the origin of the change in
structure is the reduction of the FAD cofactor. The FAD isoalloxazine ring is planar, but
reduction should lead to a “butterfly bend” along the N5–N10 axis (38) (Figure 3.4). The
electron density of the isoalloxazine ring in NQO2red-CQ indicated that the bending upon
reduction is relatively minor. Refinement using a modified stereochemical restraint set
for FAD, in which planar restraints and associated bond and angle restraints around N5
and N10 were removed, indicated an angle of ∼4-5° between the two planes of the
“butterfly wings” (Figure 3.4).
To validate that the small change in the FAD isoalloxazine structure was due to reduction
of the FAD, and not simply removal of stereochemical restraints, the refined NQO2
structures were subjected to simulated annealing refinement against data from both
oxidized and reduced crystals. In the absence of stereochemical restraints around N5 and
N10, the isoalloxazine ring of NQO2ox in complex with PQ refined to an average bend of
∼1.6°; for NQO2ox in complex with CQ, the average bend was 2.3°; whereas for NQO2red
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Figure 3.4 Structural Changes in the Isoalloxazine ring.
(A) Chemical structure and atom designations in the FAD isoalloxazine ring, and the axis
for the “butterfly bend” that is brought about by reduction of FAD to FADH2. (B) An
edge-on view of the structure of the isoalloxazine ring for the following: NQO2ox with PQ
(black), NQO2ox with CQ (red), and NQO2red with CQ (blue). (C) Binding of PQ induces
a slight (∼1.6°) concave bend in the isoalloxazine system, whereas binding of CQ induces
a convex bend of ∼2.3°. Reduction of FAD further increases this bend to 4.8°. To
determine the bend in the isoalloxazine rings, the crystal structures were subjected to
simulated annealing without stereochemical restraints at the N5 and N10 positions. FAD
bending along the N5-N10 axis (butterfly bend) was calculated using the atomic positions
of the dimethylbenzene and pyrimidine “wings” and principal component analysis to find
the angle between the two best fit planes. Error bars, S.D.
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in complex with CQ, the bend was 4.8° (Figure 3.4C). It is noteworthy that for NQO2ox,
PQ brings about a small “upward” bend in the ring, forming a very slight concave
binding surface, whereas with CQ, the isoalloxazine system bends in the opposite
direction, with CQ binding to a slightly convex surface. Reduction of the FAD further
enhances this bend by 2–3°. Other notable changes occur around N5, which moves
toward a tetrahedral configuration in NQO2red; the C4A-N5-C5A bond angle was
decreased from 116–117° in NQO2ox-CQ and NQO2ox-PQ to 112° in NQO2red-CQ
(Table 3.3). In contrast, there was no significant difference in the C10-N10-C9A angle
between the oxidized and reduced forms. Thus, binding of CQ to NQO2ox appears to
push the isoalloxazine ring toward a slightly bent conformation, and reduction of FAD to
FADH2 results in a further increase in the bend as well as the transition of N5 toward a
tetrahedral configuration.
Table 3.3 Conformational Changes in the Isoalloxazine Ring upon Reduction
N5-N10
C4X-N5-C5X
C10-N10-C9A
a,b
a
bend
angle
anglea
Oxidized Primaquine A
-1.56 ± 0.01 117.1 ± 0.2
120.0 ± 0.1
B
-1.64 ± 0.00 116.9 ± 0.1
118.6 ± 0.1
Average -1.60
117.0
119.3
Chloroquine A
1.69 ± 0.00
118.2 ± 0.2
118.9 ± 0.1
B
2.94 ± 0.11
113.8 ± 0.2
116.5 ± 0.2
Average 2.32
116.0
117.7
Reduced Chloroquine A
4.61 ± 0.28
112.2 ± 0.5
117.6 ± 0.3
B
5.24 ± 0.05
112.1 ± 0.4
118.8 ± 0.5
C
5.36 ± 0.19
112.3 ± 1.2
116.1 ± 0.2
D
3.94 ± 0.30
113.1 ± 1.1
117.9 ± 0.2
Average 4.79
112.4
117.6
a
Both oxidized and reduced structures were subjected to three separate rounds of
simulated annealing refinement in the absence of planar restraints for N5-N10 axis and
angle restraints for the C4X-N5-C5X/C10-N10-C9A angles.
b
The “butterfly” bend along the N5-N10 axis was calculated using the atomic positions
of the dimethylbenzene and pyrimidine “wings” and principal component analysis to find
the angle between the two best-fit planes.
NQO2

3.3.6

Inhibitor

Subunit

Conformational Changes in Reduced NQO2-Chloroquine

The monoclinic crystals of NQO2red-CQ contained four NQO2 protomers, two functional
dimers, in the asymmetric unit, rather than the single functional dimer observed in the
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asymmetric unit of orthorhombic crystals of NQO2ox. Thus, reduction and CQ binding
caused a reorientation of the two dimers, removing the crystallographic symmetry that
related them in orthorhombic crystals of NQO2ox (Figure 3.5A).
The active sites in the NQO2 dimer are at the interface of the two protomers. One of the
protomers is largely responsible for binding FAD, whereas the second protomer
contributes elements that cover the surface of the isoalloxazine ring. One such element is
an irregular loop formed by residues 126–136 (Figure 3.3D). In NQO2red-CQ, the loop
closes over the active site, with I128 coming into direct contact with the CQ quinoline
ring, which becomes sandwiched between the side chain of I128 and the isoalloxazine
ring of FAD. This conformation is seen in the B, C, and D chains of the NQO2red-CQ
structure, with the loop in a slightly more open conformation in the A chain.
The loop movement outlined above, as well as other changes in the structure that could
explain the repacking of the crystal upon reduction of FAD and binding of CQ, are
relatively small and difficult to distinguish from crystal packing artifacts. To assess the
structural changes that take place upon reduction and binding of CQ, we made use of the
four NQO2 protomers in the asymmetric unit of NQO2red-CQ to eliminate random
changes in atomic positions and find regions that show a concerted difference from
protomers in crystals of oxidized NQO2. All of the individual subunits from reduced and
oxidized NQO2-CQ were superimposed, and average carbon α (CA) positions were
calculated for each of the four oxidized protomers (two protomers from each of the
NQO2ox-PQ and NQO2ox-CQ structures) and the four reduced protomers (contained in
the NQO2red-CQ asymmetric unit). Differences in the average CA positions for the
oxidized and reduced protomers were calculated, plotted, and mapped to the structure
(Figure 3.5B,C). There were seven regions where consistent differences between the
oxidized and reduced NQO2 subunits were observed. Two of these regions (regions 4 and
5 in Figure 3.5C) make direct contact with the bound chloroquine and comprise the 126–
136 active site loop and an oddly structured connecting loop that includes N161; three
other regions (regions 1, 2, and 3) form a surface patch that is not in direct contact with
either the FAD cofactor or bound chloroquine; the last two regions (regions 6 and 7)
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Figure 3.5 Conformational Changes in NQO2 upon Reduction and Binding of CQ.
(A) Stereodiagram illustrating the relationship between NQO2 in the oxidized (red) and
reduced (blue) states. CA traces of two dimers are shown, with the origin of the unit cells
indicated by a yellow sphere; the FAD molecules are drawn as stick representations. To
show the changes that take place in the crystal, the dimer from the orthorhombic
(P212121) NQO2ox-CQ crystal has been superimposed on one of the dimers from the
monoclinic (P21) crystal of NQO2red-CQ. In orthorhombic crystals of NQO2ox, there is a
single dimer in the asymmetric unit, and the second dimer shown is related by
crystallographic symmetry. When NQO2-CQ is reduced (blue), the relationship between
the two dimers changes, and the crystallographic symmetry is broken, resulting in a
monoclinic space group with two dimers in the asymmetric unit. (B) A plot of differences
in average CA positions between protomers of oxidized NQO2 (NQO2ox-PQ and
NQO2ox-CQ) and protomers of NQO2red-CQ. (C) Two views of the NQO2 dimer (CA
trace) colored from blue to red according to the magnitude of the difference in average
CA position between reduced and oxidized NQO2-CQ. The views are related by 90°
rotation around a vertical axis; the FAD co-enzyme and bound CQ are represented as
yellow and magenta CPK models. Regions of NQO2 (numbered 1–7) that demonstrate a
significant shift upon reduction and binding of CQ (B) are indicated.
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are at the N- and C-terminal ends, respectively, of a surface-exposed helix comprising
residues 196–212. Region 7 is in direct contact with the adenosine moiety of FAD but is
still far removed from the active site. In summary, only two of seven regions that exhibit
structural changes between NQO2ox and NQO2red-CQ are in direct contact with CQ and
the isoalloxazine ring. On this basis, the combination of reduction and CQ binding
appears to exert a global change in structure, consistent with the observed reorientation of
NQO2 dimers within the crystal lattice.

3.4

Discussion

NQO2 was identified as a human target of both CQ and PQ; kinetic studies showed that
PQ binds preferentially to NQO2ox, whereas chloroquine binds to NQO2red (6, 25).
Binding of inhibitors to NQO2red has not been studied, and the goal of the current work
was to understand the structural basis for the difference in binding specificity. The
NQO2red-CQ complex is the first structure of reduced NQO2, and it shows that the mode
of CQ binding to NQO2red is completely different from what is observed for CQ binding
to NQO2ox. The ring nitrogen of 4-aminoquinoline has a pKa of 9.2 (39), and therefore
CQ will be protonated and positively charged at physiological pH; in contrast, the
reduced form of the NQO2-bound isoalloxazine ring will have a negative charge,
whereas the oxidized form will be neutral. The negative charge on the reduced
isoalloxazine ring explains the preference of CQ for NQO2red and will contribute to the
striking difference in the mode of CQ binding to NQO2red and NQO2ox.
The difference in CQ binding to NQO2ox and NQO2red is noteworthy but not as
surprising and interesting as the effect of reduction and CQ binding on the overall
structure of NQO2. There are 40 NQO2ox structures in the Protein Data Bank, most of
which were crystallized as complexes with different inhibitors. Of the 40 structures, 38
were crystallized in the same orthorhombic space group observed for the NQO2ox-PQ and
NQO2ox-CQ complexes; one structure was crystallized in I422 with a single protomer in
the asymmetric unit; and one structure was crystallized in P1 with two dimers in the
asymmetric unit. The monoclinic space group and close packing of the two dimers
observed for NQO2red-CQ are therefore unique and arise due to the reduction of FAD and
chloroquine binding rather than random crystal packing effects. The unexpected
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conformational change in NQO2 provides a structural basis for the proposed role of
quinone reductases as flavin redox switches (40, 41). Flavin redox switches are FAD- or
FMN-containing proteins in which the oxidation state of the cofactor regulates
interactions with other proteins, nucleic acids, or membranes (26). The oxidation state of
the cofactor is coupled to the conformation of the switch protein through a hydrogenbonding network that incorporates the N5 atom of the isoalloxazine ring. For example, in
the LOV family of light-sensing domains, light-induced reduction of the flavin involves
reaction of a cysteine thiolate with C4A of the isoalloxazine ring; the ensuing protonation
of N5 causes the side chain amide of a conserved glutamine residue to flip, and this
change in hydrogen bonding in the vicinity of N5 is communicated to other parts of the
protein (42, 43). In the case of NQO2, reduction of FAD leads to a unique mode of CQ
binding; protonation of the isoalloxazine N5 allows it to donate a hydrogen bond to the
“keystone” water that is held in place by a second hydrogen bond from CQ. Binding of
CQ to NQO2red in this fashion stabilizes an active site loop in a “closed” conformation.
Reduction and CQ binding also cause the isoalloxazine ring of FAD to bend by 4.8°.
Because the active site of NQO2 is at the interface between the two protomers, the
“local” changes in the active site affect the overall structure of the dimer. The
reorientation of the dimers in the crystal lattice indicates global changes in structure
and/or dynamics. Thus, the flavin switch function of NQO2 requires both reduction of
FAD and binding of an appropriate ligand to the reduced isoalloxazine ring to stabilize
the protein in an alternate conformation.
Although the cellular function of NQO2 is not understood, it binds many drugs and
bioactive compounds and has been implicated in apoptosis and cancer (22, 44–46). A role
as a flavin redox switch, the function of which is dependent on cellular redox conditions
and the presence of an appropriate ligand, could explain the elusive nature of NQO2
cellular function. CQ is a good example of an NQO2-interacting compound that is used
to treat a variety of diseases, but the mechanisms underlying the cellular effects of CQ are
poorly understood. As an antimalarial, CQ is thought to interact with undimerized
ferriprotoporphyrin and prevent its detoxification and storage as β-hematin (4). On the
other hand, the process of hemoglobin digestion and storage of ferriprotoporphyrin by the
parasite involves endocytosis and a number of steps in which endosomes must fuse with
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digestive vacuoles, and CQ and related quinolone drugs may interfere with these
processes (4). Along these lines, the accumulation of CQ in lysosomes is thought to be
responsible for its inhibition of autophagy (47). Furthermore, CQ has effects on
glucocorticoid signalling and has been linked to p53 function (48, 49). It is conceivable
that some of the cellular effects of CQ are linked to its binding of NQO2 and the ensuing
conformational switch, which would only occur under an appropriate metabolic state
where NQO2 is reduced.
Both NQO1 and NQO2 have been shown to protect p53 against 20S proteosomal
degradation in the presence of their reduced nicotinamide co-substrates (22, 23, 50, 51).
In fact, the stabilization and localization of a transcription factor is a common function of
flavin redox switches. For example, the oxidized form of the flavin switch NifL forms an
inactive complex with the transcription factor NifA; reduction of NifL leads to
dissociation of the complex, allowing NifA to activate genes involved in nitrogen
fixation. Lot6p, a yeast homologue of human NQO1 and NQO2 (52), provides an
example of a quinone reductase that functions as a flavin redox switch; in this case,
reduction of Lot6p helps it to stabilize the Yap4p transcription factor against 20S
proteosomal degradation, similar to the way in which NQO1 and NQO2 appear to
stabilize p53 (40, 53). Lot6p is actually a poor catalyst (the rate of the oxidative halfreaction is slower than that of non-enzymatic model reactions), and this led Sollner and
coworkers (41) to propose that Lot6p may have evolved primarily as a flavin redox
switch to regulate 20S proteosomal degradation. The conformational switch that we have
observed with NQO2 provides a structural basis for the proposed role of NQO2 and
possibly other quinone reductases in the redox-dependent regulation of p53.
As a flavin redox switch, it is not clear why NQO2 uses NRH as an electron donor
instead of NAD(P)H, which is used by NQO1 and all other members of the flavodoxin
family. NQO2 is the only enzyme known to use NRH, and although oxidized
nicotinamide riboside exists as a metabolite of NAD, the origin of cellular NRH is not
known. On this basis, the metabolic signal that facilitates conformational switching of
NQO2 remains elusive. CQ has been reported to activate the p53 pathway, but whether
this process involves NQO2 was not determined (49). In any case, there may be a number
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of small molecule “inhibitors” of NQO2, as well as proteins or peptides, that could
interact specifically with the reduced form of NQO2 and function in a manner similar to
CQ to stabilize NQO2 in an alternate conformation. Thus, although there are many
unanswered questions regarding the cellular function of NQO2, a flavin switch function
that is dependent on the cellular redox state and the presence of an appropriate ligand
provides an intriguing, met abolically regulated, link between NQO2, p53, and the poorly
defined cellular effects of the many drugs and bioactive compounds that interact with
NQO2.

74

3.5
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

14.
15.

References

Hill, D. R., Baird, J. K., Parise, M. E., Lewis, L. S., Ryan, E. T., and Magill, A. J.
(2006) Primaquine: report from CDC expert meeting on malaria chemoprophylaxis
I. Am. J. Trop. Med. Hyg. 75, 402–15
Lalloo, D. G., Shingadia, D., Pasvol, G., Chiodini, P. L., Whitty, C. J., Beeching,
N. J., Hill, D. R., Warrell, D. a, and Bannister, B. a (2007) UK malaria treatment
guidelines. J. Infect. 54, 111–21
Foley, M., and Tilley, L. (1997) Quinoline antimalarials: mechanisms of action
and resistance. Int. J. Parasitol. 27, 231–40
Fitch, C. D. (2004) Ferriprotoporphyrin IX, phospholipids, and the antimalarial
actions of quinoline drugs. Life Sci. 74, 1957–1972
Vale, N., Moreira, R., and Gomes, P. (2009) Primaquine revisited six decades after
its discovery. Eur. J. Med. Chem. 44, 937–53
Graves, P. R., Kwiek, J. J., Fadden, P., Ray, R., Hardeman, K., Coley, A. M.,
Foley, M., and Haystead, T. a J. (2002) Discovery of novel targets of quinoline
drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–72
Benfield, T., Atzori, C., Miller, R. F., and Helweg-Larsen, J. (2008) Second-line
salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case
series and systematic review. J. Acquir. Immune Defic. Syndr. 48, 63–7
Berman, J. D., and Lee, L. S. (1984) Activity of antileishmanial agents against
amastigotes in human monocyte-derived macrophages and in mouse peritoneal
macrophages. J. Parasitol. 70, 220–5
Kinnamon, K. E., Poon, B. T., Hanson, W. L., and Waits, V. B. (1996) Primaquine
analogues that are potent anti-Trypanosoma cruzi agents in a mouse model. Ann.
Trop. Med. Parasitol. 90, 467–74
Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., and Venuturupalli, S. R.
(2012) New insights into mechanisms of therapeutic effects of antimalarial agents
in SLE. Nat. Rev. Rheumatol. 8, 522–533
Solomon, V. R., and Lee, H. (2009) Chloroquine and its analogs: a new promise of
an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625, 220–
33
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., and Cauda, R. (2003)
Effects of chloroquine on viral infections: An old drug against today’s diseases?
Lancet Infect. Dis. 3, 722–727
Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M.,
Fernbach, N. V, Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Köcher, T.,
Superti-Furga, G., Durnberger, G., Rix, R., L, L., Kocher, T., Du, G., Rix, L. L. R.,
and Ko, T. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors
imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood
110, 4055–63
Winger, J. a, Hantschel, O., Superti-Furga, G., and Kuriyan, J. (2009) The
structure of the leukemia drug imatinib bound to human quinone reductase 2
(NQO2). BMC Struct. Biol. 9, 7
Duncan, J. S., Gyenis, L., Lenehan, J., Bretner, M., Graves, L. M., Haystead, T. a,
and Litchfield, D. W. (2008) An unbiased evaluation of CK2 inhibitors by

75

16.
17.
18.

19.
20.
21.
22.

23.

24.
25.
26.
27.
28.
29.
30.

chemoproteomics: characterization of inhibitor effects on CK2 and identification
of novel inhibitor targets. Mol. Cell. Proteomics 7, 1077–88
Brehmer, D., Godl, K., Zech, B., Wissing, J., and Daub, H. (2004) Proteome-wide
identification of cellular targets affected by bisindolylmaleimide-type protein
kinase C inhibitors. Mol. Cell. Proteomics 3, 490–500
Buryanovskyy, L., Fu, Y., Boyd, M., Ma, Y., Hsieh, T. C., Wu, J. M., and Zhang,
Z. (2004) Crystal structure of quinone reductase 2 in complex with resveratrol.
Biochemistry 43, 11417–26
Mailliet, F., Ferry, G., Vella, F., Berger, S., Cogé, F., Chomarat, P., Mallet, C.,
Guénin, S. P., Guillaumet, G., Viaud-Massuard, M. C., Yous, S., Delagrange, P.,
and Boutin, J. a. (2005) Characterization of the melatoninergic MT3 binding site
on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol. 71, 74–88
Calamini, B., Santarsiero, B. D., Boutin, J. a, and Mesecar, A. D. (2008) Kinetic,
thermodynamic and X-ray structural insights into the interaction of melatonin and
analogues with quinone reductase 2. Biochem. J. 413, 81–91
Vella, F., Ferry, G., Delagrange, P., and Boutin, J. A. (2005) NRH:quinone
reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 71, 1–12
Bogan, K. L., and Brenner, C. (2008) Nicotinic acid, nicotinamide, and
nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in
human nutrition. Annu. Rev. Nutr. 28, 115–30
Gong, X., Kole, L., Iskander, K., and Jaiswal, A. K. (2007) NRH:quinone
oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor
suppressor p53 against 20s proteasomal degradation leading to stabilization and
activation of p53. Cancer Res. 67, 5380–8
Khutornenko, A. A., Roudko, V. V, Chernyak, B. V, Vartapetian, A. B.,
Chumakov, P. M., and Evstafieva, A. G. (2010) Pyrimidine biosynthesis links
mitochondrial respiration to the p53 pathway. Proc. Natl. Acad. Sci. U. S. A. 107,
12828–33
Reybier, K., Perio, P., Ferry, G., Bouajila, J., Delagrange, P., Boutin, J. A., and
Nepveu, F. Ç. O. (2011) Insights into the redox cycle of human quinone reductase
2. Free Radic. Res. 45, 1184–95
Kwiek, J. J., Haystead, T. a J., and Rudolph, J. (2004) Kinetic mechanism of
quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.
Biochemistry 43, 4538–47
Becker, D. F., Zhu, W., and Moxley, M. a (2011) Flavin redox switching of
protein functions. Antioxid. Redox Signal. 14, 1079–91
Leung, K. K. K., Litchfield, D. W., and Shilton, B. H. (2012) Flavin adenine
dinucleotide content of quinone reductase 2: analysis and optimization for
structure-function studies. Anal. Biochem. 420, 84–9
Kabsch, W. (2010) XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125–32
Leslie, A. G. W., and Powell, H. R. (2007) Processing diffraction data with
mosflm. Evol. Methods Macromol. Crystallogr. 245, 41–51
Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr. D. Biol.
Crystallogr. 62, 72–82

76

31.
32.

33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.

45.

Foster, C. E., Bianchet, M. a, Talalay, P., Zhao, Q., and Amzel, L. M. (1999)
Crystal structure of human quinone reductase type 2, a metalloflavoprotein.
Biochemistry 38, 9881–6
Adams, P. D., Afonine, P. V, Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N.,
Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J.,
Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S.,
Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr. D. Biol.
Crystallogr. 66, 213–21
Rubin, J. R., Swaminathan, P., and Sundaralingam, M. (1992) Structure of the
anti-malarial drug primaquine diphosphate. Acta Crystallogr. Sect. C Cryst. Struct.
Commun. 48
Karle, J. M., and Karle, I. L. (1988) Redetermination of the crystal and molecular
structure of the antimalarial chloroquine bis(dihydrogenphosphate) dihydrate. Acta
Crystallogr. Sect. C Cryst. Struct. Commun. 44
Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993)
PROCHECK: a program to check the stereochemical quality of protein structures.
J. Appl. Crystallogr. 26, 283–291
CLARK, W. M., and LOWE, H. J. (1956) Studies on oxidation-reduction. XXIV.
Oxidation-reduction potentials of flavin adenine dinucleotide. J. Biol. Chem. 221,
983–992
Levitt, M., and Perutz, M. (1988) Aromatic Rings Act as Hydrogen bond
acceptors. J. Mol. Biol., 751–754
Hemmerich, P., Nagelschneider, G., and Veeger, C. (1970) Chemistry and
molecular biology of flavins and flavoproteins. FEBS Lett. 8, 69–83
Lange, N. A. (1999) Lange’s Handbook of Chemistry, 15th Ed. (Dean, J. A., ed.),
McGraw-Hill Book Company, New York
Sollner, S., Schober, M., Wagner, A., Prem, A., Lorkova, L., Palfey, B. a, Groll,
M., and Macheroux, P. (2009) Quinone reductase acts as a redox switch of the 20S
yeast proteasome. EMBO Rep. 10, 65–70
Sollner, S., Deller, S., Macheroux, P., and Palfey, B. a (2009) Mechanism of flavin
reduction and oxidation in the redox-sensing quinone reductase Lot6p from
Saccharomyces cerevisiae. Biochemistry 48, 8636–43
Zoltowski, B. D., Schwerdtfeger, C., Widom, J., Loros, J. J., Bilwes, A. M.,
Dunlap, J. C., and Crane, B. R. (2007) Conformational Switching in the Fungal
Light Sensor Vivid. Science (80-. ). 316, 1054–1057
Möglich, A., and Moffat, K. (2007) Structural Basis for Light-dependent Signaling
in the Dimeric LOV Domain of the Photosensor YtvA. J. Mol. Biol. 373, 112–126
Long, D. J., Iskander, K., Gaikwad, A., Arin, M., Roop, D. R., Knox, R., Barrios,
R., and Jaiswal, A. K. (2002) Disruption of dihydronicotinamide riboside:quinone
oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and
decreased sensitivity to menadione toxicity. J. Biol. Chem. 277, 46131–9
Ahn, K. S., Gong, X., Sethi, G., Chaturvedi, M. M., Jaiswal, A. K., and Aggarwal,
B. B. (2007) Deficiency of NRH:quinone oxidoreductase 2 differentially regulates
TNF signaling in keratinocytes: up-regulation of apoptosis correlates with downregulation of cell survival kinases. Cancer Res. 67, 10004–11

77

46.

47.
48.

49.

50.
51.
52.
53.

Yu, K.-D., Di, G.-H., Yuan, W.-T., Fan, L., Wu, J., Hu, Z., Shen, Z.-Z., Zheng, Y.,
Huang, W., and Shao, Z.-M. (2009) Functional polymorphisms, altered gene
expression and genetic association link NRH:quinone oxidoreductase 2 to breast
cancer with wild-type p53. Hum. Mol. Genet. 18, 2502–17
Rubinsztein, D. C., Codogno, P., and Levine, B. (2012) Autophagy modulation as
a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11, 709–
730
He, Y., Xu, Y., Zhang, C., Gao, X., Dykema, K. J., Martin, K. R., Ke, J., Hudson,
E. a, Khoo, S. K., Resau, J. H., Alberts, A. S., MacKeigan, J. P., Furge, K. a, and
Xu, H. E. (2011) Identification of a lysosomal pathway that modulates
glucocorticoid signaling and the inflammatory response. Sci. Signal. 4, ra44
Kim, E. L., Wüstenberg, R., Rübsam, A., Schmitz-Salue, C., Warnecke, G.,
Bücker, E.-M., Pettkus, N., Speidel, D., Rohde, V., Schulz-Schaeffer, W., Deppert,
W., and Giese, A. (2010) Chloroquine activates the p53 pathway and induces
apoptosis in human glioma cells. Neuro. Oncol. 12, 389–400
Asher, G., Lotem, J., Cohen, B., Sachs, L., and Shaul, Y. (2001) Regulation of p53
stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc.
Natl. Acad. Sci. U. S. A. 98, 1188–93
Asher, G., and Shaul, Y. (2005) p53 proteasomal degradation: poly-ubiquitination
is not the whole story. Cell Cycle 4, 1015–8
Vasiliou, V., Ross, D., and Nebert, D. W. (2006) Update of the NAD(P)H:quinone
oxidoreductase (NQO) gene family. Hum. Genomics 2, 329–335
Sollner, S., and Macheroux, P. (2009) New roles of flavoproteins in molecular cell
biology: an unexpected role for quinone reductases as regulators of proteasomal
degradation. FEBS J. 276, 4313–24

78

Chapter 4

4

Quinone Reductase 2 Is an Adventitious Target of
Protein Kinase CK2 Inhibitors TBBz (TBI) and DMAT6

Quinone reductase 2 (NQO2) exhibits off-target interactions with two protein kinase CK2
inhibitors, 4,5,6,7-1H-tetrabromobenzimidazole (TBBz) and 2-dimethylamino-4,5,6,7tetrabromo-1H-benzimidazole (DMAT). TBBz and DMAT induce apoptosis in cells
expressing an inhibitor-resistant CK2, suggesting that the interaction with NQO2 may
mediate some of their pharmacological effects. In this study, we have fully characterized
the binding of TBBz and DMAT to NQO2. Fluorescence titrations showed that TBBz
and DMAT bind oxidized NQO2 in the low nanomolar range; in the case of TBBz, the
affinity for NQO2 was 40-fold greater than its affinity for CK2. A related CK2 inhibitor,
4,5,6,7-tetrabromobenzotriazole (TBB), which failed to cause apoptosis in cells
expressing inhibitor-resistant CK2, binds NQO2 with an affinity 1000-fold lower than
those of TBBz and DMAT. Kinetic analysis indicated that DMAT inhibits NQO2 by
binding with similar affinities to the oxidized and reduced forms. Crystal structure
analysis showed that DMAT binds reduced NQO2 in a manner different from that in the
oxidized state. In oxidized NQO2, TBBz and DMAT are deeply buried in the active site
and make direct hydrogen and halogen bonds to the enzyme. In reduced NQO2, DMAT
occupies a more peripheral region and hydrogen and halogen bonds with the enzyme are
mediated through three water molecules. Therefore, although TBB, TBBz, and DMAT
are all potent inhibitors of CK2, they exhibit different activity profiles toward NQO2. We
conclude that the active site of NQO2 is fundamentally different from the ATP binding
site of CK2 and the inhibition of NQO2 by CK2 inhibitors is adventitious.

6

This chapter was published: Leung, K. K., & Shilton, B. H. (2015). Quinone Reductase 2 Is an
Adventitious Target of Protein Kinase CK2 Inhibitors TBBz (TBI) and DMAT.
Biochemistry, 54, 47–59.

79

4.1

Introduction

Protein kinases are often deregulated in cancer, and the development of kinase inhibitors
for cancer chemotherapy has received much attention in the past 30 years (1). Protein
kinase CK2 (CK2) is a constitutively active kinase that phosphorylates more than 200
protein targets and regulates a myriad of cell signalling events in cell cycle, apoptosis,
and transcriptional control (2, 3). With regard to apoptosis, CK2 attenuates cell death by
phosphorylation of caspases and caspase targets (4). Therefore, the overexpression of
CK2 in many tumor types suggests that CK2 is involved in tumorigenesis by preventing
cell death (5). As such, CK2 is an attractive cancer therapy target and CK2 inhibitors that
cause apoptosis in cancer cells have been extensively developed over the past two
decades (6). However, despite tremendous efforts to increase the specificity of inhibitors
for CK2, many of these compounds exhibit off-target interactions.
The tetrabromobenzene compounds 4,5,6,7-tetrabromobenzotriazole (TBB), 4,5,6,7tetrabromobenzimidazole (TBBz), and 2-dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole (DMAT) are some of the most widely used inhibitors of CK2 (Figure 4.1).
TBB inhibits CK2 activity in the submicromolar range with relatively high specificity
over other kinases (7–9), and treatment of cells in culture with TBB leads to apoptosis
(10). Further development of TBB led to the discovery of another potent inhibitor of
CK2, TBBz, that is more selective for yeast CK2 (11, 12). Based on the
tetrabromobenzene moiety in TBBz, another CK2 inhibitor, DMAT, was developed that
was more selective for CK2 than TBB and bound with an affinity 10-fold greater than
that of either TBB or TBBz (13, 14). Despite being optimized for CK2 inhibition, both
TBBz and DMAT inhibit at least three other subfamilies of kinases: DYRKs, PIM, and
HIPK2 (15). Furthermore, they also bind several non-kinase targets with ATP binding
sites (16). Such nontargeted interactions may contribute to the cellular effects of the
inhibitors.
In a series of unbiased validation studies of the specificity of these inhibitors, Duncan and
co-workers identified quinone reductase 2 (NQO2) as a particularly interesting nonkinase target of TBBz and DMAT (17). Briefly, an inhibitor-resistant mutant of CK2 was
transfected into cells to rescue them from CK2 inhibitor-induced apoptosis; however,
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Figure 4.1 Chemical Structure and Electrostatic Properties of CK2 Inhibitors.
Chemical structure and electrostatic properties of CK2 inhibitors 4,5,6,7tetrabromobenzotriazole (TBB), 4,5,6,7-tetrabromo-1H- benzimidazole (TBBz), and 2dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT). Partial charges were
calculated and displayed on the molecular surfaces using Marvin 6.3.1 by ChemAxon
(http://www.chemaxon.com).
only TBB-treated cells were rescued, while TBBz- and DMAT-treated cells underwent
apoptosis. Therefore, inhibition of CK2 alone did not fully account for the cell death
caused by TBBz and DMAT treatment. This challenges the notion that CK2 is the bona
fide target of the two inhibitors and indicates that TBBz and DMAT act through alternate
mechanisms to cause cellular apoptosis. Further investigation using a proteomics
approach identified a non-kinase target, NQO2, that eluted from an ATP-Sepharose
affinity column when it was washed with TBBz and DMAT but not with a similar
concentration of TBB. This corresponded to the rescue experiment in which TBBz and
DMAT but not TBB caused cell death and suggests that NQO2 inhibition may contribute
to the apoptotic effects of the drugs. Thus, it prompted our investigation of NQO2
inhibition by the three inhibitors.
Historically, NQO2 and related quinone reductases have been characterized as enzymes
involved in quinone detoxification. They do so by catalyzing an obligate two-electron
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transfer to a quinone to produce the relatively stable quinonol, thus preventing nonenzyme-catalyzed single-electron transfer that produces redox active semiquinones (18).
NQO2 is unusual, however, because it uses dihydronicotinamide riboside (NRH) as a
reducing co-substrate, rather than NAD(P)H (19); moreover, in the presence of NRH,
NQO2 was found to protect p53 from degradation by the 20S proteasome (20, 21). At the
molecular level, reduction of NQO2 and binding of chloroquine (an antimalarial) were
shown to induce a conformational change in NQO2, suggesting that NQO2 may function
as a flavin redox switch (22). Therefore, in addition to its role in quinone detoxification,
NQO2 appears to have a signalling function, possibly connecting the metabolic status of
the cell to p53 levels. While its cellular functions remain to be determined, mice deficient
for NQO2 develop skin tumors more frequently than wild-type mice in a chemical
carcinogenesis model (23), indicating that NQO2 plays a role in cell proliferation and/or
apoptosis.
In addition to CK2 inhibitors, several chemotherapeutic inhibitors of the Abelson kinase
and protein kinase C (PKC) were found to inhibit NQO2 with nanomolar and micromolar
affinity, respectively (24–27). The fact that multiple kinase-directed drugs also inhibit
NQO2 raised the question of whether the drug binding site of NQO2 somehow mimics
the ATP binding site of kinases. In this study, we performed kinetic and structural
analyses to characterize the inhibition of NQO2 by TBB, TBBz, and DMAT. The three
inhibitors exhibit different binding profiles with respect to NQO2 that do not correspond
to their interactions with CK2.
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4.2
4.2.1

Methods
Protein Expression and Purification

Recombinant NQO2 was expressed in Escherichia coli and purified as previously
described (28). A critical step in the purification was full reconstitution of the enzyme
with the FAD co-enzyme. When expressed in E. coli, recombinant NQO2 typically
contains substoichiometric levels of flavin mononucleotide (FMN) and no FAD. A partial
denaturation of NQO2 and reconstitution with FAD was incorporated into the
purification procedure, leading to full saturation of the enzyme with FAD (28).

4.2.2

Affinity of Inhibitors by Fluorescence Quenching.

To assess direct binding of inhibitors to oxidized NQO2 (NQO2ox), fluorescence
quenching of FAD was monitored with an excitation wavelength of 350 nm and an
emission wavelength of 430 nm. NQO2 (775 or 38.75 nM) was titrated with the indicated
concentrations of TBB, TBBz, and DMAT. The binding data were fit to equation 4.1 to
obtain the dissociation constant (KD) for binding of the inhibitors to NQO2ox.
K + I + NQO2 − (K D + I + NQO2) 2 − 4(I )(NQO2)
F − Fo
= D
Fmax − Fo
2(NQO2)

Equation 4.1 Fluorescence Quenching by Inhibitors
€
where NQO2 and I are the final concentrations in the cuvette of the enzyme and inhibitor,

respectively, Fo is the initial fluorescence reading in counts per second without an
inhibitor, and F is the fluorescence after the addition(s) of TBBz or DMAT. KD and Fmax
were determined by nonlinear regression using Prism 4.0b (GraphPad Software Inc., San
Diego, CA). The data are presented as fractional saturation of NQO2 with an inhibitor (F
- Fo)/(Fmax - Fo).

4.2.3

Enzymatic Assays.

Enzyme activity was measured by monitoring the consumption of 1-(3-sulfonatopropyl)3-carbamoyl-1,4-dihydropyrimidine (SCDP) (Sigma) co-substrate (a
dihydronicotinamide riboside analogue) at an absorbance peak of 360 nm using a Cary
100-Bio spectrophotometer (Varian). The reaction was initiated by addition of NQO2 at a
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final concentration of 154 pM to a stirring cuvette containing SCDP (10-365 µM) as cosubstrate and menadione (0.5-50 µM) (Sigma) as the substrate at 30 °C. The linear
portion of the decrease in absorbance was determined using Cary Kinetics Software
(Varian) and converted to turnover number (inverse seconds) using the extinction
coefficient of SCDP (ε360 = 4480 M−1 cm−1). Because menadione inhibits the reaction at
high concentrations by competing with SCDP for binding to the oxidized enzyme, kinetic
data were fit to Equation 4.2 that describes a ping-pong kinetic mechanism with substrate
inhibition (29).

Vobs =

K

app
M(SCDP)

Vmax [SCDP][Md]
[Md]+ K M(Md) [SCDP]+[SCDP][Md]

app
where K M(SCDP)
= K M(SCDP) (1+

[Md]
)
K I(Md)

Equation 4.2 Ping-pong Mechanism of NQO2 Catalysis
where Vobs is the observed rate of reaction, Vmax is the maximal rate, [SCDP] and [Md] are
the concentrations of SCDP and menadione, respectively, KM(SCDP) and KM(Md) are the
Michaelis constants for substrates SCDP and menadione, respectively, and KI(Md) is the
competitive binding constant of menadione. Initial values were obtained from the
previous study of NQO2 kinetics using N-methyldihydronicotinamide (NeMH) as the cosubstrate (29). Kinetic parameters were fit to the data by nonlinear regression using Igor
Pro (Wavemetrics, Portland, OR); the χ2 values were calculated as

" y − yi %
χ = ∑$
'
i # σi &

2

2

Equation 4.3 Determination of Chi-squared Values
where y and yi are the fitted and measured values, respectively, and σi is the estimated
standard deviation of the measured value.

84

4.2.4

Enzyme Inhibition by TBBz and DMAT.

To determine the constants for inhibition (KI values) of NQO2 by TBBz and DMAT,
inhibition kinetics were performed using the same techniques that were used for the
uninhibited reaction described above. For each inhibitor, kinetic assays were performed
either with a constant SCDP concentration of 150 µM and a varying menadione
concentration or with a constant menadione concentration of 5 µM and a varying SCDP
concentration. Because inhibitors of NQO2 can be competitive against SCDP,
menadione, or both, we adapted the kinetic equation to account for both types of
inhibition:

Vobs =

K

app
M(SCDP)

Vmax [SCDP][Md]
app
[Md] + K M(Md)
[SCDP] + [SCDP][Md]

app
where K M(SCDP)
= K M(SCDP) (1+

and

app
K M(Md)
= K M(Md) (1+

[Md] [I]
+
)
K I(Md) K I(α )

[I]
)
K I(β )

Equation 4.4 Inhibition of NQO2 Catalysis
On the basis of equation 4.2, [I], KI(α), and KI(β) were introduced into equation 4.3, where
[I] is the concentration of inhibitor and KI(α) and KI(β) are the inhibition constants that
app
app
modify the “apparent” Michaelis constants K M(SCDP) and K M(Md) respectively. That is, KI(α)

is the constant that accounts for the change in KM(SCDP) in the presence of inhibitor; hence,
it describes the component of inhibition that is competitive against SCDP. KI(β) is the
constant that accounts for the change in KM(Md) in the presence of inhibitor; hence, it
describes the component of inhibition that is competitive against menadione. The kinetic
parameters KM(SCDP), KM(Md), and KI(Md) were fixed using values determined for the
uninhibited reaction (Table 4.2), while Vmax, KI(α), and KI(β) were determined by globally
fitting data to equation 4.4 using nonlinear regression (Igor Pro version 6.34A) with the
IC50 values as initial values.
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4.2.5

IC50 Measurements.

To determine the IC50 value of each inhibitor, reactions were initiated by addition of 154
pM NQO2 to a reaction buffer containing 150 µM SCDP and 5 µM menadione with TBB
(0.625-640 µM), TBBz (2.5-640 nM), or DMAT (2.5-640 nM). IC50 values were then
calculated using a dose-response model and represented as relative inhibition.

4.2.6

Crystallization of NQO2.

Oxidized NQO2 (NQO2ox) was co-crystallized with TBBz or DMAT by hanging drop
vapor diffusion against reservoirs containing 0.1 M Hepes (pH 7.5) and 1.3-2.0 M
(NH4)2SO4. Because TBBz and DMAT are not soluble in mother liquor, TBBz or DMAT
(100 µM) was added to a final concentration of 2 mg/mL (77 µM) of NQO2. The NQO2inhibitor complex was then concentrated 10-fold to 20 mg/mL and used for
crystallization.
To obtain a structure of reduced NQO2 in complex with DMAT, reduction of NQO2oxDMAT crystals was performed as previously described (22). Briefly, N NQO2ox-DMAT
crystals were repeatedly soaked into 1 µL of a reducing soak solution with 0.1 M Hepes
(pH 7.5), 2.0 M (NH4)2SO4, 10 mM SCDP, and 1 mM DMAT, for 2 min intervals until
the crystals were bleached. They were then transferred to a soak without SCDP before
briefly being passed through a cryoprotectant solution [2.0 M (NH4)2SO4, 0.1 Hepes (pH
7.5), and 20% glycerol] and plunged into liquid nitrogen. To prevent oxidation of NQO2,
the entire crystal mounting process from harvesting to cryocooling was performed under
an anoxic atmosphere in a glovebag purged with N2.

4.2.7

X-ray Data Collection, Refinement, and Analysis.

Crystallographic data were collected at Canadian Light Source beamline 08ID-1 or from
a rotating anode source, processed using MOSFLM (30), and merged using Scala (31).
The structures were determined by molecular replacement with Protein Data Bank (PDB)
entry 1QR2 as a starting model (32); refinement was conducted using PHENIX (33).
Given the high resolution of the crystallographic data, NCS restraints were not used for
any of the refinements. For structures with detectable anomalous scattering (NQO2ox-
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TBBz and NQO2red-DMAT), zinc and bromine were refined as anomalous groups. For
the oxidized NQO2-DMAT structure, the high resolution of the data allowed for
anisotropic refinement of the zinc and bromine atoms. These refinement strategies
lowered both Rwork and Rfree.
Topology files for TBBz and DMAT were generated using PHENIX.ELBOW (33). For
refinement of the NQO2red-DMAT structure, the FAD topology file was modified to
allow bending along the N5-N10 axis of FAD: the planarity restraints incorporating N5
and N10 of the isoalloxazine ring were removed so that it was separated into two planes,
one incorporating the pyrimidine ring and the second the benzyl ring. Also, the estimated
standard deviations of the bond lengths attached to N5 and N10 were increased 10-fold,
and the bond angle and dihedral angle restraints involving N5 and N10 were removed.
To compare FAD bending among the three structures, each structure was refined three
times using simulated annealing with the relaxed FAD topology parameters that allow for
bending of the isoalloxazine ring. The degree of bending in the isoalloxazine ring was
then calculated using principal component analysis incorporating all atoms in each of the
two planes, and the angles in each of the three refined structures were averaged. The
NQO2ox-TBBz, NQO2ox-DMAT, and NQO2red-DMAT final structures were deposited as
PDB entries 4U7G, 4U7H, and 4U7F, respectively.
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4.3
4.3.1

Results
NQO2 Is a Target of TBB, TBBz, and DMAT.

Halogenated benzotriazoles were identified as inhibitors of CK1 and CK2, with 4,5,6,7tetrabromobenzotriazole (TBB) strongly inhibiting CK2 (7). From this starting point,
brominated benzimidazoles, in particular, 4,5,6,7-1H-tetrabromobenzimidazole (TBBz)
and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) (Figure 4.1), that
increased selectivity for CK2 were developed (11, 14). DMAT is the most potent of these
compounds, exhibiting a 10-fold lower dissociation constant and a 3-fold lower IC50
compared to those of TBB and TBBz (Table 4.1). All three compounds target the ATP
binding site of CK2, and on this basis, it is not surprising that they are also active against
other kinases (15). On the other hand, it was surprising that both TBBz and DMAT were
identified as interactors with NQO2, which neither is a kinase nor has a known ATP
binding site (17). However, NQO2 does bind other kinase inhibitors (24, 27), raising the
possibility that its active site mimics a kinase binding site. Our goal in this study was to
characterize the binding and inhibition of NQO2 by these three compounds and compare
their activities against NQO2 with those against CK2.
Table 4.1 Binding Affinity and Inhibition of TBB, TBBz, and DMAT towards CK2
and NQO2
Inhibitor
KD
IC50
a
b
a
CK2
NQO2
CK2
NQO2c
TBB
400 nM
7.11 ± 0.04 µM
500 nM
12.8 ± 2 µM
TBBz
700 nM
18.1 ± 0.4 nM
500 nM
79.4 ± 12 nM
DMAT
40 nM
36.4 ± 1.7 nM
140 nM
484 ± 80 nM
a
KD and IC50 values for CK2 were reported previously (14, 34).
b
The dissociation constants for oxidized NQO2 were determined by fluorescence
titrations; values are mean ± standard deviation for three independent titrations.
c
IC50 values for NQO2 were determined by an in vitro assay with 150 µM SCDP and 5
µM menadione and varying concentrations of inhibitors. Kinetic data were fit to a
sigmoidal response curve (Figure 4.2B); values are the estimated IC50 ± the range of the
95% confidence interval.
TBB, TBBz, and DMAT are planar aromatic compounds and as such are expected to bind
to NQO2 by stacking onto the isoalloxazine ring of FAD. On this basis, fluorescence
titrations were used to directly measure binding affinities for oxidized NQO2. Both TBBz
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and DMAT bound tightly to NQO2, with KD values of 18 and 36 nM, respectively, while
TBB bound much more weakly with a KD of 7.1 µM (Table 4.1 and Figure 4.2A).
To characterize the ability of these compounds to inhibit NQO2’s enzymatic activity,
IC50 values were determined using an in vitro assay (Figure 4.2B). NQO2 operates by a
ping-pong catalytic mechanism: the first step is reduction of the FAD isoalloxazine ring
by dihydronicotinamide riboside (NRH), followed by dissociation of the oxidized
nicotinamide and binding of a quinone substrate. For the assay, a commercially available
NRH analogue, 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP),
which exhibits a change in absorbance at 360 nm upon oxidation by NQO2, was used
along with menadione as the quinone substrate. All three compounds inhibited the
enzymatic activity of NQO2. The IC50 values were all higher than the dissociation
constants, but the difference depended on the compound (Table 4.1). That is, the IC50
value for DMAT was > 12-fold higher than its KD, while the IC50 value for TBBz was 4fold higher; for the relatively weak binding inhibitor, TBB, the IC50 was only slightly
greater than the KD (Table 1). This indicates that the compounds are inhibiting NQO2
through somewhat different mechanisms.
The activity profiles of TBB, TBBz, and DMAT against NQO2 are different from those
against CK2. First, both TBB and TBBz bind to CK2 with similar affinity (KD values of
400 and 700 nM, respectively), whereas with NQO2, the binding of TBB is almost 3
orders of magnitude weaker than that of TBBz. Second, a comparison of DMAT and
TBBz shows that DMAT binds to CK2 with an affinity more than 1 order of magnitude
greater than that of TBBz, whereas binding of DMAT to NQO2 is slightly weaker than
that of TBBz (Table 1). Finally, the large differences between KD and IC50 values
observed for NQO2 (particularly in the case of DMAT) were not observed for CK2;
instead, for CK2, the IC50 and KD values for TBB and TBBz were almost equal, and the
IC50 for DMAT was only 3-fold greater than the KD. On the basis of these binding and
inhibition data, the properties of the NQO2 binding site do not fully mimic the properties
of the CK2 ATP binding site. To improve our understanding of the interactions between
NQO2 and the nanomolar inhibitors TBBz and DMAT, we performed a more detailed
kinetic analysis to determine the mode of enzymatic inhibition.
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Figure 4.2 Binding and Inhibition of NQO2 by TBBz, DMAT, and TBB.
(A) Representative data for binding of TBBz (▲), DMAT (▼), and TBB (■) to oxidized
NQO2. Binding was characterized by fluorescence titrations of the inhibitors against
oxidized NQO2 at a concentration of 38.75 nM (TBBz and DMAT) or 775 nM (TBB).
The stirred sample was monitored at an excitation wavelength of 350 nm and an emission
wavelength of 430 nm. The solid curves represent the binding isotherms, which were
determined by nonlinear regression as outlined in Methods; the dissociation constants for
the inhibitors are listed in Table 1. (B) Inhibition of steady-state catalysis by TBBz (▲),
DMAT (▼), and TBB (■). Reactions were initiated with the addition of 154 pM NQO2 to
150 μM SCDP and 5 μM menadione and varying concentrations of the inhibitors; IC50
values were calculated from these data and are listed in Table 4.1.

4.3.2

Kinetic Analysis of Inhibition of NQO2 by TBBz and DMAT.

The ping-pong catalytic mechanism of NQO2 means that the active site cycles through an
oxidized state and a reduced state for each catalytic turnover. In this study, the steadystate kinetic parameters of the uninhibited reaction were determined using the NRH
analogue SCDP as the co-substrate and menadione as the substrate. Because previous
studies have shown that menadione acts as a competitive inhibitor toward SCDP (29),
substrate inhibition by menadione was incorporated into the kinetic model (equation 4.2,
Methods). Consistent with previous results, our kinetic data (Figure 4.3) confirm that the
binding of menadione to oxidized NQO2 [KI(Md)] is similar to the Michaelis constant of
menadione [KM(Md) (Table 4.2)]. Thus, menadione exhibits limited discrimination
between the two redox states of NQO2.
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Figure 4.3 Steady-state Ping-pong Kinetics of NQO2 with Substrate Inhibition.
Steady-state kinetic analysis was performed to obtain the kinetic parameters listed in
Table 2. Initial concentrations of SCDP were 10 (■), 25 (▲), 50 (▼), 100 (◆), and 365 (●)
μM, and concentrations of menadione varied as indicated. Data points are measured rates,
and solid curves represent the nonlinear regression fits derived from globally fitting all
data to equation 4.1 (Methods) that describes a ping-pong kinetic mechanism with
substrate inhibition by menadione. The χ2 value for the global fit was 7.4 × 104.
Table 4.2 Steady-state Kinetic Parameters of NQO2
Parametera
Value
kcat
981 ± 90.4 s-1
KM(SCDP)
142 ± 23.2 µM
KM(menadione)
1.62 ± 0.31 µM
KI(menadione)
8.07 ± 1.48 µM
a
Calculated by globally fitting rate data to equation 4.2 as described in Materials and
Methods.
An inhibitor of NQO2 can be competitive toward the SCDP co-substrate and/or the
quinone substrate depending on whether the inhibitor binds preferentially to the oxidized
or reduced form of NQO2. We used equation 4.4 (Methods) to account for the
competitive inhibition model. In this model, each inhibitor is expected to compete with
SCDP, menadione, or both, and the inhibition constants KI(α) and KI(β) describe the degree
to which the presence of the inhibitor alters the apparent Michaelis constants for the
reaction. Another way of viewing the KI(α) or KI(β) constants is that their relative values
should indicate the preference of the inhibitor for either the oxidized or reduced form of
NQO2, respectively. Global fitting of the rate data (Figure 4.4) to equation 4.4 yielded
values of KI(α) and KI(β) for TBBz and DMAT as well as kcat values (Table 4.3). Thus, the
inhibition constant of TBBz toward SCDP (KI(α) = 19.6 ± 2.9 nM) is very close to the
binding affinity of TBBz for oxidized NQO2 (KD = 18.1 ± 0.4 nM). The high value and
very high standard error for the inhibition constant of TBBz toward the quinone substrate,
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Figure 4.4 Kinetic Analysis of NQO2 Inhibition by TBBz and DMAT.
Steady-state rate measurements of NQO2-catalyzed reduction of menadione were taken
in the presence of TBBz (A and B) or DMAT (C and D) to obtain the values for KI(α),
KI(β), and kcat listed in Table 3. In panels A and C, assays included a constant menadione
concentration of 5 μM, while in panels B and D, assays included a constant SCDP
concentration of 150 μM. The concentrations of TBBz were 0 (■), 50 (▲), 100 (▼), and
500 (◆) nM (A) and 0 (■), 25 (▲), 50 (▼), and 100 (◆) nM (B). The concentrations of
DMAT were 0 (■), 100 (▲), 500 (▼), and 1000 (◆) nM (C) and 0 (■), 25 (▲), 50 (▼), 100
(◆), and 500 (●) nM (D). The solid curves in the panels represent global fits to all of the
data in panels A and B [to obtain KI(α), KI(β), and kcat for inhibition by TBBz] or panels C
and D [to obtain KI(α), KI(β), and kcat for inhibition by DMAT]. The χ2 value for the global
fit to TBBz-inhibited NQO2 (A and B) was 1.4 × 105, while that for the DMAT-inhibited
NQO2 (C and D) was 4.6 × 104.
Table 4.3 Inhibition of NQO2 by TBBz and DMAT
Inhibitor
TBBzc
DMATd

KI(α)a (nM)

KI(β)b (nM)

kcat (s-1)

19.3 ± 2.5
801 ± 3280
948.0 ± 34.4
131.2 ± 27.5 252.0 ± 124.0 929.9 ± 24.7
a
KI(α) is the component of the inhibition that is competitive against SCDP.
b
KI(β) is the component of the inhibition that is competitive against menadione.
c
The parameters (with standard errors) were calculated by globally fitting the rate data
illustrated in Figure 4.4, Panels A and B.
d
The parameters (with standard errors) were calculated by globally fitting the rate data
illustrated in Figure 4.4, Panels C and D.
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menadione (KI(β) = 865 ± 3790 nM), indicate that the interaction of TBBz with the
oxidized form of NQO2 is sufficient to completely account for TBBz-mediated
inhibition, and therefore, binding to the reduced form cannot be assessed using steadystate kinetics. The situation for DMAT is more complicated: the inhibition constant of
DMAT toward SCDP (KI(α) = 121 ± 20 nM) is 3-fold higher than its affinity for oxidized
NQO2 (KD = 36.4 ± 1.7 nM). Furthermore, we find that the inhibition constant of DMAT
toward menadione (KI(β) = 302 ± 131 nM) is similar to its inhibition constant against
SCDP. This indicates that DMAT is binding to both oxidized and reduced NQO2; it
exhibits relatively poor discrimination between the two. This was surprising but not
unprecedented as the substrate menadione also shows poor discrimination between the
two redox states of NQO2; however, DMAT is the first inhibitor shown to exhibit similar
affinity for both redox states of NQO2.

4.3.3

Structures of Oxidized NQO2 with TBBz and DMAT.

Crystal structures of NQO2−inhibitor complexes were used to determine the structural
basis for binding of TBBz and DMAT to oxidized NQO2. Cocrystallization of NQO2 and
TBBz yielded crystals that diffracted to 1.86 Å; the structure was determined by
molecular replacement and refined to an Rfree value of 0.2288 (Table 4.4). Crystals of
NQO2 contain a dimer in the asymmetric unit, and TBBz was modeled in two
orientations in both active sites of the NQO2 dimer. Because TBBz has four bromine
atoms that contribute to anomalous scattering, the first orientation of TBBz was modeled
using an anomalous difference map that indicated four prominent peaks (two peaks at
5−6 σ and two peaks at 4 σ) in the active site of NQO2 (Figure 4.5A). In the first
orientation, the tetrabromobenzene makes π-stacking interactions with the FAD
isoalloxazine ring and the phenyl ring of F178. Bromine atoms 4 and 5 of TBBz make
halogen bonds (35) to the backbone carbonyl of G174 and to the carboxyamide of N161.
The benzimidazole nitrogen makes a π-hydrogen bond (36) with the benzene ring of the
W105 indole side chain. During the refinement, inconsistencies in the relative values for
the atomic displacement parameters (ADPs) within the imidazole ring of TBBz suggested
that TBBz was binding in an alternative orientation (Figure 4.5B). The second orientation
of TBBz is related by a 60° rotation around the benzene ring that places a bromine atom
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Figure 4.5 Binding of TBBz and DMAT to Oxidized (A-D) and Reduced (E-F)
NQO2
Complexes between oxidized NQO2 and TBBz or DMAT (A−D) show the inhibitors are
sandwiched between the isoalloxazine ring of FAD (yellow) and F178 (above the plane
of the inhibitor). (A) In one orientation, TBBz makes two halogen bonds and a πhydrogen bond to N161, G174, and W105, respectively. (B) In its second orientation,
TBBz is rotated 60° to make three halogen bonds with N161, G174, and W105. (C)
DMAT makes two halogen bonds to N161 and G174 in one orientation, but the presence
of the dimethylamine group hinders the imidazole nitrogen from π-hydrogen bonding
with W105. (D) In the second orientation, DMAT makes three halogen bonds with N161,
G174, and W105, similar to what was observed for TBBz. In the structure of reduced
NQO2 (E and F), DMAT occupies a more peripheral position, makes fewer π-stacking
interaction with FAD, no longer contacts F178, and instead makes somewhat stronger
hydrophobic contact with F126. (E) In one orientation of DMAT, bromine 6 makes a
halogen bond to a water molecule, which is in turn bonded to N161, while bromine 5
makes a halogen bond to W105. (F) In the second orientation with reduced NQO2,
DMAT is rotated 60° and the same halogen bonds are mediated by bromines 4 and 5. The
electron density maps represent the Fo - Fc (green mesh) and anomalous (magenta mesh)
differences calculated after simulated annealing with the inhibitors omitted from the
structure; all electron density maps were contoured at 3σ around the inhibitors. In all
three structures, the inhibitor binding orientations are the same for both subunits (the A
and B chains) of the NQO2 dimer that constitutes the asymmetric unit of the crystal.
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Table 4.4 Crystallographic Data Collection and Refinement Statistics
Crystal
Ligand
Wavelength (Å)
Space Group
Unit Cell Dimensions (Å)
Resolution

Reduced NQO2

TBBz

DMAT

DMAT

1.54

1.03

1.54

P212121

P212121

P212121

56.24, 83.17,
106.65

56.25, 83.01,
106.48

56.12, 83.14,
106.46

18.18-1.91

30.02-1.45

17.99 - 1.73

a

Rsym

0.098 (0.57)

0.06 (0.43)

0.073 (0.66)

a

I/σ(I)

7.5 (2.0)

9.7 (1.7)

14.8 (2.6)

a

Completeness

92.8 (57.3)

96.0 (74.5)

89.9 (74.5)

4.4

4.6

6.2

36697

85781

47314

0.1745/0.2288

0.1843/0.1958

0.1840/0.2254

90.2%
9.3%
0.5%
0%

91.7%
7.8%
0.5%
0%

90.7%
8.8%
0.5%
0%

0.009
1.150
14.665

0.010
1.353
14.702

0.009
1.128
14.238

20.990
20.084
21.913

21.913
20.285
23.282

23.698
22.608
24.809

27.553
22.305
26.988

31.850
22.682
46.165

26.960
25.113
37.759

Redundancy
Unique Reflections
Rwork/Rfree
Ramachandran Plotb (%)
Most Favoured
Additionally Allowed
Generously Allowed
Disallowed
RMS Deviations
Bond Lengths (Å)
Bond Angles (deg)
Dihedral Angles (deg)
Mean A.D.P. values (Å2)
Protein
All Atoms
Main Chain
Side Chain
Solvent
Water
FAD
Inhibitor
a

Oxidized NQO2

Values in parentheses refer to the highest resolution shell.
Ramachandran plot statistics were calculated using PROCHECK (Laskowski et al.
1993).
b
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in the position of one of the benzimidazole nitrogens. Refinement of the structure with
the two TBBz orientations yielded consistent values for the ADPs. As a result of the
rotation, the halogen bonds to G174 and N161 are maintained but are made with
bromines 5 and 6 rather than bromines 4 and 5 as in the first orientation. In addition, the
π-hydrogen bond to the W105 indole is replaced with an interaction between bromine 4
and the W105 side chain. Thus, both orientations of TBBz involve similar interactions
with NQO2.
Oxidized NQO2 was also co-crystallized with DMAT. Data from an NQO2ox−DMAT
crystal were collected to 1.5 Å, and the structure was refined to an Rfree value of 0.2023
(Table 4.4). Because these data were collected from a synchrotron source at a wavelength
farther from the bromine edge, the anomalous signal for bromine was weaker.
Nonetheless, DMAT was modeled in two orientations by anchoring the bromines to
anomalous scattering peaks (Figure 4.5C,D). Like the NQO2ox-TBBz complex, DMAT
makes π-stacking interactions with the FAD isoalloxazine ring and the phenyl ring of
F178. The first orientation of DMAT is similar to that of TBBz, in which the inhibitor
makes two halogen bonds to the backbone carbonyl of G174 and the carboxyamide of
N161; however, the dimethylamine substituent of DMAT prevents the benzimidazole
nitrogen from making a π-hydrogen bond with W105. The alternate orientation of DMAT
(Figure 4.5D) is rotated 60° clockwise and binds in an orientation almost identical to that
of TBBz (Figure 4.5B). As one might anticipate from their structures, TBBz and DMAT
show very similar modes of binding to the NQO2 active site. The fact that the
dimethylamine moiety of DMAT prevents it from binding optimally in the preferred
mode explains its slightly lower affinity for NQO2 (a KD of 36 nM compared to a KD of
18 nM for TBBz).

4.3.4

Binding of DMAT to Reduced NQO2.

Our kinetic analysis indicated that DMAT binds with a similar affinity to the reduced and
oxidized forms of NQO2. To elucidate the mode of binding of DMAT to reduced NQO2,
crystals of oxidized NQO2 in complex with DMAT (NQO2ox-DMAT) were reduced in a
soaking solution containing SCDP. A data set from a crystal of the NQO2red-DMAT
complex was collected to 1.90 Å and the structure refined to an Rfree value of 0.2268
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(Table 4.4). It was clear that reduction of the FAD co-substrate had a major effect on
binding of DMAT: it was less deeply buried in NQO2red than in NQO2ox, and the space
made available was filled with water molecules that mediate interactions between DMAT
and reduced NQO2. As with the NQO2ox-DMAT complex, DMAT bound to the reduced
enzyme in two orientations: this was clear from the presence of three strong anomalous
scattering peaks representing the common positions of the bromine atoms in the two
orientations (Figure 4.5 E,F). Two of the bromines interact with three water molecules
(numbers 32, 16, and 85) that in turn are hydrogen-bonded to the backbone carbonyl of
G174 and the carboxyamide of N161. The third common bromine atom makes a πhalogen bond to the W105 indole group. The less deeply buried position of DMAT in the
reduced NQO2 structure means that it no longer makes π-stacking interactions with F178,
and the area in contact with the isoalloxazine ring is also reduced.

4.3.5

Structural Changes in FAD in the NQO2red-DMAT Complex.

The reduction of the planar isoalloxazine ring of FAD leads to a “butterfly bend” along
the N5-N10 axis (37). On this basis, refinement of the NQO2red-DMAT structure was
conducted using a modified stereochemical restraint set for FAD, in which planar
restraints and associated bond and angle restraints around N5 and N10 were removed.
The final refined structure indicated butterfly bend angles of 3.0° and 5.4° for the
isoalloxazine ring systems in chains A and B, respectively. To validate that the small
change in the FAD isoalloxazine structure was due to reduction of the FAD, and not
simply removal of stereochemical restraints, the refined NQO2 structures were further
subjected to simulated annealing refinement against data from both oxidized and reduced
crystals (Table 4.5). In the absence of stereochemical restraints around N5 and N10, the
isoalloxazine ring of NQO2ox in complex with TBBz refined to 1.8° and 2.4° for each
FAD co-substrate; for NQO2ox in complex with DMAT, the bend was 2.7° and 2.4° for
each FAD co-substrate. Thus, FAD is bent approximately 2° upon reduction and binding
of DMAT.
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Table 4.5 Conformational Changes in the Isoalloxazine Ring upon Reduction
Subunit
N5-N10 bend a,b
A
1.81 ± 0.06
B
2.44 ± 0.04
Average
2.13
DMAT
A
2.74 ± 0.01
B
2.39 ± 0.06
Average
2.57
Reduced
DMAT
A
2.95 ± 0.11
B
5.37 ± 0.23
Average
4.16
a
Both oxidized and reduced structures were subjected to three separate rounds of
simulated annealing refinement in the absence of planar restraints for N5-N10 axis and
angle restraints for the C4X-N5-C5X/C10-N10-C9A angles.
b
The “butterfly” bend along the N5-N10 axis was calculated using the atomic positions
of the dimethylbenzene and pyrimidine “wings” and principle component analysis to find
the angle between the two best-fit planes.
NQO2
Oxidized

	
  
	
  

Inhibitor
TBBz
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4.4

Discussion

TBB, TBBz, and DMAT are ATP-competitive inhibitors of CK2 that reduce the level of
autophosphorylation of CK2β by CK2α and CK2α′. The three inhibitors induce apoptosis
in HeLa, Jurkat, and HL-60 cells (10, 14, 17, 34) ostensibly by preventing CK2 function
to promote cell survival over apoptosis (3, 38, 39). However, both TBBz and DMAT, but
not TBB, were potent inducers of apoptosis in cells expressing an inhibitor-resistant CK2.
Furthermore, in cells expressing wild-type CK2, both TBBz and DMAT are more potent
inducers of apoptosis than TBB (10, 14, 17, 34). On this basis, interactions of TBBz and
DMAT with molecule(s) other than CK2 appear to contribute to their induction of
apoptosis. Through a proteomics screen, NQO2 was identified as a target of TBBz and
DMAT, but not TBB. In the study presented here, we have shown that both TBBz and
DMAT bind to and inhibit NQO2 at nanomolar concentrations, whereas the interaction
between NQO2 and TBB is much weaker. The interactions of TBB, TBBz, and DMAT
with NQO2 therefore correlate with their apoptotic effects in cells transformed with
inhibitor-resistant CK2 (17). Because several other kinase inhibitors also bind NQO2 (24,
25, 27, 40), we sought to understand the structural basis for the interaction between
NQO2 and TBBz or DMAT. In particular, we wanted to determine how similar the active
site of NQO2 was to the ATP binding site of CK2 and other kinases.
While TBB, TBBz, and DMAT all bind CK2 with nanomolar affinity (11, 14, 41) (Table
4.1), the affinity of TBB for oxidized NQO2 is 3 orders of magnitude lower than that of
TBBz and DMAT (Table 4.1). Similarly, the IC50 values of TBB, TBBz, and DMAT for
inhibition of NQO2 are dramatically different (Table 4.1), with TBB exhibiting much
weaker inhibition of NQO2, consistent with its relatively low binding affinity. The
difference in binding affinities between TBB and TBBz/DMAT can be explained by the
charge of the inhibitors (Figure 4.1). The triazole function of TBB has an estimated pKa
of 5 and is expected to be anionic at physiological pH, whereas the imidazole functions of
TBBz and DMAT have pKa values of approximately 9 and will therefore be neutral at
physiological pH (34). In CK2, the negatively charged triazole portion of TBB interacts
with a region of positive electrostatic potential (Figure 4.6A,B) (6, 42). In the case of
oxidized NQO2, the surface of the active site has a negative electrostatic potential that
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precludes high-affinity interactions with anionic TBB (Figure 4.6C). Thus, differences in
the electrostatic potential of the active sites of NQO2 and CK2 explain why TBB binds
with a relatively low affinity to the NQO2 active site.
DMAT and TBBz bind with a similar high affinity to oxidized NQO2, and our structural
analysis shows that they bind in a similar manner, stacking on top of the isoalloxazine
ring of FAD with the bromine atoms making halogen bonds to nearby carbonyl groups as
well as the indole side chain of W105 (Figure 4.5). Both TBBz and DMAT bind in two
orientations. For TBBz, the preferred orientation is one in which two bromine atoms and
one of the imidazole nitrogens make bonds with two carbonyl groups and W105,
respectively (Figure 4.5A). The small difference in affinity between TBBz and DMAT is
likely due to the inability of DMAT to fully adopt the preferred conformation (Figure
4.5A) because of a steric clash between its dimethylamine function and the indole side
chain of W105 (Figure 4.5C). Structures of CK2 in complex with TBBz and DMAT
show that the two inhibitors bind to the CK2 active site in an identical manner (PDB
entries 1ZOE and 2OXY, respectively) (42, 43). In CK2, the two drugs are sandwiched
between hydrophobic residues and two of the bromine atoms make halogen bonds with
backbone carbonyl groups of E114 and V116 (Figure 4.6B). In the case of CK2, DMAT
binds with 10-fold greater affinity than TBBz because of additional favorable interactions
mediated by the dimethylamine group.
In summary, the NQO2 active site appears to mimic the adenine binding site of CK2 in
the sense that it provides a hydrophobic crevice that can accommodate planar aromatic
molecules, and there are two carbonyl groups that are well placed to mediate charge
interactions with the bromine atoms of these inhibitors in a manner similar to that
observed in CK2. On the other hand, NQO2 provides an environment that allows both
TBBz and DMAT to bind in alternate orientations, whereas binding to CK2 is limited to a
single orientation. Furthermore, the presence of the dimethylamine group on DMAT
favors binding to CK2 but disfavors binding to NQO2. These observations, in addition to
the striking differences in the electrostatic potential in the two active sites, indicate that
the binding of TBBz and DMAT to NQO2 is adventitious and on the whole the NQO2
active site is not a good mimic of the CK2 active site.
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Figure 4.6 Binding of DMAT to CK2, Oxidized NQO2, and Reduced NQO2.
(A) The molecular surface of the CK2 active site is shown with bound DMAT (PDB
entry 1ZOE, (42)) and colored according to electrostatic potential. (B) Details of
interactions between DMAT (orange carbons) and the CK2 active site. Note that TBBz
(not displayed) binds in exactly the same manner as DMAT(42). The position of CK2bound TBB (green carbons, PDB entry 1J91,(44)) is also shown: the negative charge of
the triazole moiety (Figure 4.1) causes a shift toward a more positively charged region in
the CK2 active site (42). (C) Molecular surface of the active site in oxidized NQO2 with
bound DMAT in two orientations. (D) Details of the binding of DMAT to oxidized
NQO2. (E) Molecular surface of reduced NQO2 with bound DMAT in two orientations,
including three water molecules (cyan) that are present in the reduced, but not the
oxidized, structure. (F) Details of the binding of DMAT to reduced NQO2. Electrostatic
potentials were calculated using APBS (45), and partial charges were calculated using
PDB entry 2PQR (46). In the case of oxidized FAD, the sum of the partial charges in the
isoalloxazine ring yielded an overall charge of -0.2; for reduced FAD, an additional full
charge was added and distributed roughly evenly between the N1 and O2 atoms. The
figures were made in PyMol (version 1.7.0.5, Schrödinger, LLC), and the color limits for
the electrostatic surfaces were set to -12 kT (red) to 12 kT (blue) for all three structures.
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Another major difference between the active sites of NQO2 and CK2 is that the NQO2
active site can exist in either an oxidized or reduced form. The origin of the change in
oxidation state is the isoalloxazine ring of FAD: upon interaction with a reduced
nicotinamide co-substrate (NRH or SCDP), two electrons are transferred onto the
isoalloxazine ring of FAD (47). Upon reduction, the N5 atom is protonated and its orbital
changes from planar sp2 to trigonal pyramidal sp3 hybridization. These changes allow it to
donate a hydrogen bond, and the change in orbital hybridization also disrupts the
planarity of the isoalloxazine ring, leading to a small butterfly bend. Thus, reduction of
FAD leads to a relatively minor structural change in the isoalloxazine ring but more
importantly imparts a negative charge that will be largely centered around N1 and O2 of
the isoalloxazine ring. Our crystallographic study indicates that reduction of the
isoalloxazine ring completely changes the mode of binding of DMAT: it binds in a more
peripheral location, and the interactions of the bromine atoms with the carbonyl groups
are mediated through intervening water molecules.
Compounds that bind with high affinity to only one form of NQO2, either oxidized or
reduced, exhibit predictable effects on the steady-state kinetics of the system. Thus,
TBBz binds with high affinity to oxidized NQO2 and competes with SCDP, resulting in
significant changes in the apparent Michaelis constant for SCDP; furthermore, the
inhibition constant against SCDP is close to its dissociation constant, as expected. This
does not mean that TBBz completely fails to bind to reduced NQO2; in fact, given the
similarity between TBBz and DMAT, it is likely that TBBz binds to the reduced form of
NQO2 in a manner similar to that observed for DMAT. However, because the affinity of
the interaction between TBBz and reduced NQO2 is relatively weak compared to binding
of TBBz to oxidized NQO2, the inhibition observed in the steady-state kinetic analysis is
due almost entirely to its binding to oxidized NQO2, and therefore, TBBz has little
impact on the Michaelis constant for menadione.
The situation appears to be more complicated for an inhibitor such as DMAT that binds
with similar affinities to both oxidized and reduced NQO2. The lower affinity of DMAT
for oxidized NQO2 made the interaction between DMAT and reduced NQO2 apparent in
our steady-state kinetic analysis, where the presence of DMAT had a significant effect on
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the Michaelis constants for both SCDP and menadione. In this case, changes in both
Michaelis constants were used to calculate inhibition constants (KI values) of 121 nM
against SCDP and 302 nM against menadione, both of which are significantly higher than
the dissociation constant (36 nM) for binding of DMAT to oxidized NQO2. This is a
confusing result because the inhibition constant is expected to represent a dissociation
constant for the inhibitor. The relatively high KI values for DMAT are in line with the
high IC50 for DMAT, which is 6-fold higher than the IC50 for TBBz, despite the fact that
DMAT binds to oxidized NQO2 with a KD that is only twice as high as that of TBBz. It
seems as though the ability of DMAT to bind with similar affinities to both the oxidized
and reduced forms of NQO2 actually weakens its ability to inhibit NQO2-mediated
catalysis. Although we can only speculate about the molecular origins of this effect, it
highlights the complicated nature of NQO2 and the fact that binding interactions may
have unpredictable effects on catalysis and, by extension, in vivo function.

4.4.1

Inhibition of NQO2 by Other Kinase Inhibitors

Interestingly, NQO2 was also found to be the only non-kinase target of two Abl kinase
inhibitors as well as protein kinase C bisindolylmaleimide inhibitors (24, 25, 27).
Specifically, the cancer wonder drug imatinib and its second-generation derivative,
nilotinib, were found to bind and inhibit NQO2. Structural investigation showed that
rings A and B of imatinib that occupy the ATP binding site of the Abelson kinase were
also found to occupy the active site of NQO2 (26). While imatinib does not inhibit CK2
(48) and CK2 inhibitors do not inhibit the BCR-ABL kinase (15), both were found to
interact with the non-kinase target NQO2 (17, 25). Therefore, there are several classes of
kinase inhibitors that bind NQO2 fortuitously, and the specific cellular effects of these
kinase inhibitors may be due in part to their interaction with NQO2.
One of the cellular functions of NQO2 may be the detoxification of quinones by twoelectron reduction; however, the natural substrates have not been identified, and it is not
obvious why NQO2 would have evolved a preference for NRH over NAD(P)H to fulfill a
detoxification function. A second possible function for NQO2 may involve cellular
signalling in response to changes in metabolic and/or redox status. In particular, NQO2
was shown to stabilize p53 from 20S proteasomal degradation in the presence of NRH
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(20, 21). While the canonical degradation pathway of p53 is ubiquitin-dependent and uses
the 26S proteasome, degradation by the 20S proteasome is ubiquitin-independent and is
modulated by quinone reductase 1 (NQO1) and NQO2 (20, 21, 49). Interestingly, NQO1,
the “sister enzyme” of NQO2, uses NAD(P)H as a co-substrate and is specific for a
different set of inhibitors. Given their difference in co-substrate specificity, NQO1 and
NQO2 may be regulating p53 stability in response to changes in the cellular redox state,
as reflected in the levels of NAD(P)H and NRH, but this remains a matter of speculation.
Strikingly, numerous NQO2 inhibitors such as melatonin, resveratrol, chloroquine,
imatinib, 9-aminoacridine, and quinacrine have been shown to induce p53-dependent
apoptosis (50–54). Melatonin and resveratrol both induce p53 phosphorylation at serine
15, which is essential to the transactivation of p53-induced apoptotic genes (50, 53);
chloroquine, 9-aminoacridine, and quinacrine, on the other hand, increase p53 levels
without phosphorylation at serine 15, which is thought to lead to transcriptionindependent apoptosis modulated by p53 (51, 54, 55). The fact that NQO2 binds all of
these bioactive compounds is remarkable, but a contribution from NQO2 to the cellular
effects of these compounds has yet to be demonstrated.
The cellular roles of NQO2 are still very much a matter of debate. In this regard, the
cellular effects of two high-affinity (nanomolar) inhibitors of NQO2 have been
investigated. S29434 was developed by the French pharmaceutical company Servier as a
compound that inhibits the third melatonin binding site (MT3), which is NQO2, without
inhibition of the two other melatonin binding sites, both of which are G-protein coupled
receptors (56, 57). S29434 prevents generation of reactive oxygen species in vitro and in
vivo, and it prevents paraquat induced toxicity to cell lines in a ROS-dependent manner
(58, 59). Similarly, NQO2 knockout mice were resistant to menadione induced toxicity
(60), which likely occurs through oxidative stress resulting from NQO2-mediated
metabolism of menadione. Therefore, inhibitors of NQO2 can prevent cell death caused
by compounds that are toxic when they are metabolized by NQO2; however, inhibition of
NQO2 appears to have little effect on cells in the absence of these toxic compounds.
A second series of inhibitors, based on an imidazoacridin-6-one core, was identified
through a computational screen of the National Cancer Institute chemical database (61).
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The compound that was initially identified (C1311 or NSC645809) is a known DNA
intercalating agent and an inhibitor of FLT3 kinase (62). This compound, as well as
related imidazoacridin-6-ones, inhibits NQO2 in the nanomolar range and is cytotoxic to
cells. N-Oxide derivatives of the imidazoacridin-6-one compounds that retained
nanomolar affinity for NQO2 but had reduced DNA intercalating properties were
developed (61). Surprisingly, the presence of the N-oxide modification also decreased
cytotoxicity by 10 to 20-fold in a variety of cell lines. As such, it appears that the
apoptotic effects of this class of inhibitors are due largely to their ability to intercalate
DNA. It was also noteworthy that the seven breast cancer cell lines tested in the study
exhibited up to 50-fold differences in NQO2 activity but virtually no difference in their
sensitivity to the imidazoacridin-6-one inhibitors (61). The N-oxide derivatives of the
imidazoacridin-6-one compounds were much less toxic than the parent compounds but
still had toxicity IC50 values in the low micromolar range; this toxicity was probably not
due to inhibition of NQO2, because the IC50 values for NQO2 inhibition were typically
2−3 orders of magnitude lower than the toxicity IC50 values. That is, for N-oxide
derivatives of the imidazoacridin-6-one compounds, concentrations that would
completely inhibit NQO2 do not appear to be cytotoxic.
Article From the studies with S29434 and the N-oxide derivatives of imidazoacridin-6-

one compounds, it appears that inhibition of NQO2 is not cytotoxic; similarly, NQO2
knockout mice were almost identical to wild-type littermates, although there were some
differences, including myeloid hyperplasia due to a decreased level of apoptosis of
myeloid cells (60). The NQO2 knockout mice were also more susceptible to benzopyrene
induced carcinogenesis, and the absence of NQO2 prevented TNFα-induced apoptosis in
an NFκB-dependent manner (63, 64). In summary, it appears that, on its own, inhibition
of NQO2 or genetic knockout is not toxic to cells. Instead, it may be that inhibition or
removal of NQO2 in conjunction with other “inputs” – metabolic or oxidative stress, drug
mediated changes in the activity of kinases, DNA damage, and so on – leads to more
pronounced toxicity and/or other cellular effects. Because kinase inhibitors are designed
to be kinase specific, the fact that a number of efficacious inhibitors bind NQO2 with
high affinity challenges the “single-target” approach in drug discovery. It may be that
binding of both NQO2 and kinases is important for the cellular effects of the inhibitors,
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including enhanced apoptosis of transformed cells. As CK2 and other kinase inhibitors
continue to be developed and used as therapeutics, it will be crucial to characterize offtarget interactions with NQO2 and possibly other non-kinase targets to fully understand
the cellular effects of these compounds and the roles of the individual targets in these
effects.
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Chapter 5

5

The Binding of DNA Intercalating Agents to Oxidized
and Reduced Quinone Reductase 27

Quinone reductase 2 (NQO2) is an enzyme that may also have intracellular signalling
functions. A wide range of planar aromatic compounds bind NQO2, and we have
identified three DNA intercalating agents – ethidium bromide (EtBr), acridine orange
(AO), and doxorubicin – as novel nanomolar inhibitors of NQO2. The cationic EtBr and
AO bound reduced NQO2 with 50-fold higher affinity than oxidized NQO2, while
doxorubicin only bound oxidized NQO2. Crystallographic analysis of oxidized NQO2 in
complex with the inhibitors indicated that inhibitors bound oxidized NQO2 deeply in the
active site. The aromatic faces were sandwiched between the isoalloxazine ring of FAD
and the phenyl ring of F178, and their edges making direct contacts with active site
residues. In reduced NQO2, EtBr and AO occupied a more peripheral position in the
active site, allowing several water molecules to interact with the polar end of the
negatively charged isoalloxazine ring. We also showed that AO inhibited NQO2 at a nontoxic concentration in cells while EtBr was less effective at inhibiting NQO2 in cells.
Together, this study suggested a role of NQO2 as a sensor for potential DNA
intercalating agents.

5.1

Introduction

Quinone Reductase 2 (NQO2) was historically classified as a detoxification enzyme
responsible for the reduction of potentially cytotoxic quinones(1). Similar to its sister
enzyme Quinone Reductase 1 (NQO1), NQO2 catalyzes an obligate 2-electron transfer to
generate the hydroquinone, thereby preventing production of reactive semi-quinones.
While NQO1 efficiently catalyzed quinone reduction using NAD(P)H as a reducing
coenzyme (kcat/KM = 440 min-1ŊµM-1), NQO2 used NAD(P)H inefficiently, with a
catalytic efficiency 700-fold lower than NQO1 (kcat/KM = 0.62 min-1ŊµM-1) (2). On this
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basis, it appears that NQO2 has evolved to avoid using the canonical reducing coenzymes
NADH and/or NADPH. Instead, NQO2 exhibits a preference for unusual, and possibly
non-physiological, reducing coenzymes, such as dihydro-nicotinamide riboside (NRH)
(2). Although nicotinamide riboside (NR+) participates in NAD metabolism, it is
currently unknown how the reduced form, NRH, is generated in cells. On this basis, the
availability of the reducing coenzyme for NQO2 in cells is currently an open question.
Furthermore, the only cellular quinone substrate of NQO2 is ubiquinone, which resides in
the mitochondria and is inaccessible to NQO2 (3). Given its inefficient utilization of
NAD(P)H and lack of physiologically relevant quinone substrates, NQO2 may have
important cellular functions beyond reduction of quinones.
NQO2 has been implicated in cell signalling as well as the formation of reactive oxygen
species (4–6). Specifically, NQO2 modulated the 20S proteosomal degradation of p53 in
a NRH-dependent manner (4, 7). Furthermore, NQO2 also indirectly regulates the
AKT/cyclin-D1/Rb and NFκB signalling pathways (5, 8). Numerous bioactive
compounds interact with NQO2, raising the possibility that some of the cellular effects of
the compounds may be attributed to NQO2. These compounds ranged from targeted
kinase inhibitors (imatinib and nilotinib (9, 10), CK2 inhibitors (11), PKC inhibitors
(12)), antimalarial compounds (primaquine, chloroquine, and quinacrine (13)), natural
flavonoids (quercetin (2)), stilbenoid (resveratrol (14)), and hormones (melatonin (15)).
All of these compounds perturb cellular proliferation and/or apoptosis, but the role of
NQO2 in these processes is not known.
The active site of NQO2 is composed of a large hydrophobic pocket with a planar
aromatic surface provided by the isoalloxazine ring of the FAD cofactor (16). As such,
the planar aromatic portions of NQO2 inhibitors bind to the active site through pi-pi
stacking interactions with the isoalloxazine ring and hydrophobic residues. Given the
planar nature of NQO2 inhibitors, it is perhaps not surprising that a number of them, such
as imatinib, quinacrine, and 9-aminoacridine can also intercalate DNA (17–19). In fact,
several compounds known to intercalate into DNA (9-aminoacridine and C1311) were
identified from an in silico screening of NQO2 inhibitors (8, 20). Given the potential
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roles of NQO2 in cell signalling and the nature of compounds that bind NQO2, we
investigated whether NQO2 is a target for additional DNA intercalating agents.
DNA intercalating compounds are polycyclic aromatic molecules that act as potent
cytotoxic and mutagenic agents to cells. In 1961, Leonard Lerman proposed and
eventually showed that these compounds can unwind and extend DNA by inserting
themselves between two nucleotide bases (21). In highly proliferating cells, these
compounds are cytostatic by inhibiting DNA replication or transcription (22, 23). For
cells that overcome replicative stress, the intercalating agents elongate DNA and cause
DNA slippage leading to indel mutations during DNA replication (24, 25). When present
in the environment, cells can deal with these harmful compounds by active excretion
through efflux pumps such as P-glycoprotein (multidrug resistant-associated protein)
and/or metabolism by cytochrome P450 (26); however, cells unable to clear DNA
intercalators are at risk of cell growth retardation and genomic instability.
Since DNA intercalators can be detrimental to cells, we hypothesize that NQO2 can
recognize potential DNA intercalating agents and function, at least in part, as a sensor for
these compounds. In this study, we have tested three well-characterized DNA
intercalating agents – ethidium bromide (EtBr), acridine orange (AO), and doxorubicin –
and found that they are all nanomolar inhibitors of NQO2. We further characterized these
three novel inhibitors of NQO2 by means of enzyme kinetics, isothermal titration
calorimetry, and crystallographic analysis. We found that the cationic EtBr and AO
bound reduced NQO2 with a 50-fold higher affinity than oxidized NQO2; this can be
explained by the increased negative electrostatic potential in the active site of reduced
NQO2. In this regard, we have identified AO to be the highest affinity inhibitor for
reduced NQO2, with a dissociation constant of 0.36 nM. Structurally, the inhibitors bind
to the NQO2 active site in a manner that resembles their interaction with DNA. Lastly,
we demonstrate that a non-toxic concentration of AO can inhibit NQO2 activity in cells.
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5.2
5.2.1

Materials and Methods
Reagents

Recombinant NQO2 was expressed in E. coli and purified as previously described (27).
1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP) is an analogue of
NRH obtained from Sigma-Aldrich. Nicotinamide riboside (NR) was purchased from
High Performance Nutrition (Irving, CA, USA) and dihydronicotinamide riboside (NRH)
was prepared according to previously described protocol with NR (28). Ethidium
bromide was obtained from Bioshop, AO and doxorubicin were obtained from Caymen
Chemical.

5.2.2

Enzymatic Activity Measurements and Analysis

Enzyme activity was measured by monitoring the consumption of SCDP at an absorbance
peak of 360 nm using a Cary 100-Bio spectrophotometer (Varian). The reaction was
initiated by addition of NQO2 to a final concentration of 154 pM in a stirred cuvette
containing 150 µM SCDP and 5 µM menadione (Sigma) at 30°C with EtBr (1.9 nM to
2.6 µM), AO (7.8 nM to 1 µM) or doxorubicin (80 nM to 50 µM) in a buffer (50 mM
Tris-HCl pH 7.5, 150 mM NaCl). IC50 values were calculated using a dose-response
model and represented as relative inhibition.
The constants for inhibition (KI values) of NQO2 by EtBr were determined using the
same kinetics assay described for determination of IC50 values. For each inhibitor, kinetic
assays were performed either with a constant SCDP concentration of 150 µM and a
varying menadione concentration or with a constant menadione concentration of 5 µM
and a varying SCDP concentration. NQO2 is subject to substrate inhibition by
menadione, and inhibitors of NQO2 can be competitive against SCDP, menadione, or
both. On this basis, we used an equation for steady-state ping-pong catalysis that includes
a term for substrate inhibition by menadione (KI(Md)), as well as constants for inhibition
against both the oxidized and reduced forms of the enzyme (29):
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Equation 5.1 Inhibition of NQO2 Catalysis
In Equation 5.1, [SCDP] and [Md] are the concentrations of SCDP and menadione
respectively. KI(MD) is the inhibition constant that accounts for substrate inhibition. [I] is
the concentration of inhibitor and KI(α) and KI(β) are the inhibition constants that modify
the apparent Michaelis constants KM(SCDP) and KM(Md), respectively. That is, KI(α) is the
constant that accounts for the change in KM(SCDP) in the presence of inhibitor; hence, it
describes the component of inhibition that is competitive against SCDP. KI(β) is the
constant that accounts for the change in KM(Md) in the presence of inhibitor, and it
describes the component of inhibition that is competitive against menadione. Fixing the
kinetic parameters of the uninhibited steady-state kinetics KM(SCDP) (142 µM), KM(Md)
(8.07 µM), and KI(Md) (1.62 µM) with values previously determined (29), Vmax, KI(α), and
KI(β) were determined by globally fitting data to Equation 5.1 using nonlinear regression
(Igor Pro version 6.34A) with the IC50 values as initial estimates.

5.2.3

Isothermal Titration Calorimetry

Isothermal titration calorimetry (ITC) was used to assess the direct binding of the
inhibitors to NQO2. Titrations were performed using a MicroCal VP-ITC
microcalorimeter and all data were analyzed using Origin 7.0 (MicroCal). Samples of
concentrated NQO2 (700 µM in 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) and
concentrated inhibitors (20 to 60 mM in H2O or DMSO) were diluted into ITC buffer (50
mM sodium phosphate, 150 mM NaCl pH 7.55) to final concentrations of 8 µM and 80 to
260 µM respectively. In cases where inhibitor stocks were suspended in DMSO, an equal
amount of DMSO was also added to the protein sample to match the buffer composition
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between the sample and titrant. All solutions were thoroughly degassed by stirring under
vacuum. All titrations were performed at 25°C or 35°C with 3-10 µl injections spaced by
3 to 5 minute intervals. The integrated binding isotherms were corrected for the heat of
dilution using data from titrations of the individual inhibitors into the respective matched
buffers in the absence of NQO2. For the binding of inhibitors to oxidized NQO2, the 1.35
mL sample cell was filled with an 8 µM solution of NQO2 and the 250 µL syringe was
filled with 80 µM EtBr, AO, or doxorubicin. All ITC titration data towards oxidized
NQO2 were fitted to a single-site binding model with MicroCal Origin7 software.
Reduced NQO2 is subject to rapid oxidation (30); however, the calorimeter provided a
closed environment that limited diffusion of oxygen into the solutions. To titrate
compounds against reduced NQO2, SCDP was added to degassed solutions of both
NQO2 and the inhibitors to a final concentration of 500 µM. To measure the very high
affinities of EtBr and AO towards reduced NQO2, competition titrations were performed
by adding 80 µM of EtBr or AO into 8 µM of NQO2 pre-mixed with 80 µM chloroquine
(CQ) and 500 µM SCDP. Additionally, the binding of CQ alone to reduced NQO2 was
determined by titrating 160 µM CQ into 8 µM of NQO2 and 500 µM SCDP. This second
binding isotherm was fitted to a single-site binding model. Using the thermodynamic
parameters of CQ to reduced NQO2, the binding isotherms of the displacement titrations
were fitted to a competitive binding model using MicroCal Origin7 software to determine
the thermodynamic parameters EtBr and AO.

5.2.4

Crystal Structure Analysis

Oxidized NQO2 (NQO2ox) was co-crystallized with EtBr, AO, or doxorubicin by
hanging drop vapour diffusion against reservoirs containing 0.1 M HEPES pH 7.5, and
1.3 – 2.0 M (NH4)2SO4. To obtain crystals of reduced NQO2 in complex with EtBr or
AO, reduction of NQO2ox-inhibitor crystals was performed as previously described (30).
Briefly, crystals of NQO2ox-EtBr or AO were repeatedly soaked into 1 µL of reducingsoak solution with 0.1 M HEPES pH 7.5, 2.0 M (NH4)2SO4, 10 mM SCDP, and 1 mM of
inhibitor, for 2 minute intervals until the crystals bleached. They were then transferred to
a soak without SCDP before briefly passing through a cryoprotectant solution (2.0 M
(NH4)2SO4, 0.1 Hepes pH 7.5, 20% glycerol) and plunged into liquid nitrogen. To

117

prevent auto-oxidation of NQO2, the entire crystal mounting process from harvesting to
cryo-cooling was performed under an anoxic atmosphere in a glove bag purged with N2.
Crystallographic data were collected from a rotating anode source, processed using
MOSFLM (31), and merged using Scala (32). The structures were solved by molecular
replacement with PDB-ID 1QR2 as a starting model (16); refinement was carried out
using PHENIX (33). All crystals had the same primitive orthorhombic space group and
contained a dimer in the asymmetric unit; given the high resolution of the
crystallographic data, NCS restraints were not used for any of the refinements. Topology
files for EtBr and AO were generated using PHENIX.ELBOW (33). The “butterfly bend”
of the isoalloxazine ring was determined by simulated annealing with planar restraints
removed, as previously described (30).

5.2.5

DNA Binding Pocket Comparison

The solvent accessible area in DNA or NQO2 binding pocket was calculated using
POVME 2.0 (34, 35). Briefly, a contiguous area was generated from an arbitrary point in
the binding site of the ethidium unwound DNA structure (36) or reduced NQO2-EtBr
structure for a 10 Å spherical radius. Dimensions of the binding pockets were then
measured at arbitrary points along the edge of the binding pocket.

5.2.6

Effect of AO on HCT116 Colon Carcinoma Cells

To determine the cytotoxicity of AO, HCT116 cells were seeded at 1000 cells per well in
96-well plates and allowed to attach overnight. Cells were then treated with AO (0.014 to
230 µM) and grown for an additional 48 hrs before assaying using Sulforhodamine B
(SRB; Sigma) assay according to established protocol(37). Briefly, cells are fixed with
trichloroacetic acid for 1 hr at 4°C and washed with water 3 times. Cells were then
stained with 0.3% SRB in 1% acetic acid for 20 mins at room temperature and washed
with 1% acetic acid 4 times. The dye was re-solubilized in 10 mM Tris base and
absorbance was measured using at 560 nm (Victor multi-plate reader, Perkin Elmer). Cell
growth in treated samples was normalized against controls that were not treated. Data
were analyzed and plotted using Prism 6.0f (GraphPad Software Inc).
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To assay the ability of AO to inhibit NQO2, HCT116 cells were seeded at 1000 cells per
well in 96-well plates and allowed to attach overnight. Cells were then treated with 7.8
µM to 1000 µM CB1954 with 50 µM NRH, with 50 µM NRH and 78 nM AO, or without
NRH. Cells grew for an additional 48 hrs before being assayed using MTT dye. Briefly,
cells were treated with 1 mM of MTT dye and were incubated at 37˚C for 2-4 hrs. Media
was completely removed and the dye was solubilized in DMSO to be measured at 560
nm using a plate reader. Cell growth in treatment wells was normalized against cells with
no treatment and data were analyzed using Prism 6.0f (GraphPad Software Inc).
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5.3
5.3.1

Results
DNA Intercalating Agents Inhibit NQO2

Ashman and co-workers first characterized NQO2 in 1962 and showed that a small
concentration (10 nM) of a number of anthracene derivatives inhibited its activity (38).
Since then, many other planar polycyclic aromatic compounds were identified as
inhibitors of NQO2 including compounds that also intercalate DNA (8, 20, 39). To
characterize the interaction between NQO2 and DNA intercalating agents in greater
detail, we investigated the ability of 5 different DNA intercalating molecules to inhibit
NQO2 (Figure 5.1). Three of the intercalating agents – ethidium bromide (EtBr), acridine
orange (AO), and doxorubicin – exhibited IC50 values in the nanomolar range; the other
two, mitoxantrone and methylene blue, showed relatively weak inhibition of NQO2
catalysis with IC50 values greater than 10 µM (Figure 5.2A and Table 5.1).

Figure 5.1 Chemical Structures of DNA Intercalating Agents.
NQO2 catalyzes quinone reduction by a ping-pong mechanism: the dihydronicotinamide
co-enzyme is first oxidized, transferring a hydride ion to the NQO2-bound FAD cofactor; the quinone substrate then binds to reduced NQO2, and electrons are transferred to
produce the corresponding hydroquinone. Thus, NQO2 can exist in either an oxidized or
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reduced state, and inhibitors can be competitive towards the dihydronicotinamide coenzyme or the quinone substrate. In a kinetic assay, this means that an inhibitor can raise
the apparent KM for the dihydronicotinamide coenzyme or the quinone substrate. Using
our previously established kinetic model (Equation 5.1), the terms KI(α) and KI(β) account
for changes in the apparent KM of SCDP (an NRH analogue) and menadione (the quinone
substrate) respectively (29). Our kinetic characterization of EtBr inhibition towards
NQO2 showed that competition with menadione was the dominant mode of NQO2
inhibition (KI(β) = 6.7 nM versus KI(α) > 500 nM; Figure 5.2B, Table 5.2). In other words,
EtBr binds reduced NQO2 with much greater affinity compared to oxidized NQO2, and
this interaction is responsible for inhibition of NQO2 catalysis.

Figure 5.2 Ethidium Bromide, Acridine Orange, and Doxorubicin are Inhibitors of
NQO2.
(A) Determination of IC50 values for EtBr (), AO (¢), and doxorubicin (p) against
NQO2-catalyzed reduction of menadione. The IC50 values are listed in Table 1. (B)
Determination of kinetic inhibition constants for EtBr. The inhibition of NQO2 by EtBr
was characterized using a constant menadione concentration (5 µM) and varying SCDP
(left), and a constant SCDP concentration (150 µM) with varying menadione (right). The
enzymatic activity was measured in the absence of EtBr () and at EtBr concentrations
of 2 nM (¢), 10 nM (p), 50 nM (q), and 250 nM (u). The data were globally fitted to
Equation 5.1 as described in Materials and Methods. The kinetic constants are
summarized in Table 5.2.
Table 5.1 Inhibition of NQO2 by DNA Intercalating Agents.
Intercalating Agent
Ethidium Bromide
Acridine Orange
Doxorubicin
Mitoxantrone
Methylene Blue

IC50 (nM)
11.8 ± 0.4
24.6 ± 4.1
254 ± 41.7
> 10 000
> 10 000
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Table 5.2 Steady-state Kinetic Parameters for Inhibition of NQO2 by EtBr.
Vmax a
1184 ± 30 s-1
a,c
KI(α)
555 ± 2270 nM
a,c
KI(β)
6.7 ± 1.24 nM
Km (SCDP)b
142 µM
b
Km (menadione)
1.62 µM
Ki (menadione)b
8.07 µM
a
Calculated by globally fitting data to equation 1 as described in Methods.
b
Steady state kinetic parameters for the uninhibited reaction were determined previously
(29)
c
KI(α) and KI(β) are the constants for inhibition against SCDP and menadione,
respectively.

5.3.2

Binding of DNA Intercalating Agents to Oxidized and
Reduced NQO2

The preferential binding of EtBr to reduced NQO2 is of interest because the reduced form
of NQO2 appears to play an important role in cells. That is NQO2 was shown to inhibit
p53 degradation in the presence of NRH, and on this basis it appears that reduced NQO2
is the “active” state of the enzyme that is capable of regulating p53 (4). To further
characterize interactions between DNA intercalating agents and NQO2, the binding of
EtBr, AO, and doxorubicin to both oxidized and reduced NQO2 was measured using
Isothermal Titration Calorimetry (ITC). Of the three compounds, AO bound oxidized
NQO2 with the highest affinity, almost 10-fold greater than both EtBr and doxorubicin
(Table 5.3, Figure S5.1A-C). Preliminary titrations of AO and EtBr against reduced
NQO2 indicated that their binding affinities were much higher compared to oxidized
NQO2. To accurately characterize the very high affinity binding of both EtBr and AO to
reduced NQO2, competition ITC was used (40). In competition ITC, a compound with
high binding affinity is titrated against the target protein in complex with a relatively low
affinity ligand. In the case of NQO2, chloroquine (CQ) was used as the low-affinity
ligand. A direct titration of reduced NQO2 with CQ yielded a KD value of 0.57 µM
(Table 5.3, Figure S5.1G) similar to its inhibition constant (0.6 µM) determined
previously using enzyme kinetics (13). Consistent with the kinetics assays, EtBr bound
most tightly to reduced NQO2, with a KD over 60 times lower compared to the oxidized
form (Table 5.3, Figure S5.1D). The situation was similar for AO, which bound
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preferentially to reduced NQO2 with sub-nanomolar affinity (Table 5.3, Figure S5.1E).
Doxorubicin bound to oxidized NQO2 with sub-micromolar affinity but there was no
observable binding to the reduced form (Table 5.3, Figure S5.1F).
Table 5.3 Binding of NQO2 Inhibitors to Oxidized and Reduced NQO2
NQO2

ΔG
ΔH
-TΔS
(kcal/mol) (kcal/mol)
(kcal/mol)
Oxidized EtBr
215 ± 33
-9.4
-7.8 ± 0.1
-1.6
AO
29.4 ± 28.7
-10.3
-7.6 ± 0.2
-2.6
Doxorubicin
274 ± 49
-8.9
-8.1 ± 0.2
-0.8
Reduced EtBra
3.47 ± 0.33
-11.5
-6.7 ± 0.1
-4.8
a
AO
0.36 ± 0.12
-12.9
-6.5 ± 0.1
-6.3
Doxorubicinb
NB
CQ
578 ± 116
-8.5
-17.7 ± 0.5
9.2
a
Thermodynamic parameters were determined by competition titrations against NQO2 in
complex with CQ as described in Methods.
b
There was no observable binding of doxorubicin to reduced NQO2 (Figure S5.1F).

5.3.3

Inhibitor

KD (nM)

Crystal Structures of NQO2 with DNA Intercalating Agents

There are numerous structures of oxidized NQO2 in complex with a variety of inhibitors,
but only two in which inhibitor binding to reduced NQO2 has been structurally
characterized (29, 30). In both cases, reduction of the FAD cofactor led to a striking
change in the binding mode of the inhibitors. We have extended this comparative analysis
by solving the high resolution crystal structures of oxidized and reduced NQO2 in
complex with EtBr and AO, as well as doxorubicin in complex oxidized NQO2 (Table
S5.1). In all of the oxidized NQO2 inhibitor complexes, the inhibitors are deeply buried
in the active site and sandwiched between the isoalloxazine ring of FAD and the phenyl
ring of F178 (Figure 5.3A, C, and E). As such, binding of the inhibitors to oxidized
NQO2 includes common aromatic stacking interactions. In the structure of reduced
NQO2 with EtBr (Figure 5.3B) the overall orientation of ethidium has not changed, but it
is positioned less deeply in the active site. The space vacated by the ethidium is filled
with three water molecules that mediate hydrogen bonds between the amino group on the
ethidium and N161 and G174 of NQO2. The situation is similar for AO: when bound to
oxidized NQO2, AO is positioned deep in the active site, stacking over the oxygens of
the isoalloxazine ring and making direct contact with N161 and G174 (Figure 5.3C).
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However, AO has rotated and occupies a more peripheral location when bound to
reduced NQO2 (Figure 5.3D), and again the space next to N161 and G174 is filled with
water molecules.
The difference in binding mode for EtBr and AO resembles what was observed for
chloroquine (CQ) (30) and the protein kinase CK2 inhibitor DMAT (29), which both
bound to oxidized NQO2 such that they were positioned deep in the active site and made
direct contact with N161 and G174. When bound to reduced NQO2, however, both CQ
and DMAT were positioned in a more peripheral location, and there were water
molecules filling the space between N161, G174, and the inhibitors. It appears that the
properties of the reduced isoalloxazine ring, which include a “butterfly bend” of
approximately 5° (Table S5.1 and Figure S5.2) and a negative charge that will be
delocalized between N1 and O2, make the region above the isoalloxazine oxygens less
suitable for the aromatic stacking interactions observed in the oxidized structures.
Instead, the inhibitors move away from this region which is then occupied by polar, nonaromatic water molecules.
The active site of NQO2 has a negative electrostatic potential that becomes much
stronger when the isoalloxazine ring is reduced and carries a formal negative charge (29).
Both EtBr and AO are positively charged at neutral pH, which explains their preference
towards the negatively charged FADH over neutral FAD. Doxorubicin also has a positive
net charge, but the charge resides on non-aromatic portions of the molecule that are
excluded from the active site (Figure 5.3E). Therefore, a positive charge in the planar
aromatic portions of NQO2 inhibitors appears to determine their preference for reduced
NQO2. This is consistent with the two other NQO2 inhibitors, chloroquine and
quinacrine, which both carry a positive charge in their aromatic portions and exhibit a
marked preference for binding to reduced NQO2 (13).
NQO2 crystallizes with a dimer in the asymmetric unit, and inhibitors can sometimes
adopt different orientations in the two crystallographically distinct binding sites. This was
the case for both the NQO2ox-EtBr and NQO2red-EtBr structures where electron density

124

for a second ethidium molecule in the B-chain active site became evident during
refinement (Figure S5.3). The second ethidium interacts with the first by means of pi-pi

Figure 5.3 Binding of Ethidium, Acridine Orange, and Doxorubicin to NQO2
The inhibitors are sandwiched between the FAD co-factor (below the plane of inhibitor)
and F178 (above the plane of the inhibitor) in oxidized NQO2 (A, C, E), and the
inhibitors are excluded from this region by water molecules in reduced NQO2 (B, D). (A)
Ethidium is deeply buried in the active site of oxidized NQO2 making hydrogen bonds
with N161 directly and to D117, T71, and G68 via two water molecules. (B) Ethidium is
less buried in reduced NQO2 and makes hydrogen bonds with N161 and G174 via three
water molecules on the left side of the binding site, and with G68 and T71 directly on the
right side of the binding site. (C) Acridine orange binds oxidized NQO2 by making
hydrogen bonds to N161 via two water molecules. (D) In the reduced structure of NQO2
in complex with AO, AO makes one hydrogen bond to E193 via a water molecule. (E)
The planar moiety of doxorubicin is inserted into the left side of the binding cleft where it
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is anchored by a hydrogen bond to N161. All electron density maps surrounding the
inhibitors are Fc-Fo omit maps generated after three rounds of simulated annealing and
contoured at 3 σ.
planar stacking of their benzyl substituents, and the rest of the ethidium is loosely
sandwiched between surface residues surrounding the B-chain active site and residues
from a symmetry-related molecule. We believe that this mode of binding is induced
primarily by crystal packing and likely irrelevant for NQO2 in solution. In contrast to
EtBr, both AO and doxorubicin bound in exactly the same manner to both subunits of the
NQO2 dimer.

5.3.4

Comparison between Intercalators Binding to DNA and
NQO2

The high affinity binding of DNA intercalating agents prompted us to compare the
binding pocket in unwound (intercalated) DNA with the active site of NQO2. Molecules
that intercalate DNA create a cavity with pi-pi stacking interactions mediated by the
bases and the potential for hydrogen bonds to the DNA backbone, as shown in the
structure of ethidium bound to DNA (36) (Figure 5.4A). The binding pocket in the DNA
could accommodate molecules up to 13.5 Å in length at the major groove side and 7.9 Å
in length at the minor groove side. Since the DNA is unwound by EtBr, the adjacent base
pairs are not parallel with the space between them varying between 2.5 Å to 3.7 Å. In
NQO2, the isoalloxazine ring in the bottom of the pocket provides pi-pi stacking
interactions, and additional interactions with the other planar face of the inhibitor are
mediated by hydrophobic and aromatic residues at the top of the pocket (Figure 5.4B).
Similar to the binding pocket in DNA, the NQO2 active site can accommodate molecules
up to 13.9 Å in length and 2.7 Å in height. When the reduced NQO2-EtBr structure was
superimposed to the known DNA-EtBr structure by aligning the coordinates of EtBr, the
many residues of the NQO2 binding pocket also superimposed with the unwound DNA
as shown by the overlap of the molecular surfaces of the two molecules (Figure 5.4C). In
the reduced NQO2-AO to DNA-AO (41) comparison, the positively charged nitrogenous
base of AO makes two hydrogen bonds to the hydroxyl group of the two adjacent
guanosine nucleotides via water molecules, in addition to pi-pi stacking interactions
(Figure 5.4D). Similarly in NQO2, the nitrogenous base of AO is anchored to E193 by
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hydrogen bonds via a water molecule. Therefore, the active site of NQO2 bears a
surprising resemblance to the binding pocket in DNA.

Figure 5.4 Comparison of the Inhibitor Binding Sites in Reduced NQO2 and DNA
(A-B) Solvent accessible area (green blob) of the unwound DNA in the DNA-ethidium
structure (A; Cambridge Structure Database ID ETHUAD10) and the NQO2 active site
(B) viewed from the front (left panel) showing the hydrophobic and polar regions of the
binding sites. Views from the top (middle), and from the side (right panel) show the
estimated dimensions in the binding sites. (C) Molecular surface of reduced NQO2 bound
to EtBr (left), DNA intercalated with EtBr (middle), and superimposition of EtBr (right)
to compare the molecular surfaces of the NQO2 and DNA ethidium binding sites. (D)
Molecular surface of reduced NQO2 bound to AO (left) showing that the nitrogenous
base of AO makes a hydrogen bond to E193 via a water molecule; DNA intercalated with
AO (middle, CSD ID ACCYGA10) showing that the nitrogenous base of AO makes a
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hydrogen bond with the hydroxyl group of two adjacent guanosine bases via water
molecules; and superimposition of AO (right) showing the overlap of molecular surfaces
between NQO2 and DNA.
Even though the active site of NQO2 bears some resemblance to the binding pocked in
unwound (intercalated) DNA, the affinities of DNA intercalators for NQO2 do not
correlate well with their affinities for DNA. For example, of the agents studied in this
manuscript, doxorubicin binds DNA most tightly (KD = 384 nM) (42), while binding of
EtBr and AO is much weaker (KD values of 15 and 36 µM, respectively) (43). In the case
of NQO2, EtBr and AO bind reduced NQO2 with very high affinity, with dissociation
constants that are 4 to 5 orders of magnitude lower (i.e. 3.47 and 0.57 nM; Table 5.1)
than those for their binding to DNA; doxorubicin, on the other hand, displays a relatively
modest affinity for NQO2, roughly the same as its affinity for DNA. Furthermore, the
other DNA intercalating agents, methylene blue and mitoxantrone, that did not display
observable inhibition of NQO2 exhibit bind DNA with similar affinity as EtBr and
AO(43, 44). In summary, even though there are similarities between the NQO2 active site
and the space in DNA occupied by intercalators, it does not seem that NQO2 is a
completely faithful mimic of DNA.

5.3.5

Inhibition of NQO2 in Cells

Beyond an in vitro characterization of these novel inhibitors of NQO2, we were also
interested in whether AO, to our knowledge the highest affinity inhibitor of reduced
NQO2 characterized to date, could inhibit NQO2 in cells. First, we established the
cytotoxicity of AO in HCT116 cells. HCT116 cells are colorectal carcinoma cells with a
high level of NQO2 expression and activity (39); in addition, these cells do not express Pglycoprotein (45), preventing active efflux of AO and making them a good model to
assay in-cell inhibition of NQO2 by AO. We found that AO inhibited HCT116 cell
proliferation with an IC50 value of 3.9 ± 0.5 µM and on this basis concentrations of AO
below approximately 500 nM do not affect cell proliferation (Figure 5.5A).
To determine whether NQO2 is inhibited by AO in cells, we used the cancer prodrug
CB1954 that is specifically activated by NQO2 in the presence of NRH (28). CB1954 is a
DNA alkylating agent that can be reduced to a much more toxic DNA cross-linking agent
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by NQO2 in the presence of NRH. Without NRH, the cytotoxicity of CB1954 was 348 ±
41 µM, and in the presence of 50 µM NRH, the cytotoxicity of CB1954 increased 20-fold
to 17.8 ± 1.4 µM (figure 5.5B). Addition of a non-toxic dose of AO (78nM) was able to
partially reverse the NRH-dependent activation of CB1954 and lower its cytotoxicity in
the presence of NRH to 114 ± 15 µM (Figure 5.5C). We also tested whether EtBr was
able to inhibit NQO2 with a non-toxic concentration and found that EtBr had an IC50
value of 9.1 ± 0.9 µM. The highest concentration of EtBr tested (312nM) was only able
to slightly reverse the activation of CB1954 by NRH (data not shown). Therefore, a nontoxic concentration of AO can effectively inhibit NQO2 in cells while EtBr is less
effective at inhibiting NQO2.

Figure 5.5 Validation of NQO2 Inhibition by AO in HCT116 cells
NQO2 is inhibited by AO in HCT116 cells. (A) IC50 of AO in cells. HCT116 cells were
treated with AO at the indicated concentration for 48 hours before being assayed by SRB.
Cell growth of the treated cells was normalized to the cell growth of untreated cells and
the data were fitted to a dose-response curve to calculate an IC50 for AO of 3.9 ± 0.5 µM.
(B) Induction of CB1954 cytotoxicity by NRH. Cells were treated with the indicated
concentration of CB1954 with (¢) and without () 50 µM NRH for 48 hours before
being tested for viability using an MTT assay. (C) Cellular inhibition of NQO2 by AO.
Induction of CB1954 cytotoxicity with 50 µM NRH was partially reversed by cotreatment with 78 nM AO (p). Cytotoxicity of CB1954 with (¢) and without () 50
µM NRH are shown for reference in grey.
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5.4

Discussion

We have identified and characterized the binding of three well-known DNA intercalating
agents to NQO2. Positively charged polycyclic compounds are thought to be better DNA
intercalating agents because they are recruited to the negatively charged phosphate
backbone prior to intercalating DNA. Here, we have shown that when the positive charge
resides in the planar moiety of compounds such as EtBr and AO, they exhibit a marked
preference for binding to reduced NQO2, with affinities towards reduced NQO2 that are
over 50-fold greater compared to those for oxidized NQO2. In contrast, a positive charge
outside the planar aromatic portions of the inhibitor, as in the case of doxorubicin, does
little to enhance binding affinity for reduced NQO2. The results with EtBr and AO are in
line with those of two other NQO2 inhibitors, chloroquine and quinacrine, that bind
preferentially to reduced NQO2 and carry a positive charge in their aromatic ring systems
(13). In summary, the available data indicate that a positive charge in the aromatic ring
system of an NQO2 inhibitor will enhance preferential binding to the reduced form of the
protein.
As an alternative function to the enzymatic reduction of quinones, NQO2 has been
implicated in the regulation of p53, where it was shown that NQO2 in the presence of
NRH protects p53 from 20S proteosomal degradation (4, 7). Thus, the proposed role for
NQO2 in the regulation of p53 requires the presence of NRH, suggesting that it is the
reduced form of NQO2 that is the relevant species. Along these lines, however, is the
question of how NQO2 is reduced in vivo. NQO2 is inefficiently reduced by NAD(P)H,
and it is not clear that NRH is actually present in cells. On this basis, NQO2 in cells may
exist primarily in an oxidized state. Molecules that bind with very high affinity to
reduced NQO2 would be expected to stabilize it and extend its lifetime. Thus, molecules
such as AO and EtBr, with nanomolar affinities to NQO2, could “prime” the cell to
respond to impinging DNA damage and/or apoptotic signals.
NQO2 has been implicated in neurodegenerative disease and cancer tumorigenesis (46,
47), although the cellular functions of NQO2 remain a matter of debate. NQO2 knockout
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mice appear to have lower levels of p53, a weaker induction of p53 by cell stressors, and
decreased apoptosis (47, 48). In addition, NQO2 has been repeatedly identified as a target
for a variety of bioactive compounds, such as resveratrol (14), melatonin (15),
antimalarials (13, 30), and kinase-targeted therapeutics (11, 29). Despite these
provocative observations, the knockout or inhibition of NQO2 does not bring about acute
cellular effects. For example, Karen Nolan and coworkers found that imidazoacridine-6one compounds are potent NQO2 inhibitors but also intercalate DNA at similar
concentrations (20). An N-oxide modification of the parent compound reduced its ability
to intercalate DNA and lowered its cytotoxicity 20-fold while retaining its affinity
towards NQO2 (49). Similarly, we have shown concentrations of AO that are sufficient
to inhibit NQO2 have no obvious effect on cell proliferation. It appears that the function
of NQO2 becomes manifest only when cells are challenged by some other insult.
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5.6

Supporting tables and figures

Figure S 5.1 Inhibitor Binding to NQO2 Assayed by Isothermal Titration
Calorimetry
Titration of EtBr (A), AO (B), and doxorubicin (C) to oxidized NQO2. A syringe filled
with 80 µM of the inhibitor was titrated to a solution of 8 µM NQO2. Competition ITC of
EtBr (D) and AO (E) to NQO2 in the presence of 500 µM SCDP and 80 µM of
chloroquine (CQ). Direct titration of doxorubicin (F) and chloroquine (G) to NQO2 in the
presence of 500 µM SCDP. Titration data were fit to a single substrate model for all
direct titrations, or to a competitive model using fixed values from binding parameters
determined by a titration of CQ to reduced NQO2 (Table 5.3). The thermodynamics
parameters are summarized in Table 5.3.

136

Table S 5.1 Crystallographic Statistics
Crystal

Reduced NQO2

Ligand

Ethidium
bromide

Acridine
orange

Doxorubicin

Ethidium
bromide

Acridine
orange

PDB ID

4BUC

4ZVL

4ZVM

4ZVK

4ZVN

1.54

1.54

1.54

1.54

1.54

P212121

P212121

P212121

P212121

P212121

Unit Cell
Dimensions (Å)

56.81, 82.85,
106.43

56.37, 83.06,
106.27

56.23, 83.34,
106.62

57.02, 82.57,
106.25

56.64, 82.86,
106.23

Resolution

13.01 - 1.86

15.00 - 1.90

15.54 - 1.97

16.27 - 1.87

19.51 - 1.86

Rsym a

0.08 (0.64)

0.10 (0.43)

0.10 (0.61)

0.12 (1.11)

0.08 (0.32)

I/σ(I)a

18.1 (2.6)

13.7 (4.1)

14.3 (2.8)

9.4 (1.3)

15.9 (4.3)

Completenessa

97.9 (76.3)

98.6 (82.3)

97.9 (73.5)

92.2 (65.8)

98.6 (79.7)

6.2

7.0

7.0

4.4

6.8

Unique Reflections

42044

39969

35891

39460

42288

Rwork/Rfree

0.1535/
0.1992

0.1447/
0.1902

0.1694/
0.2289

0.1518/
0.1985

0.1602/
0.1962

Ramachandran
Plot (%)
Favoured
Allowed
Disallowed

96.8%
3.2%
0%

96.7%
3.3%
0%

95.6%
4.4%
0%

96.9%
3.1%
0%

96.5%
3.5%
0%

RMS Deviations
Bond Lengths (Å)
Bond Angles (°)
Dihedral Angles (°)

0.007
1.000
13.702

0.009
0.952
12.033

0.008
0.980
11.304

0.008
0.931
11.379

0.008
1.017
12.978

Mean ADP (Å2)
All Atoms
Solvent
FAD
Inhibitor

18.89
26.69
17.65
33.40

20.88
27.99
19.35
26.70

25.59
29.24
25.35
46.95

20.31
24.17
19.05
29.73

20.06
24.79
18.90
23.00

FAD bendb
Subunit A
Subunit B

1.51
1.70

-2.94
-3.79

-3.05
3.23

5.27
4.02

4.86
5.88

Wavelength (Å)
Space Group

Redundancy

a

Oxidized NQO2

Values in parentheses refer to the highest resolution shell.
The equations of the two planes of FAD were first calculated from the coordinates of
FAD using principal component analysis in MATLAB (MathWorks R2015a). The angle
between the planes was then calculated and each structure was visually inspected for
direction of bending. Positive values indicates downward bending.
b
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Figure S 5.2 Superimposition of FAD Co-enzyme
Seven atoms from ring A of the isoalloxazine ring were aligned to reveal the downward
butterfly bend along the N5-N10 axis in ring B. FAD of the oxidized structures in
complex with EtBr, AO, and doxorubicin were colored in blue, and FAD of the reduced
structures in complex with EtBr and AO were colored in red.

Figure S 5.3 Second Binding Site of Ethidium in NQO2
Two copies of ethidium were modeled in the active site of subunit B of oxidized NQO2
(A) and reduced NQO2 (B) to account for prominent non-solvent electron density near
the active site. The electron density map surrounding ethidium is an Fc-Fo omit map
generated after three rounds of simulated annealing contoured at 3 σ.
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Chapter 6

6

Inhibitors of Quinone Reductase 2 Modulate p53 in
HCT116 cells
6.1

Introduction

NQO2 is a cytosolic flavoprotein constitutively expressed in most tissues (1).
Historically, it was characterized as a detoxifying enzyme that prevents quinone from
acquiring a single electron and forming cytotoxic quinone radical by catalyzing an
obligate two-electron transfer from dihydronicotinamide riboside (NRH) to quinone (2).
By virtue of this detoxification role, inhibition of NQO2 could sensitize cells to oxidative
stress generated by quinone radicals. In the past two decades, a wide range of bioactive
compounds was found to inhibit NQO2 catalytic activity. These compounds included
kinase targeted inhibitors (3–6), antimalarial drugs (7), natural flavonoids (8, 9),
resveratrol (10), melatonin (11), and DNA intercalating agents (12). All of these
compounds perturb cellular functions, but it remains unclear whether inhibition of NQO2
contributes to their effects.
In addition to catalysis of quinone reduction, NQO2 was shown to modulate cellular
proteins involved in cell cycle and apoptotic pathways. These proteins included AKT,
NF-κB, CEBPα, and most notably p53 (13–18). The role of p53 regulation was initially
discovered in quinone reductase 1 (NQO1). When NQO1 was knocked down, mutated, or
inhibited in HCT116 human colorectal carcinoma (HCT116) cells, p53 levels decreased
(19, 20). Further investigation showed that NQO1 mediated the 20S proteasomal
degradation of p53 in a NAD(P)H-dependent manner (21). From these observations,
NQO1 was thought to regulate the basal level of p53 in cells (22). Subsequent studies
revealed that NQO2 stabilized p53 from 20S proteasomal degradation in a NRH8

dependent manner (17, 18) . Mice deficient for NQO2 had lower p53 levels, and
developed skin tumors more readily when challenged with a chemical carcinogen

8

Reference 17 was retracted as of February 1st, 2015.
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compared to control mice (23). This suggested that NQO2 functioned as a tumor
suppressor by maintaining basal p53 levels. From these studies, NQO2 appears to have
additional roles beyond catalyzing quinone reduction that correlated to its redox state.
This alternate function of NQO2 in stabilizing p53 in a redox-dependent manner
suggested that NQO2 could function as a flavin redox switch, which is a class of proteins
that participate in cell signalling by responding to light and/or changes in redox state
(24). The first indication of this relationship originated from studies of Lot6p, the sole
orthologue of NQO1 and NQO2 in yeast (25). Lot6p is a poor catalyst of quinone
reduction, but it prevented the 20S proteasomal degradation of the transcription factor
Yap4 in response to elevated NADH levels (26, 27). Similarly, human NQO1 and NQO2
could be functioning as flavin redox switches by sensing cellular dihydronicotinamide
levels and modulating 20S proteasomal degradation of p53. Along these lines, structural
studies of oxidized and reduced NQO2 revealed mechanistic features of a flavin redox
switch in NQO2 (28). Together, this prompted the present investigation into the
signalling role of NQO2 and how NQO2 inhibitors modulate this switch function.
Specifically, two classes of NQO2 inhibitors were investigated: CK2 inhibitors and DNA
intercalating agents.
Protein kinase CK2 (CK2) is elevated in many cancer types, and the development of CK2
inhibitors that induce apoptosis in cancer has received much attention in the past decade
(29, 30). However, CK2 inhibitors are not very specific and how CK2 inhibitors work
remains largely unknown (31). For example, the inhibitors 4,5,6,7tetrabromobenzimidazole (TBBz) and 2-dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole (DMAT), induced apoptosis even when CK2 activity was restored (5).
Coincidentally, TBBz and DMAT were identified to be targets of NQO2, and further
analysis showed that they bound NQO2 with nanomolar affinity (32). In contrast, another
CK2 inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB), did not induce apoptosis in cells
when CK2 activity was restored. It also bound NQO2, but with much lower affinity when
compared to TBBz and DMAT. Therefore, whether CK2 inhibitors induce apoptosis by
interaction with NQO2 or not remains a topic for further research.
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Recently, three additional nanomolar affinity inhibitors of NQO2 were identified:
ethidium bromide (EtBr), acridine orange (AO), and doxorubicin (33). EtBr and AO
bound to reduced NQO2 with a dissociation constant of 4 nM and 0.4 nM respectively.
To date, these two compounds have the highest affinity for reduced NQO2. As DNA
intercalators, these compounds inhibit DNA replication and RNA transcription; for cells
that overcome this cytostatic stress, they are also mutagenic. Based on these findings,
interest arose firstly, in how inhibition of NQO2 by DNA intercalators affects cellular
proliferation, and secondly, if reduced-state NQO2 inhibitors differ from oxidized-state
NQO2 inhibitors in cells.
In this present study, endogenous NQO2 was knocked out using CRISPR/Cas9
technology in HCT116 cells, and the NQO2-specific effects of substrates and inhibitors
were characterized. Initial findings revealed that the isolated HCT116ΔNQO2 clones had a
slower growth rate compared to the parental HCT116 cells. The IC50 of CK2 inhibitors
(TBB, TBBz, and DMAT) and DNA intercalators (EtBr, AO, and doxorubicin) were
determined to be the same in both HCT116 and HCT116ΔNQO2 cells. Moreover, attempts
to activate NQO2 by co-treating cells with NRH and the aforementioned inhibitors did
not alter the inhibitors’ cytotoxicity. The basal level of p53 was also equal in both the
HCT116 and HCT116ΔNQO2 cells, but the parental cells were found to modulate p53 more
dynamically in response to inhibitor treatment. Taken together, our results indicated that
NQO2’s role in p53 regulation was different then that of NQO1’s.
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6.2
6.2.1

Methods
Reagents

TBB, TBBz, and DMAT (Sigma) were a gift from Dr. David Litchfield. Ethidium
bromide was obtained from Bioshop (Burlington, ON, CAD). AO and doxorubicin were
obtained from Caymen Chemical (Ann Arbor, MI, USA).

6.2.2

NRH Synthesis

Nicotinamide riboside (NR+) was synthesized and purchased from High Performance
Nutrients (Irving, CA, USA) as a dietary supplement capsule (34). Analysis of the
commercial preparation by NMR spectroscopy indicated that it was 92% pure, and it
matched the spectrum of the synthesized compound (Biomolecular NMR Facility,
Western University, London, ON). Both synthetic and commercial NR+ contained traces
of nicotinamide.
Commercial NR+ was then reduced to dihydronicotinamide riboside (NRH) according to
the established protocol (35). Powder NR+ from the supplement capsule was dissolved in
water and insoluble material was removed using a 0.45 µm syringe filter (Millipore).
Roughly 15 mM of NR+ was reacted with 57 mM of sodium dithionite in a 200 mM
sodium carbonate-sodium bicarbonate buffer (pH 9.9) in ddH2O. The reaction mixture
was incubated at 37 °C for 30 mins, then cooled on ice. NRH was then separated by
preparative HPLC using a Waters µ-Bondapak C18 column (19mm x 150mm). The
reaction mixture was injected 5 mls at a time into the reverse phase column and eluted at
10 mL/min by an isocratic mixture of 20% acetonitrile in water. The absorbance of the
eluent was monitored at 280 nm and 340 nm. For each injection, four species with
absorbance at 340nm were resolved by the C18 column and eluted at distinct time points.
Each species was collected, pooled, and tested for their ability to reduce MTT (an NQO2
substrate) in an NQO2-dependent manner. One fraction showed NQO2-dependent
activity and was lyophilized into a yellow amorphous powder. Absorbance scan of this
species was identical to NR+ with an additional absorbance peak at 360 nm.
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6.2.3

CRISPR/Cas9 Knockout of NQO2

To knockout endogenous NQO2, the NQO2 was disrupted using CRISPR guided Cas9
nickase to generate single stranded breaks at two neighboring sites in the fourth exonic
region. The plasmid pSpCas9n(BB)-2A-Puro (PX462) encoding both the CRISPR guided
RNA cassette and Cas9 nickase was a gift from Feng Zhang (Addgene plasmid # 48141).
Using an online CRISPR Design Tool (http://crispr.mit.edu/), CRISPR motifs targeting
nucleotide 46 and 108 of exon 4 were identified as the top sequences with minimal offtargets (Figure S6.1). Oligonucleotides corresponding to the pair of guide RNAs
(sgRNA) were cloned into PX462 according to previous protocol (36) to produce the two
vectors NQO24_46 and NQO24_108 (Table 6.1). HCT116 cells at 70% confluence were
then co-transfected with the sequence verified vectors NQO24_46 and NQO24_108 using
Lipofectamine 2000 (Life technologies) according to the manufacturer’s manual. 24 hrs
after transfection, the media was supplemented with 0.7 µg/mL of puromycin (Alfa
Aesar, Ward Hill, MA, USA) for 72 hrs. Surviving cells were trypsinized and serially
diluted into 96-well plates supplemented with puromycin to select for single colonies
carrying the transfected plasmid(s). After two weeks, five clones were isolated and
expanded.

6.2.4

Validation of NQO2 Knockout

Cellular NQO2 was detected by Western blotting using rabbit anti-NQO2 polyclonal
antibodies (a gift from Dr. Tim Haystead at Duke University). Cell lysates from each
clone were resolved using SDS-PAGE, and then transferred onto a PVDF membrane.
After blocking with 5% non-fat milk, the blot was probed for NQO2 was using a 1:1000
dilution of the rabbit-anti-NQO2 antibody and visualized with 1:5000 fluorescence
labeled secondary goat anti-rabbit antibody (Licor). To validate the excision of the
targeted genome on exon 4, genomic DNA was isolated from each HCT116ΔNQO2 clones
and parental HCT116 cells according to instructions from DNA extraction kit
(Froggabio). Primers exon4_F1 and exon4_R1 were designed using Primer-Blast to
amplify exon 4 of NQO2 (Table S6.2; www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR
was performed using taq polymerase according to the manufacturer’s instructions
(Biobasic). PCR products were resolved on a 3% polyacrylamide gel to detect the
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excision of a DNA fragment in exon 4. Since no PCR products were detected in clones 2
and 4, two additional primers (exon4_F2 and exon4_R2) were designed to amplify DNA
regions that flanked the targeted cut sites (Figure S6.1, Table S6.2). PCR amplification of
these flanking regions would determine whether the exon 4 was present but disjointed or
was completely absent. Furthermore, primers were also made to validate that the Cas9
nickase did not introduce unwanted mutations in off-target sites for the paired guide RNA
used (Table S6.2).

6.2.5

Functional Validation of HCT116ΔNQO2 cells

To validate that functional NQO2 was absent in the cells, activation of CB1954 by NRH
was used as a reporter of NQO2 activity (15). HCT116 or HCT116ΔNQO2 clone 3 cells
were seeded at 1000 cells per well 96-well plates, and were allowed to attach overnight.
Cells were then treated with: 1) 7.8 – 1000 µM of CB1954 and 6 – 200 µM of NRH, 2)
7.8 – 1000 µM of CB1954 alone, 3) 4.8 – 625 µM of NRH alone or 4) nothing (n=3).
Cells were allowed to grow for an additional 48 hrs before they were counted using
sulforhodamine B (SRB) assay.

6.2.6

SRB Assay

The SRB assay was a technique that stained total protein content of fixed cells (37). Cells
were first fixed with trichloroacetic acid (TCA) for 1 hr at 4°C, then washed with water 3
times. They were then stained with SRB dye (Sigma) for 20 mins at room temperature,
then washed with 1% acetic acid. The dye was re-solubilized in 10 mM Tris base and its
absorbance was measured using a multi-reader at 560 nm (Victor multi-plate reader,
Perkin Elmer). Absorbance readings of treated cells were normalized against untreated
cells, and the data was fitted to a dose-response curve and graphed using Prism 6.0f
(GraphPad Software Inc).

6.2.7

Growth Curve of HCT116ΔNQO2 Cell Lines

To characterize cell growth, HCT116 and HCT116ΔNQO2 cells from clone 3 and clone 5
were seeded at 1000 cells in 96-well plates. For 8 consecutive days, cells were
trypsinized and counted using a haemocytometer each day. In a parallel experiment, cell
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growth of HCT116 and HCT116ΔNQO2 clones 2, 3, and 4 were determined using the SRB
assay. In the SRB assay, cells were fixed each day with TCA for 20 mins at room
temperature, washed four times with water, dried, and then returned to the incubator. On
day 8, all fixed cells were stained with SRB and protein content was measured as
described above.

6.2.8

Cell Cycle Analysis by Flow Cytometry

Cell cycle analysis using flow cytometry was performed as previously described (38).
Briefly, HCT116 and HCT116ΔNQO2 cells were seeded at 500,000 cells in a 10 cm culture
dish to grow for 40 hrs until reaching 50-70% confluence. The cells were then labeled
with bromodeoxyuridine (BrdU) for 1 hr, harvested, fixed in 95% ethanol, and stored at
4ºC until they were used. Prior to flow cytometry analysis, the cells were stained with
mouse-anti-BrdU (BD Bioscience), FITC conjugated goat-anti-mouse IgG antibodies,
and propidium iodide (PI).

6.2.9

Toxicity of Inhibitors of NQO2

To determine the toxicity of NQO2 inhibitors, HCT116 and HCT116ΔNQO2 cells were
seeded in 96-well plates, 1000 per well, and allowed to attach overnight. The two cell
lines were then treated with one of the following compounds: 7 nM – 115 µM of TBB,
TBBz, or DMAT, or 14 nM – 230 µM of EtBr, AO, or doxorubicin. The experiment was
then replicated with the addition of 61 µM of NRH co-treatment to determine whether
activation of NQO2 sensitize cells to inhibitor-induced cytotoxicity. Cells were harvested
after 48 hrs and were counted using the SRB assay.

6.2.10

Western Blot Analysis of Inhibitor-treated Cells

HCT116 and HCT116ΔNQO2 cells were seeded at 250,000 cells per well in 6-well plates
and allowed to attach overnight. They were then treated with the concentrations of CK2
inhibitors and DNA intercalating agents indicated in individual experiments. The cells
were harvested at the indicated time points by the addition of Tris lysis buffer (50 mM
Tris HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% Deoxycholic acid) with a cocktail of
protease inhibitors (1 mM PMSF, 7 µg/ml Pepstatin A, 20 µg/ml Leupeptin, and 2.9
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µg/ml Aprotinin). Since cells treated with a high concentration of TBB detached from
their plates, all non-adherent cells were collected and pooled with the adherent cells. The
concentration of cell lysates was determined using a BCA assay (Bio-RAD) and
normalized to the least concentrated sample. For each sample, 10 – 15 µg of lysate was
separated on a 12% SDS-PAGE gel and transferred to a PVDF membrane. The
membrane was then blocked with 3% milk and probed with one of the following primary
antibodies: monoclonal mouse-anti-p53 (DO-1, Santa Cruz), monoclonal mouse-antiGAPDH (Millipore), polyclonal rabbit-anti-PARP (Cell Signal), or monoclonal rabbitanti-cleaved PARP (Asp214, Cell Signal). The blot was then probed with fluorescence
labeled goat-anti-mouse/rabbit secondary antibodies and visualized on a LiCor scanner
(LiCor). All the antibodies used were a generous gift from Dr. David Litchfield
(University of Western Ontario).
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6.3
6.3.1

Results
CRISPR/Cas9 Knockout of NQO2

Disrupting the expression of endogenous NQO2 using RNA interference was effective in
some cell lines but was challenging in others (39, 40). Previous attempts to knock-down
NQO2 in Hela cells using shRNA resulted in roughly 60 percent decrease in NQO2
protein levels (data not shown). Therefore, the decision was made to completely abolish
endogenous NQO2 expression using CRISPR/Cas9 technology (14). This way,
unpredictable cellular changes caused by transfection reagents and residual quantities of
NQO2 were avoided. To minimize off-target DNA double-strand cleavage events, the
Cas9 nickase was targeted to two neighboring sequences in the fourth exon of NQO2 by
a pair of guide RNA to generate two single stranded breaks (Figure 6.1A). HCT116
colorectal carcinoma cells were chosen to model NQO2-mediated p53 regulation for the
following reasons: they have a normal p53 status, they have high levels of NQO2
expression and activity, and there is no basal expression of the P-glycoprotein efflux
pump known to excrete toxic compounds (41–43). Five clonal populations of HCT116
cells were isolated after transfection of the CRISPR/Cas9 nickase constructs. In four of
these clones, there was no detectable level of NQO2 expression (Figure 6.1B). To verify
the success of the NQO2 gene disruption, PCR amplification of the targeted exon was
performed. Clones 2 and 4 had no PCR amplicon, while clones 3 and 5 had a shorter PCR
amplicon compared to the parental HCT116 cells (Figure 6.1C). Sequence analysis of the
PCR amplicon of clones 3 and 5 showed that 18 DNA basepairs were deleted near the
targeted exonic region. Since these two clones had the same genotype, it is possible they
originated from the same colony.
The sequence analysis of the PCR amplicon from parental HCT116 showed a single
nucleotide deletion in the intronic region upstream of exon 4 in one allele. However, this
heterozygosity was not present in the PCR amplicons of HCT116 ΔNQO2 clone 3 and 5,
indicating that only one of the NQO2 exon 4 alleles was amplified. CRISPR/Cas9
mediated genome editing can cause excessive gene deletion and/or chromosomal
translocations (44). Furthermore, HCT116 cells are known to be defective in their
mismatch repair machinery, and their ability to repair DNA damage using non-
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Figure 6.1 NQO2 Gene Knock Out in HCT116 using CRISPR/Cas9 Nickase.
(A) Illustration of the knockout strategy. The paired guide RNA was designed to generate
a single strand nick at positions 46 and 108 of the fourth exon of NQO2. (B) Western blot
of NQO2 in HCT116 (WT) and five knock out clones (numbered 1-5) transfected with
the paired guide RNA. Four of the clones (2 to 5) had no detectable amount of NQO2. A
non-specific band (*) was detected by the polyclonal anti-NQO2 antibody. (C) PCR
amplification of exon 4 of NQO2 in HCT116 and HCT116 ΔNQO2 clones. Clone 1 showed
a product size of 425 bp as expected, clones 2 and 4 did not have a PCR product, and
clones 3 and 5 had a shorter PCR amplicon (top). PCR products were separated on a 3%
polyacrylamide gel. Regions upstream and downstream of exon 4 were also individually
amplified (bottom). A PCR product was observed for all clones in the 5’ flank and 3’
flank regions of exon 4. Thus, the two flanking regions of exon 4 exist in the genome but
are disjointed in clone 2 and 4. PCR products of the flanking regions were separated on a
1% agarose gel.

148

homologous end-joining (NHEJ) is also impaired (45). Therefore, it is also possible that
HCT116 cells are prone to genomic instability when manipulated by CRISPR/Cas9
genome editing tools. Accordingly, the regions that flanked the targeted cut sites were
amplified to determine whether the genomic content was lost or disjointed. To our
surprise, the 5’ and 3’ regions flanking the targeted cut sites were present in all clones
and the genomic content was not lost (Figure 6.1C). Therefore, it is likely that a
translocation event had disjointed the 4th exon of NQO2 in both alleles of clone 2 and 4,
and in one allele of clone 3 and clone 5. Since one allele could be accounted for in clone
3 and clone 5, all subsequent experiments were performed using clone 3 unless otherwise
specified.

6.3.2

Characterization of HCT116∆NQO2 Cell Lines

HCT116 cells are colorectal carcinoma cells that have epithelial-like cell morphology. An
initial comparison in morphology between the parent HCT116 cell and HCT116∆NQO2
showed no observable differences. However, a slower overall growth rate was observed
in the HCT116∆NQO2 clones during normal cell passage. Consistent with these
observations, it was previously reported that knockdown of NQO2 in prostate cancer
cells slowed cell growth (16). To further investigate changes in proliferation, growth
curves were generated for the HCT116 parental and HCT116∆NQO2 cell lines. The growth
rates of HCT116∆NQO2 clones 3 and 5 were markedly slower than the parental cell line
(Figure 6.2A). The greatest difference in cell counts occurred at the end of an exponential
growth phase on day 4. At this point, there were 4- and 6-fold fewer cells in clones 3 and
5, respectively. The growth curves for HCT116∆NQO2 clones 2-4 were also generated
using SRB assay and similar growth suppression was observed (Figure S6.2).
To understand the cause of growth suppression, the cell cycle distribution was analyzed
by flow cytometry using BrdU and PI staining (38). Asynchronous HCT116ΔNQO2 cells
from clones 2-4 had up to a 2-fold higher distribution in the S phase compared to parental
HCT116 (Figure 6.2B). HCT116ΔNQO2 also had an overall lower distribution in the G1
and G2/M phases. In combination with the slow growth phenotype observed in
HCT116ΔNQO2 cells, a higher distribution of cells in the S phase is indicative of a defect
in the intra-S phase checkpoint. Since NQO2 was shown to modulate AKT, NF-κB,
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Figure 6.2 Characterization of HCT116ΔNQO2 clones
(A) Growth curve of HCT116 (), HCT116ΔNQO2 clone 3 (¢) and clone 5 (p) assayed
by cell count (left). Cells were initially seeded at 1000 cells/well in a 96-well plate. Each
day, cells were trypsinized for cell counting using haemocytometer immediately (n=4).
On day 4, cell counts were plotted on a linear scale to illustrate the difference in cellular
proliferation between the three cell lines (right). (B) Increased S phase distribution in
HCT116ΔNQO2 cells. Asynchronously proliferating cells of HCT116 (), HCT116ΔNQO2
clone 2 (¢), clone 3 (p), and clone 4 (▼) were stained with propidium iodide and BrdU,
followed by flow cytometry analysis. As a reference, a line was drawn for the cell cycle
distribution of parental HCT116.
CEBPα, and p53 (13–16), cell cycle perturbation could be the result of dysregulation of
these proteins.

6.3.3

Cytotoxicity of Substrate CB1954

To determine the catalytic activity of NQO2 in cells, Knox and coworkers established a
protocol in which the cytotoxic compound CB1954 can be activated up to 1000-fold in
the presence of NRH when transfected NQO2 was over-expressed (35). Here, it was
found that as little as 12.5 µM of NRH could maximally induce the cytotoxicity of
CB1954 in parental HCT116 cells. The IC50 value of CB1954 was decreased over 40-fold
from 203 ± 19.1 µM to 4.5 ± 0.4 µM (Figure 6.3A,C). In contrast, activation of CB1954
by NRH in HCT116∆NQO2 cells was completely abolished even when co-treated with 200
µM NRH (Figure 6.3B-C). As such, cellular activity of NQO2 was completely abolished.
In the absence of NRH co-treatment, the toxicity (IC50) of CB1954 was the same between
the HCT116 and HCT116∆NQO2 cell lines. This indirectly indicated that NRH (or any
other NQO2 reducing co-substrate) was not abundant in HCT116 cells.
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6.3.4

Toxicity of NR and NRH

The bioactivation of CB1954 in cells required the addition of exogenous NQO2 cosubstrate (35). To this end, the cytotoxicity of NR+ and NRH was initially determined as
an experimental control to find a non-toxic concentration of NRH suitable to activate
CB1954. Unexpectedly, treating cells with NR+ or NRH alone at concentrations above
100 µM or 200 µM respectively were cytotoxic to both HCT116 and HCT116ΔNQO2 cells
(Figure 6.3C). This was contrary to previous findings by Knox and coworkers, who
indicated that treating cells with up to 10 mM of NRH or other NQO2 co-substrates were
not cytotoxic in four human cancer cell lines (PC-3 prostate carcinoma, U373-MG and
U87-MG glioblastoma multiforme, and T98G glioblastoma) (35). Furthermore, up to 1
mM of the same commercial NR+ used in this experiment was not cytotoxic to human
aortic endothelial cells, HITC6 smooth muscle cells, and primary mouse smooth muscle
cells (Krista Hawrylyshyn, personal communications). From these findings, it appears
that HCT116 cell proliferation was sensitive to high concentrations of NR+ or NRH. In a
recent study, mice deficient of a gene implicated in NAD+ synthesis more readily
developed liver tumors when challenged with a carcinogen (46). Restoration of cellular
NAD+ levels with a high NR+ diet prevented tumor formation and progression. In the
same regard, an increase of NAD+ levels in HCT116 by NR+ and NRH treatment may be
the cause of cytotoxicity for these cells, while it was non-toxic to other cell lines.

6.3.5

Toxicity of NQO2 Inhibitors

It is well known that CK2 inhibitors (TBB, TBBz, and DMAT) and DNA intercalators
(EtBr, AO, and doxorubicin) are cytotoxic. These compounds were all previously
identified to be NQO2 inhibitors (5, 33), but it is unclear how NQO2 inhibition
contributes to the cellular effects of these chemicals. To explore this question, the IC50 of
each inhibitor was determined in HCT116 and HCT116ΔNQO2 cells. Surprisingly, the
status of NQO2 did not affect the cytotoxicity of these inhibitors (Figure 6.3D, Table
6.1). Since NRH was required by NQO2 to stabilize p53 in vitro (17), NRH co-treatment
could sensitize cells towards the apoptotic effects of the inhibitors. However, the addition
of 61 µM NRH did not change the IC50 values of the inhibitors tested. Comparing the
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Figure 6.3 Cytotoxicity of Substrate, Co-substrate, and Inhibitors in HCT116 and
HCT116ΔNQO2 cells.
(A) Cytotoxicity of substrate CB1954. HCT116 (left) and HCT116ΔNQO2 (right) cells
were treated with CB1954 at the indicated concentration with 6 µM (●), 12.5 µM (■) 25
µM (p), 50 µM (q), 100 µM (◊), 200 µM (⬣), or without NRH (○) for 48 hrs and
assayed for cell proliferation using SRB dye (n=3). All cellular growth measured by SRB
assay was normalized to cell growth without treatment, and data was fitted to a doseresponse curve. Fitted curve was only shown for 100 µM NRH co-treatment cells (◊) for
clarity. (B) IC50 values CB1954 in HCT116 (●) and HCT116ΔNQO2 (○) cells when cotreated with NRH. The cytoxicity of CB1954 increased 50-fold in the presence of NRH
in parental HCT116 but the induction of CB1954 toxicity was completely abolished in
HCT116ΔNQO2. (C) Cytotoxicity of co-substrate NR+ and NRH. HCT116 (●) and
HCT116ΔNQO2 (○) cells were treated with NR+ (left) and NRH (right) at the indicated
concentration for 48 hrs and assayed for cell proliferation using SRB dye (n=3). Cellular
proliferation was attenuated at NR+ concentrations above 100 µM and NRH
concentrations above 200 µM as indicated by the dotted line. (D) Representative curve of
cytotoxicity of inhibitor treatment. HCT116 (●) and HCT116ΔNQO2 (○) were treated with
TBBz at the indicated concentrations for 48 hrs and assayed for cellular proliferation
using SRB dye (n=2). Further co-treatment with 61 µM NRH in HCT116 (■) and
HCT116ΔNQO2 (◻︎) cells did not affect cell growth (n=2). All cellular growth measured by
SRB assay was normalized to cell growth without treatment. Data was fitted to a doseresponse curve and IC50 values are summarized in Table 1. Fitted curve was only shown
for TBBz treatment of HCT116 WT cells (●) for clarity.
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Table 6.1 IC50 (µM) of Inhibitors in HCT116 and HCT116ΔNQO2 Cellsa
WT
KO
WT
KO
KD (nM)
NRHb
+
+
TBB
43 ± 8.1
68 ± 23
57 ± 15
74 ± 23
7110 ± 40c
TBBz
12 ± 2.4
16 ± 3.9
12 ± 2.5
18 ± 4.1
18 ± 0.4c
DMAT
182 ± 31
134 ± 18
139 ± 25
147 ± 27
36 ± 1.7c
EtBr
9.1 ± 0.9
9.5 ± 1.3
12 ± 1.7
8.1 ± 0.9
3.5 ± 0.3d,e
AO
3.9 ± 0.4
3.8 ± 0.4
4.5 ± 0.5
3.7 ± 0.4
0.4 ± 0.1d,e
Doxorubicin 0.61 ± 0.14 0.37 ± 0.07
274 ± 49d
a
IC50 values were determined by treatment of inhibitors at various concentrations for 48
hrs. Fitted curves are shown in Figure S6.2.
b
Cells were co-treated with and without 61 µM NRH
c
KD values of TBB, TBBz, and DMAT towards NQO2 were previously determined using
fluorescence titration (32)
d
KD values of EtBr, AO, and doxorubicin towards NQO2 were previously determined by
ITC (To be published)
e
Dissociation constants of EtBr and AO towards reduced NQO2
IC50 values of each inhibitor to their respective in vitro KD values, the concentrations
needed to inhibit cell growth were roughly 2 to 3 orders of magnitude higher than their
dissociation constants for NQO2 (Table 6.1). TBB and doxorubicin were the only
exception where their cellular IC50 values were similar to their in vitro KD values.
Altogether, it appears that NQO2 inhibition was not directly responsible for the cytotoxic
effects of the inhibitors even though the concentrations used adequately inhibited NQO2
in vitro.

6.3.6

Modulation of p53 Expression Levels by NQO2 Inhibitors

NQO2 protected p53 from degradation in vitro. Accordingly, mice deficient in NQO2
also had a lower expression of p53 (17, 23). According to these findings, a downregulation of p53 expression in HCT116ΔNQO2 cells was expected. However, the basal
level of p53 expression remained the same even when endogenous NQO2 was knocked
out in HCT116 cells (Figure 6.4A). This was contrary to previous findings and raised the
question of whether NQO2 is active in stabilizing p53 in tumorigenic cells.
NQO2 status did not change how CK2 inhibitors and DNA intercalators attenuated cell
growth, but the six inhibitors modulated p53 levels in an NQO2-dependent manner
(Figure 6.4B-C). To compare the effects of these inhibitors, HCT116 and HCT116ΔNQO2
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cells were treated with inhibitors at concentrations of either 1/5th of the IC50 or IC50 for 18
or 24 hrs (Table 6.1). When cells were treated with inhibitors at 1/5th concentrations of
IC50, p53 levels did not vary greatly. Specifically, p53 was slightly down-regulated in
TBB and AO treated cells, while p53 levels increased in doxorubicin treated cells. At the
IC50 concentration where all the inhibitors attenuated cell growth to the same degree, the
modulated levels of p53 expression were drastically different. TBBz, EtBr, and
doxorubicin highly induced p53 expression, while TBB and DMAT down-regulated p53.
In comparison, AO had the least effect on p53 regulation despite binding most tightly to
NQO2 in vitro. Therefore, NQO2 inhibitors did not uniformly modulate p53 expression.
Furthermore, inhibitor-induced changes in p53 levels did not differ much between
HCT116 and HCT116ΔNQO2 cells. The most drastic difference was observed in TBBz
treatment at the IC50 concentration where p53 levels was roughly two times greater in
HCT116 cells compared to HCT116 ΔNQO2 cells. NQO1 inhibitors dicoumarol and
curcumin induced p53 degradation in HCT116 cells (19, 47), yet our data showed that
NQO2 inhibitors did not degrade p53 in a consistent manner. Drawing from these
observations, NQO2 could function differently compared to NQO1 in HCT116 cells.

6.3.7

Apoptotic Response and p53 Modulation by TBB and TBBz

Since mutation or down-regulation of endogenous NQO1 prevented inhibitor-induced
p53 degradation (19, 20, 47), NQO2 could modulate inhibitor-induced p53 degradation.
As such, apoptotic signalling and p53 modulation by TBB and TBBz were more carefully
examined. HCT116 and HCT116ΔNQO2 cells were treated with three concentrations of
TBB and TBBz (corresponding to 1/5th of IC50, IC50, and 5 times the IC50) for 6, 12, 18,
and 24 hrs. At 5 times the IC50 concentration of TBB, cells detached from the plates after
12 hrs. Despite detaching, they were still viable as determined by a trypan blue exclusion
assay. In light of this finding, all cells were pooled for western blot analysis. Initial
blotting using a polyclonal PARP antibody was unable to reliably detect cleaved PARP
products (Figure S6.4). Using a monoclonal antibody against cleaved PARP, this
apoptotic signal was clearly detected and appeared to be no different between HCT116
and HCT116ΔNQO2 cells (Figure 6.5A). Following TBB treatment, apoptosis was
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Figure 6.4 Western Blot Analysis of p53 in HCT116 and HCT116ΔNQO2 Cells Treated
with Six NQO2 Inhibitors
(A) Western blot of p53, NQO2, and GAPDH in HCT116 cells and HCT116ΔNQO2 clone
2-5. Fold difference was calculated by integrated intensity of p53 normalized to GAPDH
compared to levels of p53 of WT cell line. (B) HCT116 and HCT116ΔNQO2 cells were
treated with six NQO2 inhibitors at 1/5th IC50 and IC50 concentrations for 18 and 24hrs
(refer to table 6.1). Cell lysates were analyzed by western blot for p53 and GAPDH. (C)
Quantification of p53 was performed by normalizing the intensity of each p53 band
against GAPDH band and shown as a bar graph.
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only apparent in the detached cells treated with 5 times the IC50 concentration at 6 and 12
hrs. In contrast, TBBz induced apoptosis most strongly at the IC50 concentration at 18 and
24 hrs, but was almost absent at 1/5th and 5 times the IC50 concentrations. Therefore,
inhibitor-induced apoptosis was dependent on time and concentration of inhibitors used,
but not dependent on NQO2 status.
The inhibitor-induced modulation of p53 also appeared to be time and dose dependent
(Figure 6.5A-B). Overall, TBB treatment down regulated p53 levels while TBBz induced
its expression. For the low and medium concentrations of TBB, p53 levels were not
drastically perturbed. At 5 times the IC50 concentration of TBB, however, p53 was down
regulated in HCT116ΔNQO2 cells and almost undetectable in parental HCT116 cells. In
contrast, all three concentrations of TBBz treatment induced p53 expression. At the IC50
concentration, TBBz induced p53 almost twice as much in HCT116ΔNQO2 cells compared
to the parental HCT116 cells at 12, 18, and 24 hrs. In terms of temporal differences,
changes in p53 levels were more gradual in cells deficient of NQO2 compared to
HCT116 cells for all concentrations of TBB and TBBz treatment. Specifically, inhibitormediated p53 levels rose and fell at an earlier time point in parental HCT116 cells
compared to the same inhibitor treatment in HCT116ΔNQO2 cells. Finally, HCT116ΔNQO2
cells had an overall lower p53 levels compared to parental HCT116 cells. The only
exception was for TBB treatment at the IC50 concentration. On the whole, the data
showed that NQO2 played a role in modulating p53 in very complex manner.
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Figure 6.5 Analysis of PARP Cleavage and p53 Modulation in HCT116 and
HCT116ΔNQO2 Cells Treated with TBB and TBBz
(A) Cells were treated with 11, 55, or 275 µM TBB and or 2.8, 14, or 69 µM TBBz
(corresponding to 1/5th IC50, IC50, and 5 x IC50 of the individual inhibitors). At 6, 12, 18,
and 24 hrs, cells lysed with Tris lysis buffer. At 12, 18, and 24 hrs, cells treated with 275
µM TBB all lifted from plate. As such, all cells were pooled for analysis. The
concentration of cell lysates was normalized and 15 µg of each sample were resolved on
SDS-PAGE. After being transferred onto a PVDF membrane, it was probed with anticleaved PARP, anti-p53, and anti-GAPDH antibodies. The membrane was then probed
with fluorescence labeled secondary antibodies and visualized using a LiCor imaging
system. (B) Quantification of p53 was performed by normalizing the intensity of each
p53 band against GAPDH band and was shown as a bar graph.
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6.4

Discussion

NQO2 was traditionally characterized as an enzyme, but recent findings suggest it also
functions as a flavin redox switch to modulate p53 degradation (17, 28). As such, NQO2
inhibitors that inactivate catalysis may be modulating NQO2 in an unexpected manner by
modifying the switch function of NQO2. Furthermore, numerous bioactive compounds
were found to interact with NQO2 as an “off-target” but how these interactions contribute
to their effects is poorly understood. To this end, we knocked out endogenous NQO2 in
HCT116 cells using CRISPR/Cas9 technology to study the effects of NQO2 inhibitors.
However, the six NQO2 inhibitors studied did not affect cell viability in an NQO2dependent manner. Thus, the cytotoxic effects of NQO2 inhibitors were not directly
caused by NQO2 inhibition. Instead, inhibitors modulated p53 in a time-, dosage-, and
NQO2-dependent manner.
In 2001, the modulation of p53 by NQO1 was shown for the first time (19). In that study,
an NQO1 specific inhibitor, dicourmarol, drastically decrease p53 levels in HCT116
cells. Since NQO2 was thought to function similarly to NQO1, NQO2 inhibitors were
expected to affect p53 levels in the same way. However, this was not the case in this
current study. For the six inhibitors studied, each inhibitor modulated p53 levels
differently. Some inhibitors induced p53 (TBBz, EtBr, and doxorubicin), others down
regulated p53 (TBB, DMAT), and one inhibitor didn’t change p53 levels (AO).
Furthermore, the two inhibitors specific to reduced NQO2 (EtBr and AO) modulate p53
in an unpredictable way compared to inhibitors specific to oxidized NQO2. From these
results, the role of NQO2 in modulating p53 appears to be different compared to NQO1.
The stabilization of p53 by NQO2 and NQO1 was dependent on NRH and NADH
respectively (17). Since the co-substrate specificity of NQO2 and NQO1 are exclusive to
one other (8), cellular concentrations of NRH and NADH would be crucial in
determining how NQO2 and NQO1 modulate p53. However, the availability of cytosolic
NRH is questionable. On one hand, activation of the NQO2 substrate CB1954 in cells
required the addition of either NRH or another NQO2 co-substrate (35); as confirmed in
this study. On the other hand, activation of the NQO1 substrate EO9 in cells did not
require the addition of NADH (48, 49). Therefore, cellular concentrations of NQO2 co-
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substrates are normally too low for reduction of substrates, while concentrations of
NQO1 co-substrates are sufficient for catalysis. On this basis, it is possible that NQO2
remains in an oxidized state in the absence of NRH, unable to stabilize p53 from
degradation; hence inhibition of NQO2 has no effect on p53. In contrast, NQO1 could
stay in a reduced state in the presence of NADH, which allows it to maintain basal p53
levels. The inhibition of NQO1 then prevents NQO1 reduction and induces p53
degradation. Along these lines, NQO2 and NQO1 may be constantly sensing the balance
between NR+/NRH and NAD+/NADH levels in cells in regulating p53. Together, NQO2
as a flavin redox switch appears to be regulated differently compared to NQO1.
To further complicate the interpretation of our observations, the NQO2 inhibitors used in
this study were not very specific to NQO2. The six NQO2 inhibitors were studied for
their NQO2-dependent effects at concentrations that attenuated cell growth by 50% (IC50). With the exception of TBB and doxorubicin, the inhibitor’s IC50 were 2 – 3 orders of
magnitude higher than their dissociation constants (KD) towards NQO2. As such, the
inhibitors could also be binding to other targets and affecting multiple cellular processes:
TBB, TBBz, and DMAT were originally designed to inhibit CK2, while EtBr, AO, and
doxorubicin were well-characterized DNA intercalating agents. Furthermore, some of
these compounds also inhibited additional targets in cells. For example, TBBz and
DMAT potently inhibit kinase from three other families, and doxorubicin inhibits
topoisomerase II (31, 50). Consequently, the cytotoxicity and p53 expression induced by
inhibitors may not be direct effects of NQO2 interactions.
Differences in how HCT116 and HCT116ΔNQO2 modulated inhibitor-induced p53 changes
were initially not apparent in the six inhibitors studied. Further investigation into cells
treated with TBB and TBBz showed that p53 was modulated in a time-, dose-, and
NQO2-dependent manner. As such, NQO2-mediated modulation of p53 was not easily
detected. Owing to the lack of NRH in normal proliferating cells, three possible scenarios
regarding how inhibitors could affects p53 modulation in an NQO2-dependent manner
were postulated. Firstly, the direct binding of inhibitors to oxidized NQO2 may generate
a novel state of NQO2 whose functions are directly responsible for p53 regulation.
Secondly, since inhibitors also target other cellular processes, oxidized NQO2 may play
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an indirect role in modulating p53. Lastly, the inhibitors of NQO2 could induce NRH
production through an unknown mechanism. In turn, elevated NRH concentrations could
reduce NQO2 to stabilize p53 levels. In all three scenarios, the mechanism of p53
modulation by NQO2 is complicated and deciphering it will require further investigation
using specific inhibitors, different cell lines, and robust p53 detection techniques.
In summary, endogenous NQO2 was successfully knocked out in HCT116 cells using the
CRISPR/Cas9 genome editing tool. Even though NQO2 was historically characterized to
function similarly to NQO1, NQO2 inhibitors did not consistently degrade p53 as NQO1
inhibitors were shown to do. Furthermore, the lack of NQO2 slowed cell growth, but had
no effect on cell viability when treated with inhibitors. Drawing from these observations,
the role of NQO2 as a flavin redox switch is complex and is different compared to its
homologue NQO1.
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6.6

Supporting information

Table S 6.1 Oligonucleotides Used for CRISPR Cassette Construct.
Guide	
  RNA	
  oligos	
  
Exon4_46_top	
  
Exon4_46_bottom	
  
Exon4_108_top	
  
Exon4_108_bottom	
  

Sequence	
  
CACCGACCTTTGCTTGTAGGCTTCG	
  
AAACCGAAGCCTACAAGCAAAGGT	
  
CACCGTGAGCAGAAAAAGGTTCGGG	
  
AAACCCCGAACCTTTTTCTGCTCA	
  

Table S 6.2 Oligonucleotides Used for PCR Validation of HCT116ΔNQO2 cells
Primers	
  
Exon4_F1	
  
Exon4_R1	
  
Exon4_F2	
  
Exon4_R2	
  
46oF1	
  
46oR1	
  	
  
108oF1	
  
108oR1	
  

Sequence	
  
TGCTAGGTAGCAAGTGCTCAATC	
  
CTTCCAGAAGCAGCACAAAACTC	
  
CTGACCTAGTGATATTTCAGGTTTGTTTTTCTC0	
  
GTTTCCACTCCATAATTGAAAACCTCAGG	
  
ATGGAAGCAGGAACTCAAACTCA	
  
GTACATGCTGGCCTAGAAAACAC	
  
AGTAGGACATCACAGAAGTTGGG	
  
TTCTGCTCAAAGGTTTCGCC	
  

Figure S 6.1 Cartoon Illustration of Primers Used for PCR Validation in of
HCT116ΔNQO2 Cells.
PCR amplification of wild-type NQO2 gene using primers Exon4_F1 and Exon4_R1 will
generate a PCR product of 425bp, while the PCR product of the knockout gene is
estimated to be 363bp if exonuclease excise single stranded nucleotides up to the targeted
cut sites. PCR amplification of the 5’ flank and 3’ flank regions in genomes where fulllength PCR products are absent will show that the two ends of exon4 still exist in the
genomic DNA. This suggests that a chromosomal translocation event has occurred.
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Figure S 6.2 Growth Curve of HCT116 and HCT116ΔNQO2 Cells Assayed by SRB.
HCT116 (), HCT116ΔNQO2 clone 2 (¢), clone 3 (p), and clone 4 (▼) cells were
seeded at 1000 cells/well in a 96-well plate (n=3). Each day, cells were fixed with 10%
TCA for 20 mins at room temperature and returned to the incubator. On day 8, the fixed
cells were stained with 0.3% SRB dye and absorbance at 560nm was recorded using a
plate reader (left). On day 4, HCT116 cell proliferation was markedly higher than any of
the clones of HCT116ΔNQO2 (right).
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Figure S 6.3 Cytotoxicity of NQO2 Inhibitors in HCT116 and HCT116ΔNQO2 cells.
HCT116 (●) and HCT116 ΔNQO2 (■) cells were treated with TBB (A), TBBz (B), DMAT
(C), EtBr (D), AO (E), and doxorubicin (F) at the indicated concentrations for 48 hrs and
assayed for cellular proliferation using SRB dye (n=2). HCT116 (p) and HCT116 ΔNQO2
(q) cells co-treated with inhibitors and 61 µM NRH did not show marked differences in
proliferation (n=2). All cellular growth measured by SRB assay was normalized to cell
growth without treatment. Data was fitted to a dose-response curve and IC50 values are
summarized in Table 1. Fitted curves are only shown for inhibitor treatment of HCT116
WT cells (●) for clarity.
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Figure S 6.4 Analysis of PARP Cleavage and p53 Modulation in HCT116 and
HCT116ΔNQO2 Cells Treated with TBB and TBBz
(A) Cells were treated with 11, 55, or 275 µM TBB and or 2.8, 14, or 69 µM TBBz
(corresponding to 1/5th IC50, IC50, and 5 x IC50 of the individual inhibitors). At 6, 12, 18,
and 24 hrs, cells lysed with Tris lysis buffer. At 12, 18, and 24 hrs, cells treated with 275
µM TBB all lifted from plate. As such, all cells were pooled for analysis. The
concentration of cell lysates was normalized and 15 µg of each sample were resolved on
SDS-PAGE. After being transferred onto a PVDF membrane, it was probed with
polyclonal anti-PARP, anti-p53, and anti-GAPDH antibodies. The membrane was then
probed with fluorescence labeled secondary antibodies and visualized using a LiCor
imaging system. (B) Quantification of p53 was performed by normalizing the intensity of
each p53 band against GAPDH band and shown as a bar graph.
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7

Summary and Perspectives

NQO2 was historically characterized as an enzyme that catalyzed the reduction of
quinone. However, recent evidence had revealed that NQO2 also had a role in regulating
the 20S proteasomal degradation of p53. On this basis, my hypothesis is that NQO2
functions as a flavin redox switch that senses intracellular NRH levels and recognizes
inhibitors. The work presented in this thesis addressed the molecular aspects of how
NQO2 behaved as a flavin redox switch, and showed that inhibitors could perturb cellular
signalling by modulating p53 stabilization. In this chapter, the structural features that
allow NQO2 to function as a flavin redox switch will be summarized. Next, the
fundamental differences between how NQO2 and NQO1 function as a flavin redox
switch will be discussed. Finally, a hypothesis of how NQO2 could function as a multidrug sensor will be explored. In each section, some of the unpublished work initiated for
NQO2 will also be highlighted and the direction of research will be proposed.

7.1
Structural Indication of NQO2 as a Flavin Redox
Switch
The ability of NQO2 to stabilize p53 is redox-dependent (1). However, little is known
about reduced NQO2. Using one of the two known reduced-state inhibitors of NQO2 at
that time, the structure of reduced NQO2 in complex with chloroquine (CQ) was solved
(Chapter 3). This was a challenging endeavor because NQO2 spontaneously oxidizes in
the presence of oxygen. By reducing the oxidized protein-ligand crystal complex in an
anoxic environment, NQO2 was kept reduced. Solving this structure, reduced NQO2 in
complex with an inhibitor was characterized for the first time. Compared to oxidized
NQO2, three observations were made in reduced NQO2-CQ: an FAD bend, an altered
hydrogen bond network at the active site mediated by several water molecules, and a
global conformation change.
Subsequently, the structures of oxidized and reduced NQO2 were obtained in complex
with the following four inhibitors: DMAT (chapter 4), ethidium, acridine orange (chapter
5), and quinacrine (unpublished). Compared to their respective oxidized NQO2-inhibitor
structures, all the reduced NQO2-inhibitor complexes had approximate a 5º “butterfly”
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bend at the isoalloxazine ring of the reduced FAD that was repeatedly detected.
Additionally, all the reduced structures showed a consistent rearrangement of the
hydrogen bond network mediated by several water molecules at the active site. The water
molecules prevented the inhibitors from binding in a deeply buried manner, which
indicated that they were coordinated more strongly in reduced NQO2 compared to
oxidized NQO2.
In the reduced NQO2-CQ structure, a global conformation change indicated by a loss in
crystallographic spacegroup symmetry was also observed. However, this change was
absent in the other four reduced NQO2 structures. From a technical perspective, the
change in spacegroup may be only apparent at higher-resolutions. The data of reduced
NQO2-CQ crystals was collected to 1.25Å, whereas the dataset for the other reduced
NQO2-inhibitor crystals were collected to 1.9Å. Another explanation for this unique
conformational change could be attributed to the chemical structure of CQ. Compared to
the other inhibitors, CQ has a tail moiety in addition to a planar moiety. In the reduced
NQO2-CQ structure, this tail moiety of CQ was in close contact with I128. This
particular isoleucine residue was part of a loop region in NQO2 that was in contact with
symmetry-related NQO2 molecules. Therefore, the “closing” of the loop region mediated
by CQ (Figure 3.3) could be responsible for the change in spacegroup.
Since reduced NQO2 underwent a global conformation change in the crystal structure,
reduction of NQO2 in solution was also investigated using small angle X-ray scattering
(SAXS). SAXS is a low-resolution technique used to probe conformational changes of
proteins in solution. To determine whether NQO2 was drastically different in its two
redox states, oxidized NQO2, reduced NQO2, and reduced NQO2 in the presence of CQ
were analyzed using SAXS and the data was summarized in Table 7.1. It was found that
the radiuses of gyration (Rg) between the three samples were no different from each
other. In essence, conformational changes seen in the reduced crystal structure were too
small to be observed using SAXS.
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Table 7.1 SAXS Analysis of NQO2 in Solution a
I(o)b	
  
Rgb	
  
Dmaxb	
  
	
  
NQO2	
  
alone	
  
55.10	
  
23.31	
  
71	
  
NQO2	
  with	
  SCDP	
  
55.80	
  
23.28	
  
72	
  
NQO2	
  with	
  SCDP	
  and	
  CQ	
  
55.10	
  
23.12	
  
72	
  
Cytochrome	
  C	
  
27.90	
  
13.75	
  
40	
  
a
Data was collected at the Advance Photon Source BioCAT 18ID Beamline
b
Data was analyzed using Scatter (Robert Rambo, Diamond Light Source (Didcot, UK))
To investigate minute changes in reduced NQO2, one approach would be to compare
protein dynamics at the molecular level. In a crystal structure, the atomic displacement
parameter of each atom describes how “mobile” a certain residue is. Using this data, the
normalized atomic displacement factors (nADP, as described in chapter 2) between the
main chain atoms of oxidized and reduced NQO2-CQ were compared (Figure 7.1). In the
reduced NQO2-CQ structure, an increase in nADP was localized on one side of the
protein, while a decrease was localized on the opposite side. These concerted changes in
nADP indicated that the reduction of NQO2 in complex with CQ facilitated the mobility
of residues globally. Therefore, these minute changes in protein dynamics may be crucial
in mediating its interaction with the 20S proteasome and p53.

Figure 7.1 Protein Dynamic Changes in Reduced NQO2.
The NQO2 dimer was coloured according to the difference in the normalized atomic
displacement parameter (nADP) between oxidized and reduced NQO2-CQ complex.
Increases in nADP (indicated in red) was localized to the bottom half of NQO2, and
decreases in nADP (indicated in blue) was localized to the top half of NQO2 shown in
this figure. The two views of the NQO2 dimer are related by a 90° turn about the vertical
axis.
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Having solved the reduced structures of NQO2 with four other inhibitors, a
comprehensive comparison of nADP between oxidized and reduced NQO2 could reveal
trends in protein dynamics. Pairing such analysis with molecular dynamic simulations of
oxidized and reduced NQO2 could reveal the nature of how NQO2 behaves in a redox
dependent manner. In conclusion, further molecular analysis will shed more light on the
protein dynamics of NQO2 as a flavin redox switch.

7.2

Cellular Inhibition of NQO2

Historically, NQO2 was thought to function in a similar fashion to NQO1. While the
mechanism of quinone catalysis was the same, their co-substrate, substrate, and inhibitor
specificity were exclusive to one another. In this regard, it was unclear whether NQO2
had the same role in modulating p53 degradation as NQO1. For NQO1, p53 levels
decreased in response to NQO1 knockdown, mutation, or inhibition, in HCT116 cells (2–
5). Furthermore, p53 was undetectable in mice deficient of NQO1 (6). For NQO2, p53
degradation was dependent on NRH, and mice deficient of NQO2 had a lowered
expression of p53 (1, 7). However, it remained unknown how NQO2 inhibitors would
affect p53 degradation. In chapter 6, six NQO2 inhibitors were shown to modulate p53
levels, albeit inconsistently, in HCT116 cells. Knocking out endogenous NQO2 had the
effect of partially dampening the inhibitor-mediated induction/degradation of p53.
Therefore, NQO2 inhibitors modulated p53 in a different manner compared to NQO1, but
exactly how NQO2 participates in p53 degradation remains poorly understood (2).
As a flavin redox switch, the one fundamental difference between NQO1 and NQO2 is
their co-substrate specificity. NQO1- and NQO2-mediated degradation of p53 in vitro is
dependent on NADH and NRH respectively (1). On this basis, the ability of NQO1 and
NQO2 to stabilize p53 would depend on the availability of these dihydronicotinamide
concentrations in cells. However, endogenous concentrations of NRH or another NQO2
co-substrate was insufficient to reduce NQO2 specific substrate CB1954 (Chapter 6, (8)).
In contrast, NQO1 specific substrates EO9 and mitomycin C were readily activated in
cells without the addition of NADH (9–11). As a result of these findings, the belief that
NRH is a natural co-substrate of NQO2 is questionable. Inferring from the different
cellular concentrations of NRH and NADH, it appears that NQO2 is normally in the
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oxidized state, while NQO1 is in the reduced state in proliferating HCT116 cells. In the
next section, the potential sources of NRH will be further discussed.

7.2.1

Source of NRH

There are three potential mechanisms of NRH production: 1) transfer of a hydride ion
from NADPH to NR+ by transhydrogenase, 2) truncation of NAD(P)H to NRH by NADconsuming enzymes, and 3) reduction of free NR+ to NRH by dehydrogenase.
Transhydrogenases are proteins found on the inner membrane of mitochondria that
transfer the hydride ion from NADPH to NAD+ to generate NADP+ and NADH.
However, no transhydrogenases have been identified to catalyze this function on the
cytosolic side of a mammalian cell, and it is unclear whether this enzyme can utilize NR+
(12). The second potential source of NRH could originate from enzymes that consume
NAD+. These include poly-ADP ribose polymerase (PARP), mono-ADPribosyltransferase, and deacetylase (ie. Sirtuins). These proteins transfer the ADP-ribose
moiety of NAD+ to lysine or arginine side chains, leaving nicotinamide as a by-product.
This way, NR+ may be generated by nicotinamide phosphoribosyltransferase (NAMPT)
through the NAD+ salvage pathway. However, these enzymes are strictly dependent on
NAD+ and do not utilize reduced NADH. Therefore, the first two potential sources of
intracellular NRH seem unlikely.
In a study investigating NAD+ derivatives in alcohol metabolism, Sicsic and co-workers
showed that NR+ can be used in place of NAD+ to oxidize ethanol by horse liver alcohol
dehydrogenase (HLADH) in the presence of AMP (13). Consequently, it is not
inconceivable that other mammalian dehydrogenases have the ability to reduce NR+ to
NRH. When cells are insulted by oxidative stress or DNA damage, NAD+ depletion by
PARP activation is often accompanied by ATP depletion via the inhibition of glycolysis
(14). In this low energy state, adenylate kinase is known to catalyze the reaction 2 ADP ➜
AMP + ATP to maintain high ATP levels for cell survival. Therefore, NR+ and AMP
could be abundant when cells are insulted by genotoxic and oxidative stress. Along these
lines, NRH could be produced by an abundant dehydrogenase such as glyceraldehyde 3phosphate dehydrogenase (GAPDH). Together, NRH could be produced when NR+,
AMP, and the reducing substrates are present at the right concentrations within a cell.
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Identifying enzymes capable of generating NRH will be the first step in understanding
the mechanism of NQO2 reduction in cells.
To date, the only physiological condition known to stimulate NQO2-mediated
stabilization of p53 is the inhibition of dihydroorotate dehydrogenase (DHODH) (15).
DHODH is part of the de novo pyrimidine biosynthesis pathway, and the inhibition of
this enzyme depletes pyrimidine nucleotide cells. Even though inhibition of DHODH
induced p53 stabilization in an NQO2 dependent manner, it was unclear how this type of
metabolic stress affects NQO2. One possibility is that NRH, or another NQO2 substrate,
is generated under these circumstances. To determine the cellular concentration of NRH,
CB1954 could be used as a surrogate reporter because it is strictly dependent on human
NQO2 and NRH. Using this assay, it would be valuable to determine whether common
signals of p53 induction such as oxidative stress, UV rays, gamma irradiation, and
hypoxia, could induce NRH production. Further metabolomics studies using mass
spectrometry can validate the identity of the NQO2 co-substrate. Altogether, there is a
need to determine how NRH is produced in cells and how NQO2 is reduced in a cellular
context.

7.3

NQO2 as a Sensor of Toxic Compounds

The function and regulation of p53 is very complex. As a transcription factor, it can
activate genes responsible for cell cycle arrest and apoptosis. Independent of
transcriptional activation, p53 can induce apoptosis by directly interacting with proapoptotic signalling proteins (16). Furthermore, it can modulate proteins and
transcriptional factors involved in other cellular processes. An investigation into six
NQO2 inhibitors showed that NQO2 was not responsible for the cytotoxicity or apoptotic
signalling mediated by the inhibitors (Chapter 6). However, TBB and TBBz modulated
p53 to some degree in an NQO2 dependent manner. This indicated that NQO2’s role in
cells as a flavin redox switch could involve cellular processes other than p53-induced
apoptosis. In this section, the subject of identifying CK2 inhibitors and DNA intercalating
agents as NQO2 inhibitors will be revisited. Given the diverse nature of the compounds
that bind NQO2, the potential role of NQO2 as a sensor for cytotoxic compounds will be

174

proposed. Finally, a perspective on how to study NQO2’s role as a flavin redox switch
using a proteomics approach is presented.

7.3.1

NQO2 inhibition by Kinase Inhibitors

CK2 is a constitutively active kinase essential for cell survival. It is capable of
phosphorylating a diverse range of substrates. The long-standing interest in
understanding the cellular response to CK2 inhibition at David Litchfield’s lab identified
NQO2 as the unintended target of TBBz and DMAT (17). This prompted a full
investigation into the kinetic and structural interactions between CK2 inhibitors and
NQO2 (Chapter 4). The initial rationale for obtaining the structure of NQO2 in complex
with TBBz and DMAT was to gain insight towards designing an inhibitor-resistant
NQO2 construct. Such mutant constructs could restore NQO2 activity in cells to study
NQO2-specific cellular effects. It was previously shown that mutations in the active site
9

of NQO2 decreased the affinity of the melatonin derivative [125I]iodo-MCA-NAT from
binding to NQO2 without decreasing its catalytic activity (18). Therefore, it appears
feasible to design an inhibitor-resistant NQO2 mutant to validate inhibitor-induced
cellular effects caused by NQO2 inhibition alone.
Since TBB and TBBz modulated p53 degradation in an NQO2-dependent manner
(Chapter 6), NQO2’s interactions with other kinase inhibitors may also affect this cellular
process. To determine whether other CK2 inhibitors bind to NQO2, a more specific CK2
inhibitor, CX-4945, was found. NQO2 catalytic activity was reduced to 75% in the
presence of 5 µM CX-4945, thus it was able to inhibit NQO2 weakly (Figure 7.2).
NQO2 was also known to be an unintended target of BCR-Abl kinase inhibitors imatinib
and nilotinib. While the BCR-Abl inhibitors do not inhibit CK2 and CK2 inhibitors
(TBBz and DNAT) do not inhibit Abl-kinase, both inhibited NQO2 (17, 19–22). Even
though these kinase inhibitors were initially designed to inhibit kinase activity, they are
further selected based on favorable clinical outcomes. Therefore, there is a possibility that

9 125

[

I]iodo-MCA-NAT: 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine
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a compound able to inhibit both the kinase and NQO2 outperformed compounds that only
inhibited the kinase. In this regard, a comprehensive screen of kinase inhibitors towards
NQO2 catalysis could show whether or not NQO2 inhibition contributes to the efficacy
of kinase inhibitors in general.

Figure 7.2 Inhibition of NQO2 Catalysis by CX4945. Data was fitted to a doseresponse curve.

7.3.2

Inhibition of NQO2 by DNA Intercalating Agents

Studies demonstrating that some NQO2 inhibitors could intercalate DNA prompted an
investigation into whether other DNA intercalators could perform likewise (23, 24). In
Chapter 5, three DNA intercalators were identified to be novel inhibitors of NQO2. Most
NQO2 inhibitors identified to date are oxidized-state inhibitors, so it was unexpected to
find ethidium (EtBr) and acridine orange (AO) to be reduced-state inhibitors. The
common feature between EtBr, AO, and the two previously identified reduced-state
inhibitors CQ and quinacrine was a positive charge in the planar moiety. It appears that
positively charged compounds interacted favorably with the reduced FAD. Further
structural comparisons between extended (unwound) DNA and the NQO2 active site
showed numerous similarities between the two binding cavities. Drawing from these
observations, NQO2 has the potential to recognize a diverse range of DNA intercalating
agents in cell.
The identification of DNA intercalating agents as NQO2 inhibitors also raised the
question of whether other NQO2 inhibitors also intercalate DNA. Some NQO2 inhibitors
such as imatinib, 9-aminoacridine, and resveratrol have been independently shown to
interact with DNA (25–27). Along these lines, an important question regarding NQO2
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inhibitors is whether their cytotoxic effects are primarily due to DNA intercalation or
inhibition of protein targets. A comprehensive analysis of known NQO2 inhibitors’
ability to intercalate DNA could clarify why NQO2 inhibitors are cytotoxic to cells.

7.3.3

Potential Role of NQO2 as a Sensor of Toxins

Given the ability of NQO2 to recognize low concentrations of CK2 inhibitors and DNA
intercalating agents, it is unclear if these interactions serve a function. One possible
downstream effect of inhibitor binding is to induce multidrug efflux pumps mediated by
p53. Bacterium gain drug resistances by expressing multidrug efflux pumps that excrete
non-specific compounds (28). Many of these transporters are under transcriptional
regulation by multidrug binding proteins. For example, BmrR in Bacillus subtilis (29),
QacR in Staphylococcus aureus (30), and EmrR in Escherichia coli (31) are
transcriptional regulators of multidrug efflux pumps. BmrR acted as a repressor of the
efflux pump Bmr by directly binding to the promoter region. In the presence of a toxin,
BmrR induced Bmr expression by remodeling the DNA structure to be accessed by RNA
polymerase (32). Additionally, an elaborate study on QacR showed that a range of toxic
compounds, both hydrophobic and cationic, can activate the QacA efflux pump (33).
From these studies, it appeared that bacterial multidrug proteins could sense a variety of
compounds, and act as transcriptional activators and repressors. While these proteins do
not share sequential or structural homology with mammalian quinone reductase, this
regulatory pathway could represent a primitive model of how NQO2 functions as a
mammalian multidrug efflux pump regulator.
In mammals, P-glycoproteins (MDR1) and the family of multidrug resistance-associated
proteins (MRPs) are ATP-binding cassette transmembrane transporters (ABC
transportors) that pumps xenobiotic compounds out of the cell (34). MRPs’ expression
can be induced by the presence of toxins and drugs, but their mechanism of induction is
unclear (35). Specifically, no multidrug binding protein that directly recognizes a toxic
compound has been reported in mammalian cells. As such, the fact that NQO2 is the
target of a plethora of cytotoxic compounds, and is able to modulate p53, makes it a
compelling candidate towards its identification as a mammalian multidrug binding
protein.
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While the regulation of MDR1 and MRPs is complex, a pathway through which NQO2
can modulate these proteins is by p53 and the transcription factor Sp1 (Sp1). Sp1 was
normally down-regulated by direct binding to p53, but it can induce a member of the
MRP family, MRP1, in response to a range of cytotoxic stresses (36, 37). This regulation
was further shown by an induction of MRP1 expression when p53 was inactivated or
mutated (38). Therefore, a basal p53 expression prevented the expression of MRP1, while
inactivation of p53 induced MRP1 expression. Through this transcriptional regulation
mechanism, NQO2 inhibitors could induce the degradation of p53 and release Sp1 to
initiate MRP1 expression. In this regard, NQO2 may be functioning as a multi-drug
binding protein that signals the activation of a multidrug efflux pump. Furthermore, there
are also four Sp1 recognition sites upstream of the NQO2 gene (39), which could act as
positive regulator of MRP1 until the cell clears all cytotoxic compounds. Following these
suppositions, an investigation of whether NQO2 plays a role in the regulation of MRP1 is
warranted.
A myriad of compounds inhibit NQO2 with affinities ranging from high micromolar to
nanomolar. Given that NQO2-mediated modulation of p53 may have functions other than
inducing cell cycle arrest and apoptosis, a role for regulating MRP1 efflux pump is
proposed: toxic DNA intercalating agents recognized by NQO2 could induce MPR1 and
be excreted in normal proliferating cells. In this regard, the success of chemotherapeutics
such as kinase inhibitors may not be due solely to their ability to effectively kill cancer
cells. Instead, it may be due to the ability of normal cells to excrete these compounds
such that side effects are minimized. Extending this hypothesis, kinase inhibitors
recognized by NQO2 could also induce multidrug resistance in cancer cells if the
concentrations used are not high enough to kill the cell. Taken together, NQO2 may act
as a direct sensor for toxic compounds to modulate signalling events in cells.
In the next section, the modulation of p53 by NQO2 will be revisited once more to point
out that NQO2 has the potential to regulate a number of proteins. To investigate the role
of NQO2 as a sensor for toxic compounds, an analysis of MRP1 and other proteins using
a proteomics approach will help decipher the complex function of NQO2.
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7.3.4

Protein Stabilization by NQO2

Both NQO1 and NQO2 were shown to stabilize p53 from 20S proteasomal degradation
(1). To understand this biological process, recombinant p53 from E. coli and 20S
proteasome from lamb liver were purified. However, in vitro degradation of p53 was not
detected (data not shown). This was contrary to a previous demonstration that in vitro
translation of p53 by rabbit reticulocyte lysates were degraded by rabbit 20S proteasomes
(1). This illustrated that p53 may require certain post-translational modifications to be
degraded, or that the degradation of p53 was mediated by additional components from the
rabbit reticulocyte lysate. In addition to p53 modulation, NQO2 may also stabilize other
proteins. For example, NQO1 also directly modulated the degradation of p73α and
ornithine decarboxylase (5, 40). All three of these proteins have an intrinsic disordered
region that could be recognized by the 20S proteasome, and were degraded in an
ubiquitin-independent manner (41–43). This led Yosef Shaul and coworkers to
hypothesized that quinone reductase could be modulating 20S proteasomal degradation in
general (44). As for NQO2, it also modulated Rb/cyclin D1 (45), NFκB (46), CEBPα
(47), and AKT (48) pathways, though it is not clear if these proteins were directly
modulated. These studies demonstrated that NQO2 could be directly regulating the
degradation of an array of intrinsically disordered proteins by the 20S proteasome. To
gain a comprehensive perspective on the function of NQO2, a global proteomics
approach is needed to decipher how NQO2 regulates protein stabilization.
Initially, the overall proteome of HCT116 and HCT116ΔNQO2 cells could be compared
using a 2D gel. Given sufficient changes in protein levels, SILAC-based (stable isotope
labeling by amino acids in cell culture) mass spectrometry techniques could be used to
quantify the differences in protein levels on a global scale (49). Having established the
basal protein difference between HCT116 and HCT116ΔNQO2, the effects of NRH on the
proteome will demonstrate how the redox state of NQO2 changes the protein stability.
Super-SILAC can also be used to monitor several NRH concentrations to detect changes
in protein levels that are most directly and immediately affected by NQO2 (50). To
further characterize specific proteins that NQO2 associates with in cells, proximity
labeling of proteins near NQO2 could be identified using cross-linking reagents or a BIO-
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ID mass-spectrometry based approach (51). Having established these mass-spectrometry
techniques, a comprehensive analysis of the proteins that NQO2 modulates directly will
illuminate the function of NQO2 as a flavin redox switch. This general approach can then
be extended to decipher how high affinity NQO2 inhibitors such as S29434 and acridine
orange affect the proteome.

7.4

Conclusion

The central question in this thesis was how NQO2 functions as a flavin redox switch. To
this end, structural analyses of NQO2 and NQO2 inhibitors revealed the mechanistic
features of a flavin redox switch. Cellular studies further identified that NQO2 exists in
an oxidized state, contrary to NQO1, which exist in a reduced state. Though the role of
NQO2 as a flavin redox switch was delineated, many questions remain. Answers to the
following questions will illuminate how NQO2 modulates cellular processes when
challenged by the diverse range of NQO2 inhibitors: How does the redox state of NQO2
affect protein degradation? What is the mechanism of NRH production, and is NRH
really the natural co-substrate? What other compounds do NQO2 recognize? What are the
consequences of NQO2 activation? What proteins do NQO2 stabilize? By using advance
techniques such as protein molecular dynamic simulation, high throughput screening of
NQO2 inhibitors, and biological mass spectrometry, the knowledge of how NQO2
functions as a flavin redox switch will be further advanced.
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